

10/6/5809

Page 1

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 23 MAR 01 INSPEC reloaded and enhanced
NEWS 24 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 25 MAR 08 X.25 communication option no longer available after June 2006

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

10615809.trn

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:38:41 ON 16 MAR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:38:53 ON 16 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAR 2006 HIGHEST RN 876856-38-1

DICTIONARY FILE UPDATES: 14 MAR 2006 HIGHEST RN 876856-38-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10615809\Struc 1.str



```

chain nodes :
7 8 9 10 12 14 16 24
ring nodes :
1 2 3 4 5 6 11 18 19 21 22 23
chain bonds :
5-7 6-9 7-8 7-12 8-14 8-16 9-10 9-24 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-18 11-23 18-19 19-21 21-22 22-23
exact/norm bonds :
5-7 6-9 7-8 7-12 8-14 8-16 9-10 9-24 10-11 11-18 11-23 18-19 19-21
21-22 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:Cb,Cy,Hy

G2:H,CH3,Et

G3:C,N

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 14:CLASS 16:CLASS 18:Atom 19:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS

```


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10615809.trn



G1 Cb,Cy,Hy

G2 H,Me,Et

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 08:39:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3533 TO ITERATE

56.6% PROCESSED 2000 ITERATIONS

23 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 67096 TO 74224

PROJECTED ANSWERS: 430 TO 1194

L2 23 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 08:39:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 71221 TO ITERATE

100.0% PROCESSED 71221 ITERATIONS

1079 ANSWERS

SEARCH TIME: 00.00.02

L3 1079 SEA SSS FUL L1

=> file medline caplus

10615809.trn

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'MEDLINE' ENTERED AT 08:39:29 ON 16 MAR 2006

FILE 'CAPLUS' ENTERED AT 08:39:29 ON 16 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l3

L4 66 L3

=> d ibib abs hitstr 1-66

L4 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:13570 CAPLUS

DOCUMENT NUMBER: 144:108346

TITLE: Preparation of 2-aminoarenecarboxamides useful as cancer chemotherapeutic agents

INVENTOR(S): Brennan, Catherine; Dixon, Julie A.; Scott, William J.; Redman, Aniko; Jones, Benjamin D.; Phillips, Barton; Wickens, Philip; Enyedy, Istvan; Kumarasinghe, Ellalahewage; Kreiman, Charles; Dumas, Jacques; Khire, Uday; Chuang, Chih-Yuan; Kluender, Harold C. E.; Hong, Zhenqiu; Wang, Lei; Bierer, Donald

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002383	A2	20060105	WO 2005-US22518	20050623
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-582326P P 20040623

GI



AB 2-Aminoarene-carboxamides (shown as I; variables defined below; e.g. 5-methoxy-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide (shown as II)) are claimed. In I: the ring containing E is a Ph, a pyridine, or a pyrimidine; A = OC(R4)2C(R4)2O, OC(R4)2OC(R4)2 or OC(R4)2O wherein R4 = halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum

number of hydrogens on A is 2 for the A groups which together with the C atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the C atoms to which it is attached forms a 5-membered ring; Z = N or CH when E forms a Ph ring, and = CH when E forms a pyridine or pyrimidine; addnl. details are given in the claims. Pharmaceutical compns. containing I and methods of treating cancer using them are also disclosed and claimed. Although the methods of preparation are not claimed, preps. and/or characterization data for >150 examples of I are included. For example, II was prepared in 3 steps (100, 52, and 16 %, resp.) starting with coupling of 5-methoxy-2-nitrobenzoic acid with 2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-amine to give 5-methoxy-2-nitro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide, which was reduced to the amine, which was condensed with 4-pyridinecarboxaldehyde and the product hydrogenated to II. Many examples of I were tested in a PAKT/PKB Cytoblot assay with H209 small cell lung carcinoma cells; some I had IC50 <500 nM.


IT 872707-46-5P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)benzamide 872707-48-7P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide 872707-88-5P, 4-[[[2-[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide 872707-89-6P, Methyl 4-[[[2-[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxylate 872707-91-0P, 4-[[[2-[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]pyridine-2-carboxamide 872707-96-5P, Ethyl 4-[[[2-[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]me

thyl]pyridine-2-carboxylate **872708-84-4P**, 2-[[[2-Aminopyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 2-aminoarenecarboxamides useful as cancer chemotherapeutic agents)


RN 872707-46-5 CAPLUS

CN Benzamide, 2-[[[2-(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)-(9CI) (CA INDEX NAME)




RN 872707-48-7 CAPLUS

CN Benzamide, 2-[[[2-(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-(9CI) (CA INDEX NAME)




RN 872707-88-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[2-(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-(9CI) (CA INDEX NAME)




RN 872707-89-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[[2-[[[2-(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 872707-91-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 872707-96-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 872708-84-4 CAPLUS

CN Benzamide, 2-[[[(2-amino-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)



IT 872707-17-0P, 5-Methoxy-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide
 872707-20-5P, 2-[[(Pyridin-4-yl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)benzamide 872707-21-6P,
 N-Methyl-4-[[[2-[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
 872707-24-9P, N-Methyl-4-[[[2-[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
 872707-25-0P, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[(pyridin-4-yl)methyl]amino]benzamide 872707-26-1P, 2-[[(Pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-27-2P, 3-Methoxy-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-28-3P, 3-Methoxy-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)benzamide
 872707-29-4P, 2-Methoxy-6-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide
 872707-30-7P, 2-Methoxy-6-[[(pyridin-4-yl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)benzamide 872707-31-8P,
 N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-methoxy-6-[[(pyridin-4-yl)methyl]amino]benzamide 872707-41-0P, 4-Fluoro-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-42-1P, 5-Fluoro-2-[[(pyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-43-2P, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-5-fluoro-2-[[(pyridin-4-yl)methyl]amino]benzamide 872707-44-3P,
 N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-4-fluoro-2-[[(pyridin-4-yl)methyl]amino]benzamide 872707-45-4P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-47-6P, 4-[[[2-[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-methylpyridine-2-carboxamide 872707-49-8P, 2-[[(2-Chloro-6-methylpyrimidin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-50-1P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-5-fluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-53-4P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-4-fluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide 872707-54-5P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-fluorobenzamide
 872707-55-6P, 2-[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-fluorobenzamide 872707-56-7P,
 4-[[[2-[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino]methyl]-N-methylpyridine-2-carboxamide
 872707-57-8P, 4-[[[5-Fluoro-2-[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]-N-methylpyridine-2-carboxamide 872707-58-9P, 4-[[[2-[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-5-fluorophenyl]amino]methyl]-N-methylpyridine-2-carboxamide 872707-59-0P, 4-[[[4-Fluoro-2-

[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino)methyl]-N-methylpyridine-2-carboxamide
872707-60-3P, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4,5-difluorophenyl]amino)methyl]-N-methylpyridine-2-carboxamide **872707-61-4P**, 2-[[[(2-Cyanopyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4,5-difluorobenzamide
872707-62-5P, 4-[[[4,5-Difluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino)methyl]-N-methylpyridine-2-carboxamide **872707-63-6P**, 2-[[[(2-Cyanopyridin-4-yl)methyl]amino]-4,5-difluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide **872707-67-0P**, 2-[[[2-(4,5-Dihydro-1H-imidazol-2-yl)pyridin-4-yl)methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)benzamide **872707-68-1P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-yl)methyl]amino]-5-fluorobenzamide **872707-69-2P**,
 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino)methyl]-N,N-dimethylpyridine-2-carboxamide **872707-70-5P**, 4-[[[4,5-Difluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino)methyl]-N-ethylpyridine-2-carboxamide **872707-72-7P**, N-Ethyl-4-[[[2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino)methyl]pyridine-2-carboxamide **872707-73-8P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-ethylpyridine-2-carboxamide **872707-74-9P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino)methyl]-N-ethylpyridine-2-carboxamide **872707-75-0P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-5-fluorophenyl]amino)methyl]-N-ethylpyridine-2-carboxamide **872707-77-2P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(dimethylamino)pyrimidin-4-yl)methyl]amino]benzamide **872707-79-4P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[1-[2-(methylamino)pyrimidin-4-yl)methyl]amino]benzamide **872707-80-7P**,
 2-[[[2-(Dimethylamino)pyrimidin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide **872707-81-8P**,
 2-[[[2-(Methylamino)pyrimidin-4-yl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)benzamide **872707-82-9P**,
 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-(2-methoxyethyl)pyridine-2-carboxamide **872707-84-1P**,
 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino)methyl]-N-(2-methoxyethyl)pyridine-2-carboxamide **872707-85-2P**, N-Cyclopropyl-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]pyridine-2-carboxamide **872707-90-9P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-[(2-furyl)methyl]pyridine-2-carboxamide **872707-92-1P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-(2,3-dihydroxypropyl)pyridine-2-carboxamide **872707-93-2P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N,N-dimethylpyridine-2-carboxamide **872707-94-3P**, N-(tert-Butyl)-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]pyridine-2-carboxamide **872707-95-4P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-[2-(methylsulfonyl)ethyl]pyridine-2-carboxamide **872707-97-6P**,
 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-2-carboxamide **872707-98-7P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-[2-(dimethylamino)ethyl]pyridine-2-carboxamide **872707-99-8P**, 4-[[[2-[[[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino)methyl]-N-[3-(dimethylamino)propyl]pyridine-2-carboxamide **872708-00-4P**,

N-[3-(Diethylamino)propyl]-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
872708-01-5P, N-[2-(Diethylamino)ethyl]-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
872708-02-6P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-methoxypropyl)pyridine-2-carboxamide **872708-03-7P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[4-(dimethylamino)butyl]pyridine-2-carboxamide **872708-04-8P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-hydroxyethyl)pyridine-2-carboxamide **872708-05-9P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(pyrrolidin-1-yl)propyl]pyridine-2-carboxamide
872708-06-0P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-hydroxypropyl)pyridine-2-carboxamide **872708-07-1P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(1H-imidazol-5-yl)ethyl]pyridine-2-carboxamide **872708-08-2P**,
 N-(3-Amino-3-oxopropyl)-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
872708-09-3P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(1H-imidazol-1-yl)propyl]pyridine-2-carboxamide **872708-10-6P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[4-(pyrrolidin-1-yl)butyl]pyridine-2-carboxamide
872708-11-7P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(piperidin-1-yl)propyl]pyridine-2-carboxamide **872708-12-8P**,
 N-[[4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridin-2-yl]carbonyl]-β-alanine **872708-13-9P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[5-(dimethylamino)pentyl]pyridine-2-carboxamide
872708-14-0P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-2-carboxamide **872708-15-1P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(1H-indol-3-yl)ethyl]pyridine-2-carboxamide
872708-16-2P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(2-hydroxyethoxy)ethyl]pyridine-2-carboxamide **872708-17-3P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(pyridin-4-yl)methyl]pyridine-2-carboxamide **872708-18-4P**
 , N-[3-(Dibutylamino)propyl]-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
872708-19-5P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-[ethyl(3-methylphenyl)amino]ethyl]pyridine-2-carboxamide **872708-20-8P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-[methyl(phenyl)amino]propyl]pyridine-2-carboxamide
872708-21-9P, N-[4-(Diethylamino)-1-methylbutyl]-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide **872708-22-0P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[1-(hydroxymethyl)-3-methylbutyl]pyridine-2-carboxamide **872708-23-1P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-ethoxypropyl)pyridine-2-carboxamide **872708-24-2P**,
 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-isopropoxypropyl)pyridine-2-carboxamide **872708-25-3P**,
 N-(3-Butoxypropyl)-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide

872708-26-4P, N-[3-(Azepan-1-yl)propyl]-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide
872708-27-5P, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-(2-propoxyethyl)pyridine-2-carboxamide **872708-28-6P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(3-ethoxyphenyl)ethyl]pyridine-2-carboxamide **872708-29-7P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(dimethylamino)-1-methylethyl]pyridine-2-carboxamide **872708-30-0P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]pyridine-2-carboxamide **872708-31-1P**, N-(1-Benzylpyrrolidin-3-yl)-4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]pyridine-2-carboxamide **872708-32-2P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[3-(2-methylpiperidin-1-yl)propyl]pyridine-2-carboxamide **872708-33-3P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(pyridin-2-yl)ethyl]pyridine-2-carboxamide **872708-34-4P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]pyridine-2-carboxamide **872708-35-5P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenyl)ethyl]pyridine-2-carboxamide **872708-36-6P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide **872708-37-7P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-(3-propoxypropyl)pyridine-2-carboxamide **872708-38-8P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]pyridine-2-carboxamide **872708-39-9P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]pyridine-2-carboxamide **872708-40-2P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[(1S)-1-(hydroxymethyl)-3-(methylthio)propyl]pyridine-2-carboxamide **872708-41-3P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(2-thienyl)ethyl]pyridine-2-carboxamide **872708-42-4P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-hydroxyphenyl)ethyl]pyridine-2-carboxamide **872708-43-5P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenoxy)propyl]pyridine-2-carboxamide **872708-44-6P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenyl)ethyl]-N-methylpyridine-2-carboxamide **872708-45-7P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]pyridine-2-carboxamide **872708-46-8P**, 4-[[[2-[[[2,2-Difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]phenyl]amino]methyl]-N-[4-(morpholin-4-yl)benzyl]pyridine-2-carboxamide **872708-48-0P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-hydroxyethyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-51-5P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-methoxyethyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-53-7P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-methoxypropyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-55-9P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-hydroxypropyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-57-1P**,

N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(2-hydroxyethoxy)ethyl]amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-59-3P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(methylamino)pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-61-7P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-isopropoxypropyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-63-9P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-hydroxy-2,2-dimethylpropyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-65-1P**, 2-[[[2-[(3-Amino-2-hydroxypropyl)amino]pyridin-4-yl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide bis(trifluoroacetate) **872708-67-3P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(dimethylamino)propyl]amino]pyridin-4-yl]methyl]amino]benzamide bis(trifluoroacetate) **872708-69-5P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(morpholin-4-yl)propyl]amino]pyridin-4-yl]methyl]amino]benzamide bis(trifluoroacetate) **872708-71-9P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]pyridin-4-yl]methyl]amino]benzamide bis(trifluoroacetate) **872708-73-1P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(1H-imidazol-1-yl)propyl]amino]pyridin-4-yl]methyl]amino]benzamide bis(trifluoroacetate) **872708-75-3P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]pyridin-4-yl]methyl]amino]benzamide bis(trifluoroacetate) **872708-77-5P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2-(tetrahydrofuran-2-yl)methyl]amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-79-7P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2,3-dihydroxypropyl]amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-81-1P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(phenylethyl)amino]pyridin-4-yl]methyl]amino]benzamide mono(trifluoroacetate) **872708-82-2P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(methoxypropanoyl)amino]pyridin-4-yl]methyl]amino]benzamide **872708-83-3P**, 2-[[[2-(Acetylamino)pyridin-4-yl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide **872708-85-5P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(methoxyethoxy)acetyl]amino]pyridin-4-yl]methyl]amino]benzamide **872708-86-6P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(methoxyacetyl)amino]pyridin-4-yl]methyl]amino]benzamide **872708-87-7P**, 2-[[[4-[[2-[[2-(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridin-2-yl]amino]-2-oxoethyl acetate **872708-88-8P**, Methyl 2-[[[4-[[2-[[2-(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]pyridin-2-yl]amino]-2-oxoethoxy]acetate **872708-89-9P** **872708-90-2P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(methoxy-2-methylpropanoyl)amino]pyridin-4-yl]methyl]amino]benzamide **872708-91-3P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(ethylamino)carbonyl]amino]pyridin-4-yl]methyl]amino]benzamide **872708-92-4P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[4-(methoxyphenyl)amino]carbonyl]amino]pyridin-4-yl]methyl]amino]benzamide **872708-93-5P**, 2-[[[2-[[2-(Anilino)carbonyl]amino]pyridin-4-yl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide **872708-94-6P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(methylamino)carbonyl]amino]pyridin-4-yl]methyl]amino]benzamide **872708-95-7P**, 2-[[[2-[[[3-(Cyanophenyl)amino]carbonyl]amino]pyridin-4-yl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide **872708-96-8P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[3-(methoxyphenyl)amino]carbonyl]amino]pyridin-4-yl]methyl]amino]benzamide **872708-97-9P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2,3-dihydro-1H-inden-5-yl]amino]carbonyl]amino]pyridin-4-

yl)methyl]amino]benzamide **872708-98-0P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(propylamino) carbonyl]amino]pyridin-4-yl)methyl]amino]benzamide **872708-99-1P**, 2-[[[2-[[[(Butylamino) carbonyl]amino]pyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide **872709-00-7P**


, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(3-methylbenzyl)amino] carbonyl]amino]pyridin-4-yl)methyl]amino]benzamide **872709-01-8P**, 2-[[[2-[[[(Benzylamino) carbonyl]amino]pyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide **872709-02-9P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(2-furyl)methyl]amino] carbonyl]amino]pyridin-4-yl)methyl]amino]benzamide **872709-03-0P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(dimethylamino) carbonyl]amino]pyridin-4-yl)methyl]amino]benzamide **872709-04-1P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(methylsulfonyl)amino]pyridin-4-yl)methyl]amino]benzamide **872709-06-3P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(4-methyl-1,3-thiazol-2-yl)amino]pyridin-4-yl)methyl]amino]benzamide **872709-07-4P**, N-(2,2-Difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(hydroxymethyl)pyridin-4-yl)methyl]amino]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-aminoarenecarboxamides useful as cancer chemotherapeutic agents)


RN 872707-17-0 CAPLUS

CN Benzamide, 5-methoxy-2-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)



RN 872707-20-5 CAPLUS


CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)



RN 872707-21-6 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[[2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino] carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

NAME)




RN 872707-24-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[2-[[[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872707-25-0 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 872707-26-1 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-27-2 CAPLUS

CN Benzamide, 3-methoxy-2-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-28-3 CAPLUS

CN Benzamide, 3-methoxy-2-[(4-pyridinylmethyl)amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-29-4 CAPLUS

CN Benzamide, 2-methoxy-6-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-30-7 CAPLUS

CN Benzamide, 2-methoxy-6-[(4-pyridinylmethyl)amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-31-8 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-methoxy-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 872707-41-0 CAPLUS

CN Benzamide, 4-fluoro-2-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-42-1 CAPLUS

CN Benzamide, 5-fluoro-2-[(4-pyridinylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-43-2 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 872707-44-3 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 872707-45-4 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-47-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-49-8 CAPLUS

CN Benzamide, 2-[[[(2-chloro-6-methyl-4-pyrimidinyl)methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-50-1 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-5-fluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-53-4 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-4-fluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-54-5 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 872707-55-6 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 872707-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-57-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[5-fluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-58-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-5-fluorophenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-59-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[4-fluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-60-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4,5-difluorophenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-61-4 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4,5-difluoro- (9CI) (CA INDEX NAME)




RN 872707-62-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[4,5-difluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872707-63-6 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-4,5-difluoro-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-67-0 CAPLUS

CN Benzamide, 2-[[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]methyl]amino]-N-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-68-1 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 872707-69-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[2,2-difluoro-1,3-benzodioxol-5-yl]amino]carbonyl]-4-fluorophenyl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 872707-70-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[4,5-difluoro-2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 872707-72-7 CAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[[2-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872707-73-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 872707-74-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino]methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 872707-75-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-5-fluorophenyl]amino]methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 872707-77-2 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(dimethylamino)-4-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872707-79-4 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[2-(methylamino)-4-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872707-80-7 CAPLUS

CN Benzamide, 2-[[[2-(dimethylamino)-4-pyrimidinyl]methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-81-8 CAPLUS

CN Benzamide, 2-[[[2-(methylamino)-4-pyrimidinyl]methyl]amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 872707-82-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-methoxyethyl)-(9CI) (CA INDEX NAME)




RN 872707-84-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]-4-fluorophenyl]amino]methyl]-N-(2-methoxyethyl)-(9CI) (CA INDEX NAME)




RN 872707-85-2 CAPLUS


CN 2-Pyridinecarboxamide, N-cyclopropyl-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-methoxyethyl)-(9CI) (CA INDEX NAME)




RN 872707-90-9 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 872707-92-1 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)




RN 872707-93-2 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 872707-94-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 872707-95-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 872707-97-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 872707-98-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(dimethylamino)ethyl]]- (9CI)
(CA INDEX NAME)




RN 872707-99-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(dimethylamino)propyl]]- (9CI)
(CA INDEX NAME)




RN 872708-00-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(diethylamino)propyl]-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]]- (9CI) (CA INDEX NAME)




RN 872708-01-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(diethylamino)ethyl]-4-[[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872708-02-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 872708-03-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[4-(dimethylamino)butyl]- (9CI) (CA INDEX NAME)




RN 872708-04-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)




RN 872708-05-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(1-pyrrolidinyl)propyl]]- (9CI) (CA INDEX NAME)




RN 872708-06-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-hydroxypropyl)]- (9CI) (CA INDEX NAME)




RN 872708-07-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 872708-08-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-amino-3-oxopropyl)-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872708-09-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 872708-10-6 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI)
 (CA INDEX NAME)



RN 872708-11-7 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(1-piperidinyl)propyl]- (9CI)
 (CA INDEX NAME)




RN 872708-12-8 CAPLUS
 CN β-Alanine, N-[[4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 872708-13-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[5-(dimethylamino)pentyl]]- (9CI)
(CA INDEX NAME)




RN 872708-14-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]]- (9CI) (CA INDEX NAME)




RN 872708-15-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(1H-indol-3-yl)ethyl]]- (9CI)
(CA INDEX NAME)




RN 872708-16-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI)
(CA INDEX NAME)




RN 872708-17-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 872708-18-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dibutylamino)propyl]-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872708-22-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[1-(hydroxymethyl)-3-methylbutyl]- (9CI) (CA INDEX NAME)




RN 872708-23-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-ethoxypropyl)- (9CI) (CA INDEX NAME)




RN 872708-24-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 872708-25-3 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-butoxypropyl)-4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 872708-26-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(hexahydro-1H-azepin-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 872708-27-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 872708-28-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(3-ethoxyphenyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 872708-29-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(dimethylamino)-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 872708-30-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 872708-31-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 872708-32-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 872708-33-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 872708-34-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]]- (9CI) (CA INDEX NAME)




RN 872708-35-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenyl)ethyl]]- (9CI) (CA INDEX NAME)




RN 872708-36-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[3-(2-oxo-1-pyrrolidiny)propyl]]- (9CI) (CA INDEX NAME)




RN 872708-37-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-(3-propoxypropyl)-(9CI) (CA INDEX NAME)




RN 872708-38-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)



RN 872708-39-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)



RN 872708-40-2 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(1S)-1-(hydroxymethyl)-3-(methylthio)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872708-41-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 872708-42-4 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-hydroxyphenyl)ethyl]- (9CI)

(CA INDEX NAME)




RN 872708-43-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 872708-44-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-(4-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 872708-45-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 872708-46-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]methyl]phenyl]amino]methyl]-N-[[4-(4-morpholinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 872708-48-0 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-hydroxyethyl)amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-47-9


CMF C22 H20 F2 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872708-51-5 CAPLUS
 CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-methoxyethyl)amino]-4-pyridinyl)methyl]amino]-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)


CM 1

CRN 872708-50-4
 CMF C23 H22 F2 N4 O4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 872708-53-7 CAPLUS
 CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-methoxypropyl)amino]-4-pyridinyl)methyl]amino]-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CM 1


CRN 872708-52-6
 CMF C24 H24 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-55-9 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-hydroxypropyl)amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-54-8


CMF C23 H22 F2 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872708-57-1 CAPLUS
 CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 872708-56-0
 CMF C24 H24 F2 N4 O5



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 872708-59-3 CAPLUS
 CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(methylamino)-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 872708-58-2
 CMF C21 H18 F2 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-61-7 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(1-methylethoxy)propyl]amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-60-6


CMF C26 H28 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-63-9 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyridinyl)methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-62-8


CMF C25 H26 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-65-1 CAPLUS

CN Benzamide, 2-[[[2-[(3-amino-2-hydroxypropyl)amino]-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-64-0


CMF C23 H23 F2 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-67-3 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(dimethylamino)propyl]amino]-4-pyridinyl]methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-66-2


CMF C25 H27 F2 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-69-5 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyridinyl]methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-68-4


CMF C27 H29 F2 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-71-9 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyridinyl]methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-70-8


CMF C27 H29 F2 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-73-1 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyridinyl]methyl]amino]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 872708-72-0


CMF C26 H24 F2 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-75-3 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-4-pyridinyl]methyl]amino]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 872708-74-2


CMF C25 H22 F2 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-77-5 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2-(tetrahydro-2-furanyl)methyl]amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-76-4


CMF C25 H24 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-79-7 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2,3-dihydroxypropyl)amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-78-6


CMF C23 H22 F2 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872708-81-1 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-phenylethyl)amino]-4-pyridinyl]methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872708-80-0


CMF C28 H24 F2 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 872708-82-2 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-methoxy-1-oxopropyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-83-3 CAPLUS

CN Benzamide, 2-[[[2-(acetylamino)-4-pyridinyl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)




RN 872708-85-5 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2-(methoxyethoxy)acetyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-86-6 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2-(methoxyacetyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-87-7 CAPLUS

CN Benzamide, 2-[[[2-[[[2-(acetyloxy)acetyl]amino]-4-pyridinyl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)




RN 872708-88-8 CAPLUS

CN Acetic acid, [2-[[[4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-2-pyridinyl]amino]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 872708-89-9 CAPLUS

CN Butanoic acid, 4,4'-[[4-[[[2-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]carbonyl]phenyl]amino]methyl]-2-pyridinyl]imino]bis[4-oxo-, diethyl ester (9CI) (CA INDEX NAME)




RN 872708-90-2 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(2-methoxy-2-methyl-1-oxopropyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-91-3 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-((4-methoxyphenyl)amino)carbonyl]amino]-4-pyridinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 872708-92-4 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[2-((4-methoxyphenyl)amino)carbonyl]amino]-4-pyridinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 872708-93-5 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[2-((4-methoxyphenyl)amino)carbonyl]amino]-4-pyridinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 872708-94-6 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(methylanino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-95-7 CAPLUS

CN Benzamide, 2-[[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)




RN 872708-96-8 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-97-9 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-98-0 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(2,3-dihydro-1H-inden-5-yl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 872708-99-1 CAPLUS

CN Benzamide, 2-[[[2-[[[(butylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)




RN 872709-00-7 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(3-methylphenyl)methyl]amino]carbonyl]amino]-4-pyridinyl]methyl]amino] - (9CI)
(CA INDEX NAME)




RN 872709-01-8 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(phenylmethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino] - (9CI)
(CA INDEX NAME)




RN 872709-02-9 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(2-furanylmethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 872709-03-0 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[[[(dimethylamino)carbonyl]amino]-4-pyridinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 872709-04-1 CAPLUS

CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(methylsulfonyl)amino]-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 872709-06-3 CAPLUS


CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-[(4-methyl-2-thiazolyl)amino]-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 872709-07-4 CAPLUS


CN Benzamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[[[2-(hydroxymethyl)-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT 872708-49-1P, 2-[[[(2-Chloropyridin-4-yl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide 872709-05-2P,
2-[[[2-[Bis(methylsulfonyl)amino]pyridin-4-yl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aminoarenecarboxamides useful as cancer chemotherapeutic agents)
RN 872708-49-1 CAPLUS
CN Benzamide, 2-[[[(2-chloro-4-pyridinyl)methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)



RN 872709-05-2 CAPLUS
CN Benzamide, 2-[[[2-[bis(methylsulfonyl)amino]-4-pyridinyl]methyl]amino]-N-(2,2-difluoro-1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1341970 CAPLUS
DOCUMENT NUMBER: 144:142010
TITLE: N-(Aryl)-4-(azolyethyl)thiazole-5-carboxamides: Novel potent inhibitors of VEGF receptors I and II
AUTHOR(S): Kiselyov, Alexander S.; Piatnitski, Evgueni; Semenova, Marina; Semenov, Victor V.
CORPORATE SOURCE: Small Molecule Drug Discovery, Chemical Diversity, Inc., San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(3), 602-606
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Novel potent derivs. of N-(aryl)-4-(azolyylethyl)thiazole-5-carboxamides are described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compds. display VEGFR-2 inhibitory activity reaching IC₅₀ < 100 nM in both enzymic and cellular assays. The compds. also inhibit the related tyrosine kinase, VEGFR-1. By controlling the substitution pattern on the 5-carboxamido pharmacophore, both dual and specific VEGFR-2 thiazoles were identified.


IT 267891-20-3 269390-77-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thiazole derivs. as novel potent inhibitors of VEGF receptors I and II)


RN 267891-20-3 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-3-quinolinyl- (9CI) (CA INDEX NAME)



RN 269390-77-4 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:953989 CAPLUS

DOCUMENT NUMBER: 143:242054

TITLE: Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor

INVENTOR(S): Siemeister, Gerhard

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: Eur. Pat. Appl., 40 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 1568368 A1 20050831 EP 2004-90071 20040226

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:

EP 2004-90071

20040226

OTHER SOURCE(S):

MARPAT 143:242054

AB Pharmaceutical combinations comprising a cyclin-dependent kinase (CDK) inhibitor and a vascular endothelial growth factor receptor (VEGF-R) inhibitor and their use for the treatment of different diseases are described. A CDK inhibitor and a VEGF-R inhibitor are used as a combined preparation simultaneously, sep. or sequentially. For example, a combination of a CDK inhibitor, i.e., N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide and a VEGF-R inhibitor, i.e., (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl]ammonium hydrogen succinate was evaluated in a human estrogen-independent mammary carcinoma model, xenografted in mice. The combination of both compds. at a dosing of 10 mg/kg i.p. once daily for the CDK inhibitor and 50 mg/kg per orally twice daily for the VEGF-R inhibitor showed a clear, synergistic or substantially greater, inhibition of tumor growth in comparison to monotherapy and the control group. The results show that a combination therapy using a CDK inhibitor and VEGF-R inhibitor was substantially superior in the efficacy of tumor growth inhibition as compared to monotherapy with the each of the sep. compds.


IT 267891-43-0 524941-35-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination comprising CDK inhibitor and VEGF receptor inhibitor for treatment or prophylaxis of various diseases)


RN 267891-43-0 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 524941-35-3 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:921402 CAPLUS

DOCUMENT NUMBER: 143:318365

TITLE: Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists

AUTHOR(S): Vasudevan, Anil; LaMarche, Matthew J.; Blackburn, Christopher; Che, Jennifer Lee; Luchaco-Cullis, Courtney A.; Lai, Sujen; Marsilje, Thomas H.; Patane, Michael A.; Souers, Andrew J.; Wodka, Derek; Geddes, Bradley; Chen, Sumiao; Brodjian, Seven; Falls, Doug H.; Dayton, Brian D.; Bush, Eugene; Brune, Michael; Shapiro, Robin D.; Marsh, Kennan C.; Hernandez, Lisa E.; Sham, Hing L.; Collins, Christine A.; Kym, Philip R.

CORPORATE SOURCE: Metabolic Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(19), 4174-4179


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB Several potent and efficacious MCHr1 antagonists containing an ortho-amino benzamide or nicotinamide chemotype have been identified, exemplified by compds. (I) and (II).

IT 865169-45-5P 865169-47-7P 865169-55-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists)


RN 865169-45-5 CAPLUS

CN Benzamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-2-[(cyclohexylmethyl)amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 865169-47-7 CAPLUS

CN Benzamide, 5-methoxy-2-[(5-pyrimidinylmethyl)amino]-N-[1-[(5-pyrimidinylmethyl)amino]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 865169-55-7 CAPLUS

CN Benzamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-5-methoxy-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2005:518952 CAPLUS

DOCUMENT NUMBER: 143:229720


TITLE: Preparation of aminobenzamides and aminopyridinecarboxamides with blood vessel growth inhibitory activity

INVENTOR(S): Sun, Zhuangrong; Tao, Hongguang
 PATENT ASSIGNEE(S): Nanjing Kaiheng Science and Trade Co., Ltd., Peop.
 Rep. China
 SOURCE: Faming Zhuanti Shenqing Gongkai Shuomingshu, No pp.
 given
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
CN 1502608	A	20040609	CN 2002-138671	20021127
PRIORITY APPLN. INFO.: GI			CN 2002-138671	20021127



I



II

AB Title compds. I [wherein X = O or S; Y = NH or alkylamino; Z1 - Z4 = CR5 or N; A, B = bond, alkylene; R1, Cy = cycloalk(en)yl; R2 = (halo)alkyl, alkenyl; V = C, N or SO2; W, W', R5 = H, halo, alkyl; n = 0-6; etc.], which have blood vessel growth inhibitory activity and can be used for the treatment of such as cancer, diabetes and autoimmune diseases (not data), were prepared For instance, benzamide II was synthesized from 1-phenylcyclobutanecarbonitrile, via (1) nitration with HNO3/H2SO4 in HOAc, (2) nitro reduction with H2/Pd/C, (3) EDCI-mediated coupling with o-aminobenzoic acid, and (4) reductive amination with 4-pyridinecarbaldehyde.


IT 811802-99-0P 811803-00-6P 811803-01-7P
 811803-02-8P 811803-13-1P 811803-15-3P
 862898-03-1P 862898-04-2P 862898-05-3P
 862898-06-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzamides and pyridinecarboxamides with blood vessel growth inhibitory activity)


RN 811802-99-0 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclobutyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 811803-00-6 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclopropyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-01-7 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-02-8 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclohexyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-13-1 CAPLUS

CN Benzamide, N-(1',2'-dihydro-2'-oxospiro[cyclopentane-1,3'-[3H]indol]-6'-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 811803-15-3 CAPLUS

CN Benzamide, N-(1',2'-dihydro-2'-oxospiro[cyclopropane-1,3'-[3H]indol]-6'-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862898-03-1 CAPLUS

CN Benzamide, N-[4-[1-(methoxymethyl)butyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862898-04-2 CAPLUS


CN Benzamide, N-[4-[1-(hydroxymethyl)butyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 862898-05-3 CAPLUS
 CN Benzamide, N-(4-ethynylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA
 INDEX NAME)





RN 862898-06-4 CAPLUS
 CN Benzamide, N-(3-ethynylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA
 INDEX NAME)



L4 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:29180 CAPLUS
 DOCUMENT NUMBER: 142:134597
 TITLE: Preparation of pyrazoles as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinase
 INVENTOR(S): Berdini, Valerio; O'Brien, Michael Alistair; Carr, Maria Grazia; Early, Theresa Rachel; Navarro, Eva Figueroa; Gill, Adrian Liam; Howard, Steven; Trewartha, Gary; Woolford, Alison Jo-Anne; Woodhead, Andrew James; Wyatt, Paul
 PATENT ASSIGNEE(S): Astex Technology Limited, UK
 SOURCE: PCT Int. Appl., 287 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002552	A2	20050113	WO 2004-GB2824	20040705
WO 2005002552	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2531050	AA	20050113	CA 2004-2531050	20040705
PRIORITY APPLN. INFO.:			GB 2003-15657	A 20030703
			US 2003-484685P	P 20030703
			GB 2003-24919	A 20031024
			US 2003-514374P	P 20031024
			WO 2004-GB2824	W 20040705
OTHER SOURCE(S):		MARPAT 142:134597		
GI				



AB The title compds. I [X = CR₅, N; A = a bond, (CH₂)_m(B)_n; B = C(O), NR_gC(O) or OC(O); R_g = H, alkyl (optionally substituted by hydroxy or alkoxy); m = 0-2; n = 0-1; R₀ = H or, together with NR_g when present, forms a group (CH₂)_p; p = 2-4; R₁ = H, carbocyclic or heterocyclic group having from 3 to 12 ring members, or (un)substituted alkyl; R₂ = H, halo, OMe, (un)substituted alkyl; R₃ and R₄ together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; R₅ = H, R₂, R₁₀ (wherein R₁₀ = halo, OH, CF₃, CN, NO₂, CO₂H, NH₂, mono- or dialkylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members)] which are inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and

Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases, were prepared and formulated. Thus, reacting benzoic acid with 3-(1H-benzimidazol-2-yl)-1H-pyrazol-4-ylamine in the presence of EDC and HOBt in DMF afforded 30% II which has IC50 of < 10 µM or provides at least 50% inhibition of the CDK2 activity at a concentration of 10 µM.


IT 825618-49-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoles as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinase)

RN 825618-49-3 CAPLUS

CN Benzamide, N-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1127340 CAPLUS

DOCUMENT NUMBER: 142:74461

TITLE: Preparation of pyridonylemethyl anthranilamides as inhibitors of vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3.

INVENTOR(S): Huth, Andreas; Krueger, Martin; Zorn, Ludwig; Ince, Stuart; Bohlmann, Rolf; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin; Hess-Stumpp, Holger

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111005	A1	20041223	WO 2004-EP6236	20040609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10327719	A1	20050120	DE 2003-10327719	20030613
CA 2526041	AA	20041223	CA 2004-2526041	20040609
EP 1633713	A1	20060315	EP 2004-739742	20040609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2005049281	A1	20050303	US 2004-866078	20040614
PRIORITY APPLN. INFO.:			DE 2003-10327719	A 20030613
			US 2003-482009P	P 20030625
			WO 2004-EP6236	W 20040609

OTHER SOURCE(S): MARPAT 142:74461
GI




AB Title compds. (I; A = aryl, heteroaryl; X = H, F; R1, R2 = H, halo, alkyl, alkoxyalkyl, haloalkyl, cycloalkyl, halocycloalkyl; Y = bond, O, S, SO₂), were prepared. Thus, 2-[(6-oxo-1,6-dihydropyridin-3-ylmethyl)amino]benzoic acid (preparation given), N-methylmorpholine, 4-trifluoromethoxyaniline, and HATU were stirred 2.5 h in CH₂Cl₂ at room temp and 1.5 h at 100° bath temperature to give 50.1% 2-[(6-oxo-1,6-dihydropyridin-3-ylmethyl)amino]-N-(4-trifluoromethoxyphenyl)benzamide. The latter inhibited VEGFR II with IC₅₀ = 180 nM. The invention relates to selected anthranilamide pyridones that inhibit VEGFR-2 and VEGFR-3 and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis.

IT 811805-13-7P 811805-18-2P 811805-22-8P
811805-26-2P 811805-30-8P 811805-34-2P
811805-39-7P 811805-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridonylethyl anthranilamides as inhibitors of vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3)


RN 811805-13-7 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 811805-18-2 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 811805-22-8 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 811805-26-2 CAPLUS

CN Benzamide, N-(4-butoxyphenyl)-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 811805-30-8 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 811805-34-2 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-methoxy-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 811805-39-7 CAPLUS

CN Benzamide, N-[3-bromo-4-(trifluoromethoxy)phenyl]-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 811805-44-4 CAPLUS

CN Benzamide, N-[4-(difluoromethoxy)phenyl]-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

10615809.trn

ACCESSION NUMBER: 2004:1127100 CAPLUS
 DOCUMENT NUMBER: 142:74456
 TITLE: Preparation of six membered amino-amide derivatives an
 angiogenesis inhibitors
 INVENTOR(S): Chen, Guoqing P.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004259916	A1	20041223	US 2004-859733	20040602
WO 2005000232	A2	20050106	WO 2004-US17915	20040604
WO 2005000232	A3	20050428		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1633712	A2	20060315	EP 2004-754512	20040604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:

US 2003-478937P	P	20030616
US 2004-859733	A	20040602
WO 2004-US17915	W	20040604

OTHER SOURCE(S): MARPAT 142:74456
 GI



AB Title compds. I [X = O, S; Y = NR₄; Z = independently CR₅, N; A = bond, alkylenyl, alkenylenyl; B = bond, alkylenyl, etc.; R₁ = cycloalk(en)yl, heterocyclyl, etc.; Cy = cycloalk(en)yl, heterocyclyl; R₂ = haloalkyl, alkyl, alkenyl, etc.; V = C, N, SO₂; W, W' = H, halo, alkyl, etc.; n = 0-6; R₃ = heterocyclyl, aryl; R₄ = H, alkyl; R₅ = H, halo, alkyl] are prepared For instance, N-[4-(1-cyanocyclobutyl)phenyl]-2-[(pyridin-4-yl)methyl]aminobenzene-carboxamide is prepared in 3 steps from 1-phenylcyclobutanecarbonitrile, anthranilic acid and 4-

pyridylformaldehyde. In a cell proliferation assay, all example compds. show IC50 = 10-100 nM. I are useful in the treatment of the treatment of disease states associated with angiogenesis and/or increased vascular permeability.


IT 811802-99-0P 811803-00-6P 811803-01-7P
811803-02-8P 811803-07-3P 811803-09-5P
811803-13-1P 811803-15-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of six membered amino-amide derivs. an angiogenesis inhibitors)


RN 811802-99-0 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclobutyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-00-6 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclopropyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-01-7 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-02-8 CAPLUS

CN Benzamide, N-[4-(1-cyanocyclohexyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 811803-07-3 CAPLUS

CN Benzamide, N-[4-[1-(methoxymethyl)cyclobutyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 811803-09-5 CAPLUS

CN Benzamide, N-[4-[1-(hydroxymethyl)cyclobutyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 811803-13-1 CAPLUS

CN Benzamide, N-(1',2'-dihydro-2'-oxospiro[cyclopentane-1,3'-[3H]indol]-6'-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 811803-15-3 CAPLUS

CN Benzamide, N-(1',2'-dihydro-2'-oxospiro[cyclopropane-1,3'-[3H]indol]-6'-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:839017 CAPLUS

DOCUMENT NUMBER: 142:311699

TITLE: Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors
 AUTHOR(S): Mol, Clifford D.; Fabbro, Dorian; Hosfield, David J.
 CORPORATE SOURCE: Syrrx Inc, La Jolla, CA, 92121, USA
 SOURCE: Current Opinion in Drug Discovery & Development (2004), 7(5), 639-648
 CODEN: CODDDF; ISSN: 1367-6733

PUBLISHER: Thomson Scientific

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. STI-571 (Gleevec) is a highly successful cancer drug due to its activity as an inhibitor of the Abelson cytoplasmic tyrosine kinase (Abl), which is constitutively active in a majority of patients with chronic myelogenous leukemia. STI-571 also inhibits two type III receptor tyrosine kinases, c-Kit and platelet-derived growth factor receptor, and functions by targeting inactive conformations of these kinases. This review focuses on recent developments in x-ray co-crystal structure analyses of STI-571 bound to Abl and the c-Kit receptor tyrosine kinase domain, and also three other relevant kinase inhibitor co-crystal structures. The similar structural features of these inactive kinases suggest they will be useful for the successful drug discovery and development of specific and targeted gene-based cancer drugs.

IT 269390-77-4, AAL-993

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structural insights into the conformational selectivity of STI-571 and related kinase inhibitors)

RN 269390-77-4 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:515506 CAPLUS

DOCUMENT NUMBER: 141:71453

TITLE: Preparation of anthranilic acid amide derivatives as
neoplastic inhibitors

INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052884	A1	20040624	WO 2003-EP14086	20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2506164	AA	20040624	CA 2003-2506164	20031211
AU 2003294834	A1	20040630	AU 2003-294834	20031211
EP 1572686	A1	20050914	EP 2003-785795	20031211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017292	A	20051108	BR 2003-17292	20031211
PRIORITY APPLN. INFO.:			GB 2002-29022	A 20021212
			WO 2003-EP14086	W 20031211
OTHER SOURCE(S):			MARPAT 141:71453	
GI				



AB The title compds. I [wherein R and R0 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R1 = H, halo, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, OCF3, OCH2CF3, OCH2CH2CF3, or OCH2CH2CH2CF3; R2 = perfluoroalkyl; R3 = H or halo; X = OH, alkoxy, alkylthio, imino, alkylimino, halo, etc.; Z = N or CH] or salts, N-oxides, or tautomers thereof are prepared as neoplastic inhibitors for the treatment of human or animal body. For example, the compound II was prepared in a multi-step synthesis. Formulations containing I as an active ingredient were also described.


IT 524728-97-0P 524729-01-9P 657401-06-4P
 709044-84-8P 709044-87-1P 709044-88-2P
 709044-93-9P 709044-99-5P 709045-02-3P
 709045-04-5P 709045-05-6P 709045-08-9P
 709045-10-3P 709045-11-4P 709045-28-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate, reactant; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)


RN 524728-97-0 CAPLUS

CN Benzamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 524729-01-9 CAPLUS

CN Benzamide, 2-[[6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657401-06-4 CAPLUS

CN Benzamide, 2-[[2-bromo-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-84-8 CAPLUS

CN Benzamide, N-[2-fluoro-3-(trifluoromethyl)phenyl]-2-[[6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 709044-87-1 CAPLUS

CN Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 709044-88-2 CAPLUS


CN Benzamide, 2-[[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 709044-93-9 CAPLUS

CN Benzamide, 2-[[[2-(1-ethoxyethenyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-99-5 CAPLUS

CN Benzamide, 2-[[[(5-bromo-6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-02-3 CAPLUS

CN Benzamide, 2-[[[(6-methoxy-5-phenyl-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-04-5 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(2-propenyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-05-6 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-propyl-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-08-9 CAPLUS

CN Benzamide, 2-[[[5-(ethylamino)-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-10-3 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[[2-(4-methyl-1-piperazinyl)ethyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-11-4 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[[2-(4-methyl-1-piperazinyl)-2-oxoethyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A



RN 709045-28-3 CAPLUS

CN Benzamide, 2-[[[6-methoxy-3-pyridinyl)methyl]amino]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 709044-83-7P 709044-89-3P 709044-90-6P
 709044-91-7P 709044-92-8P 709044-94-0P
 709044-95-1P 709044-97-3P 709045-01-2P
 709045-03-4P 709045-06-7P 709045-07-8P
 709045-09-0P 709045-12-5P 709045-13-6P
 709045-17-0P 709045-21-6P 709045-32-9P
 709045-33-0P 709045-34-1P 709045-37-4P
 709045-38-5P 709045-39-6P 709045-40-9P
 709045-42-1P 709045-43-2P 709045-44-3P
 709045-45-4P 709045-46-5P 709045-47-6P
 709045-48-7P 709045-49-8P 709045-50-1P
 709045-51-2P 709045-52-3P 709045-53-4P
 709045-54-5P 709045-55-6P 709045-56-7P
 709045-57-8P 709045-58-9P 709045-59-0P
 709045-60-3P 709045-61-4P 709045-62-5P
 709045-63-6P 709045-64-7P 709045-65-8P
 709045-66-9P 709045-67-0P 709045-68-1P
 709045-69-2P 709045-70-5P 709045-71-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)


RN 709044-83-7 CAPLUS

CN Benzamide, 2-[[[2-methoxy-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-89-3 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-90-6 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-91-7 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[2-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-92-8 CAPLUS

CN Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 709044-94-0 CAPLUS

CN Benzamide, 2-[[[(2-acetyl-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709044-95-1 CAPLUS

CN Benzamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 709044-97-3 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-01-2 CAPLUS

CN Benzamide, 2-[[[(5-bromo-1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-03-4 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-5-phenyl-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-06-7 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-5-(2-propenyl)-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-07-8 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-propyl-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 709045-09-0 CAPLUS


CN Benzamide, 2-[[[5-(ethylamino)-1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-12-5 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-5-[[2-(4-methyl-1-piperazinyl)ethyl]amino]-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 709045-13-6 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-17-0 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-[(4-ethyl-1-piperazinyl)methyl]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-21-6 CAPLUS

CN Benzamide, N-[3-(1-azetidinylmethyl)-5-(trifluoromethyl)phenyl]-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 709045-32-9 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-33-0 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-[[2-(dimethylamino)ethyl]methylamino]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-34-1 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(2-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-37-4 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-38-5 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[2-fluoro-4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-39-6 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-40-9 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(trifluoromethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-42-1 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(3-thienyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-43-2 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-(3-thienyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 709045-44-3 CAPLUS


CN Benzamide, 2-[[[5-[1,1'-biphenyl]-3-yl]-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 709045-45-4 CAPLUS


CN Benzamide, 2-[[[5-[1,1'-biphenyl]-3-yl]-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

NAME)




RN 709045-46-5 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(2-naphthalenyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-47-6 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-5-(2-naphthalenyl)-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-48-7 CAPLUS

CN Benzamide, 2-[[[5-[3-(acetylamino)phenyl]-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-49-8 CAPLUS

CN Benzamide, 2-[[[5-[3-(acetylamino)phenyl]-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-50-1 CAPLUS

CN Benzamide, 2-[[[5-(4-formylphenyl)-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-51-2 CAPLUS

CN Benzamide, 2-[[[5-(4-formylphenyl)-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-52-3 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[3-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-53-4 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-[3-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-54-5 CAPLUS

CN Benzamide, 2-[[[2'-methoxy[2,3'-bipyridin]-5'-yl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-55-6 CAPLUS

CN Benzamide, 2-[[[1',2'-dihydro-2'-oxo[2,3'-bipyridin]-5'-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-56-7 CAPLUS

CN Benzamide, 2-[[[5-(2-furanyl)-6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-57-8 CAPLUS

CN Benzamide, 2-[[[5-(2-furanyl)-1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-58-9 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(2-thiazolyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-59-0 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-(2-thiazolyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-60-3 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(3-methyl-2-butenyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-61-4 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[(phenylmethyl)amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-62-5 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-[(phenylmethyl)amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-63-6 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-64-7 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-[[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-65-8 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[[2-(4-morpholinyl)ethyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-66-9 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-5-[[2-(4-morpholinyl)ethyl]amino]-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-67-0 CAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[[3-(4-methyl-1-piperazinyl)propyl]amino]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 709045-68-1 CAPLUS


CN Benzamide, 2-[[[1,6-dihydro-5-[[3-(4-methyl-1-piperazinyl)propyl]amino]-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 709045-69-2 CAPLUS

CN Benzamide, 2-[[[1,6-dihydro-5-[[2-(4-methyl-1-piperazinyl)-2-oxoethyl]amino]-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 709045-70-5 CAPLUS
 CN Benzamide, 2-[[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(1-piperidinylmethyl)-5-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)



RN 709045-71-6 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(1-piperidinylmethyl)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 709045-22-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)

RN 709045-22-7 CAPLUS

CN Benzamide, N-[3-(1-azetidinylmethyl)-5-(trifluoromethyl)phenyl]-2-[[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:498151 CAPLUS

DOCUMENT NUMBER: 141:206897

TITLE: Solid-Phase Synthesis of an Alkylaminobenzanilide Library

AUTHOR(S): El-Araby, Moustafa; Guo, Helen; Pottorf, Richard S.; Player, Mark R.

CORPORATE SOURCE: 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA

SOURCE: Journal of Combinatorial Chemistry (2004), 6(5), 789-795

CODEN: JCCHFF; ISSN: 1520-4766

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:206897

AB The synthesis of a library of 2- and 3-substituted benzanilides has been achieved on solid phase. Attachment of anilines to formyldimethoxyphenyl (FDMP) resin via reductive amination was optimized to allow a wide range of anilines to be used. Acylation of this resin-bound aniline was accomplished with 2- or 3-nitrobenzoyl chloride to yield nitrobenzanilides. Following reduction of the nitro group, the resulting amine was alkylated using aromatic and heteroarom. aldehydes in the presence of NaBH(OAc)₃ under controlled conditions. Finally, the products were cleaved from the resin using trifluoroacetic acid to produce a 10 800-member library.

IT 743354-79-2P 743354-81-6P 743354-82-7P

743354-83-8P 743354-85-0P 743354-86-1P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(solid-phase synthesis of an alkylaminobenzanilide library)


RN 743354-79-2 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[[(4-ethylphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 819850-48-1


CMF C22 H21 Cl N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 743354-81-6 CAPLUS

CN Benzamide, N-[4-(cyanomethyl)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]-5-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 819850-51-6


CMF C23 H20 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 743354-82-7 CAPLUS


CN 2-Propenoic acid, 3-[4-[[2-[[2-(2-bromophenyl)methyl]amino]-5-

fluorobenzoyl]amino]phenyl]-, ethyl ester, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 819850-79-8


CMF C25 H22 Br F N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 743354-83-8 CAPLUS

CN Benzamide, N-[4-(4-morpholinyl)phenyl]-2-[(phenylmethyl)amino]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 819850-82-3


CMF C24 H25 N3 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 743354-85-0 CAPLUS
 CN Benzamide, 2-[[(2-chloro-3-quinolinyl)methyl]amino]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 819850-85-6
 CMF C25 H19 Cl F N3 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 743354-86-1 CAPLUS
 CN Benzamide, 2-[[(2,3-dimethoxyphenyl)methyl]amino]-N-(2'-methoxy[1,1'-biphenyl]-4-yl)-5-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 819850-86-7
 CMF C30 H30 N2 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:216609 CAPLUS

DOCUMENT NUMBER: 140:417028

TITLE: Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

AUTHOR(S): Manley, Paul William; Bold, Guido; Brueggen, Josef; Fendrich, Gabrielle; Furet, Pascal; Mestan, Jurgen; Schnell, Christian; Stolz, Barbara; Meyer, Thomas; Meyhack, Bernd; Stark, Wilhelm; Strauss, Andre; Wood, Jeanette

CORPORATE SOURCE: Novartis Institutes of Biomedical Research, Basel, CH-4002, Switz.

SOURCE: Biochimica et Biophysica Acta, Proteins and Proteomics (2004), 1697(1-2), 17-27
CODEN: BBAPBW; ISSN: 1570-9639

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Initial studies with angiogenesis inhibitors showed little clin. benefit. However, recently reported clin. studies in colorectal cancer have shown that bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with cytotoxic therapy has pos. effects on patient survival. Furthermore, the VEGF receptor kinase (VEGF-R) tyrosine kinase inhibitor, vatalanib, has also shown encouraging results in colorectal cancer, with mol. resonance imaging providing evidence that the anti-tumor efficacy was indeed the result of anti-angiogenic activity. Both of these agents are progressing in phase III trials. This proof of concept has stimulated the desire for


second-generation VEGF-R inhibitors having an improved profile. Structural biol. insight regarding the binding mode of protein kinase inhibitors is valuable for the design of mols. possessing superior selectivity, efficacy and tolerability. Towards this goal, the authors have developed a new series of VEGF-R2 kinase inhibitors, based upon an anthranilic acid amide scaffold. An x-ray crystal structure of a representative compound, AAL993 (ZK260253), in complex with the catalytic domain of diphosphorylated VEGF-R2 has revealed that this mol. binds to an inactive conformation of the protein. This binding mode, similar to that observed for the anti-leukemia drug, imatinib in complex with c-Abl kinase, may be responsible for the high selectivity of AAL993 and provides valuable insight for the design of further compds.

IT 269390-77-4, AAL 993

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (advances in structural biol. and design and clin. development of vascular endothelial growth factor receptor (VEGF-R) kinase inhibitors for treatment of angiogenesis)

RN 269390-77-4 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:182368 CAPLUS

DOCUMENT NUMBER: 140:229401

TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands

INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304


US 2001-336962P P 20011203
 WO 2002-US6677 A2 20020304
 US 2002-234985 A2 20020903
 WO 2002-US33052 A2 20021015
 US 2003-460921P P 20030407
 US 2003-531872P P 20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

IT 269390-69-4D, conjugates 381694-53-7D, conjugates
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)


RN 269390-69-4 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 381694-53-7 CAPLUS

CN Benzamide, N-(2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:120827 CAPLUS

DOCUMENT NUMBER: 140:181330

TITLE: Preparation of anthranilamidopyridines as inhibitors of vascular endothelial growth factor receptor-2 and -3 (VEGFR-2 and -3).

INVENTOR(S): Huth, Andreas; Krueger, Martin; Zorn, Ludwig; Ince, Stuart; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin; Hess-Stump, Holger

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 88 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013102	A1	20040212	WO 2003-EP7964	20030722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10235690	A1	20040219	DE 2002-10235690	20020731
DE 10328036	A1	20050105	DE 2003-10328036	20030619
CA 2493026	AA	20040212	CA 2003-2493026	20030722
AU 2003281855	A1	20040223	AU 2003-281855	20030722
BR 2003013122	A	20050705	BR 2003-13122	20030722
CN 1671666	A	20050921	CN 2003-818334	20030722
EP 1594841	A1	20051116	EP 2003-740470	20030722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538112	T2	20051215	JP 2004-525272	20030722
US 2004147535	A1	20040729	US 2003-631018	20030731
US 2005054654	A1	20050310	US 2004-870491	20040618
NO 2005001035	A	20050429	NO 2005-1035	20050225
PRIORITY APPLN. INFO.:			DE 2002-10235690	A 20020731
			DE 2003-10328036	A 20030619
			US 2003-483896P	P 20030702
			WO 2003-EP7964	W 20030722
OTHER SOURCE(S):		MARPAT 140:181330		
GI				



AB Title compds. [I; X = CH, N; W = H, F; A, B, D, E, Q = N, C; ≤2 of A, B, D, E, Q = N; R1 = (substituted) aryl, heteroaryl; Y, Z = bond, CO, CS, SO₂; R₂, R₃ = H, CONR₉R₁₀, SO₂R₆, COR₁₁, NR₉R₁₀, (substituted) alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; R₂YNZAR₃ = atoms to form a 3-8 membered (substituted) (unsatd.) ring; R₆ = H, alkyl, haloalkyl, (substituted) aryl, heteroaryl, NR₉R₁₀; R₉, R₁₀ = H, alkyl, alkenyl, aryl, cycloalkyl, etc.; R₁₁ = alkyl, alkoxy, hydroxyalkyl, hydroxyalkoxy, cycloalkyl, (substituted) Ph, pyridyl, biphenyl, naphthyl], were prepared Thus, 2-[(2-bromopyridin-4-ylmethyl)amino]-N-(3-

trifluoromethylphenyl)benzamide (preparation given) pyridine, and N,N-dimethylaminoethylamine were heated in a pressure vessel for 5 h at 200° to give 2-[[2-(2-dimethylaminoethylamino)pyridin-4-ylmethyl]amino]-N-(3-trifluoromethylphenyl)benzamide. I inhibited VEGFR-2 with IC50 = 8-65 nM. I can be used for treatment of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, hemangioma, angiofibroma, eye disease, renal diseases, transplant rejection, fibrotic diseases, mesangial cell proliferative diseases, atherosclerosis, injuries to nervous tissue and for inhibition of the reocclusion of vessels after balloon catheter treatment, in vessel prosthetics, or after the application of mech. devices to hold open vessels, as immunosuppressants, for scar-free wound healing, age spots and contact dermatitis.

IT 657399-79-6P, 2-[[2-(2-Dimethylaminoethylamino)pyridin-4-ylmethyl]amino]-N-(3-trifluoromethylphenyl)benzamide 657399-80-9P


657399-81-0P 657399-82-1P 657399-83-2P
 657399-84-3P 657399-85-4P 657399-87-6P
 657399-88-7P 657399-89-8P 657399-90-1P
 657399-91-2P 657399-92-3P 657399-93-4P
 657399-94-5P 657399-95-6P 657399-96-7P
 657399-97-8P 657399-98-9P 657399-99-0P
 657400-00-5P 657400-01-6P 657400-02-7P
 657400-03-8P 657400-04-9P 657400-05-0P
 657400-06-1P 657400-07-2P 657400-08-3P
 657400-09-4P 657400-10-7P 657400-11-8P
 657400-12-9P 657400-13-0P 657400-14-1P
 657400-15-2P 657400-16-3P 657400-17-4P
 657400-18-5P 657400-19-6P 657400-20-9P
 657400-21-0P 657400-22-1P 657400-23-2P
 657400-24-3P 657400-25-4P 657400-26-5P
 657400-27-6P 657400-28-7P 657400-29-8P
 657400-30-1P 657400-31-2P 657400-32-3P
 657400-33-4P 657400-34-5P 657400-35-6P
 657400-36-7P 657400-37-8P 657400-38-9P
 657400-39-0P 657400-40-3P 657400-41-4P
 657400-42-5P 657400-43-6P 657400-44-7P
 657400-45-8P 657400-46-9P 657400-47-0P
 657400-48-1P 657400-49-2P 657400-50-5P
 657400-51-6P 657400-52-7P 657400-53-8P
 657400-54-9P 657400-55-0P 657400-56-1P
 657400-57-2P 657400-58-3P 657400-59-4P
 657400-60-7P 657400-61-8P 657400-62-9P
 657400-63-0P 657400-64-1P 657400-65-2P
 657400-66-3P 657400-67-4P 657400-68-5P
 657400-69-6P 657400-70-9P 657400-71-0P
 657400-72-1P 657400-73-2P 657400-74-3P
 657400-75-4P 657400-76-5P 657400-77-6P
 657400-78-7P 657400-79-8P 657400-80-1P
 657400-81-2P 657400-82-3P 657400-83-4P
 657400-84-5P 657400-85-6P 657400-86-7P
 657400-87-8P 657400-88-9P 657400-89-0P
 657400-90-3P 657400-91-4P 657400-92-5P
 657400-93-6P 657400-94-7P 657400-95-8P
 657400-96-9P 657400-97-0P 657400-98-1P
 657400-99-2P 657401-00-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anthranilylamidopyridines as inhibitors of vascular endothelial growth factor receptor)


RN 657399-79-6 CAPLUS

CN Benzamide, 2-[[[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-80-9 CAPLUS

CN Benzamide, 2-[[[2-[(2-hydroxyethyl)amino]-4-pyridinyl]methyl]amino]-N-3-isoquinoliny- (9CI) (CA INDEX NAME)




RN 657399-81-0 CAPLUS

CN Benzamide, 2-[[[2-[(3-hydroxypropyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-82-1 CAPLUS

CN Benzamide, 2-[[[2-[(4-hydroxybutyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657399-83-2 CAPLUS


CN Benzamide, 2-[[[2-[(5-hydroxypentyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657399-84-3 CAPLUS

CN Benzamide, 2-[[[2-[(2S)-2-hydroxypropyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 657399-85-4 CAPLUS

CN Benzamide, 2-[[[2-[(2R)-2-hydroxypropyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 657399-87-6 CAPLUS


CN Benzamide, 2-[[[2-[[[1S]-2-hydroxy-1-methylethyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 657399-88-7 CAPLUS

CN Benzamide, 2-[[[2-[[[3-(dimethylamino)propyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-89-8 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-(4-morpholinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657399-90-1 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657399-91-2 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-(4-thiomorpholinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 657399-92-3 CAPLUS



CN Benzamide, N-3-isoquinolinyl-2-[[[2-(1-pyrrolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 657399-93-4 CAPLUS


CN Benzamide, 2-[[[2-amino-4-pyridinyl]methyl]amino]-N-[3-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-94-5 CAPLUS

CN Benzamide, 2-[[[(2-amino-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI)
(CA INDEX NAME)




RN 657399-95-6 CAPLUS

CN Benzamide, 2-[[[(2-amino-4-pyridinyl)methyl]amino]-N-1H-indazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 657399-96-7 CAPLUS

CN Benzamide, 2-[[[(2-amino-4-pyridinyl)methyl]amino]-N-(2-methyl-2H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 657399-97-8 CAPLUS

CN Benzamide, 2-[[[2-[[[(phenylmethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-98-9 CAPLUS

CN Benzamide, 2-[[[2-[[[(phenylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657399-99-0 CAPLUS

CN Benzamide, 2-[[[2-[[[(2-phenylethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-00-5 CAPLUS

CN Benzamide, 2-[[[2-[[[(butylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 657400-01-6 CAPLUS

CN Benzamide, N-[3-(trifluoromethyl)phenyl]-2-[[[2-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI)
(CA INDEX NAME)




RN 657400-02-7 CAPLUS

CN Benzamide, N-[3-(trifluoromethyl)phenyl]-2-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-(9CI) (CA INDEX NAME)




RN 657400-03-8 CAPLUS

CN Benzamide, N-[3-(trifluoromethyl)phenyl]-2-[[[2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-(9CI) (CA INDEX NAME)




RN 657400-04-9 CAPLUS

CN Benzamide, 2-[[[2-[[[(ethylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-05-0 CAPLUS

CN Benzamide, 2-[[[2-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-06-1 CAPLUS

CN Benzamide, 2-[[[2-[[[(1-naphthalenylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-07-2 CAPLUS

CN Benzamide, 2-[[[2-[[[(methalamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-08-3 CAPLUS

CN Benzamide, 2-[[[2-[[[(2-chloroethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-09-4 CAPLUS

CN Benzamide, 2-[[[2-[[[(propylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-10-7 CAPLUS

CN Benzamide, 2-[[[2-[[[(1-methylethylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-11-8 CAPLUS


CN Benzamide, 2-[[[2-[[[(cyclopentylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-12-9 CAPLUS
 CN Benzamide, 2-[[[2-[[[(aminocarbonyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657400-13-0 CAPLUS
 CN Benzamide, N-3-isoquinoliny-2-[[[2-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-14-1 CAPLUS
 CN Benzamide, N-3-isoquinoliny-2-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-15-2 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-16-3 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[phenylamino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-17-4 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[1-naphthalenylamino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-18-5 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[(phenylmethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-19-6 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[(2-phenylethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-20-9 CAPLUS

CN Benzamide, 2-[[[2-[[[(2-chloroethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-21-0 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-22-1 CAPLUS

CN Benzamide, 2-[[[2-[[[(cyclopentylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-23-2 CAPLUS

CN Benzamide, 2-[[[2-[[[(aminocarbonyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-24-3 CAPLUS

CN Benzamide, 2-[[[2-[[[(dimethylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinoliny]- (9CI) (CA INDEX NAME)




RN 657400-25-4 CAPLUS

CN Benzamide, 2-[[[2-[(aminocarbonyl)amino]-4-pyridinyl]methyl]amino]-N-3-isoquinoliny]- (9CI) (CA INDEX NAME)




RN 657400-26-5 CAPLUS

CN Benzamide, N-1H-indazol-6-yl-2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinoliny]- (9CI) (CA INDEX NAME)




RN 657400-27-6 CAPLUS

CN Benzamide, 2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(1-methyl-1H-indazol-6-yl)]- (9CI) (CA INDEX NAME)




RN 657400-28-7 CAPLUS

CN Benzamide, 2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(2-methyl-2H-indazol-6-yl)]- (9CI) (CA INDEX NAME)




RN 657400-29-8 CAPLUS


CN Benzamide, N-[1-(2-methoxyethyl)-1H-indazol-5-yl]-2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-30-1 CAPLUS
 CN Benzamide, N- (1-ethyl-1H-indazol-5-yl)-2-[[[2-
 [[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX
 NAME)



RN 657400-31-2 CAPLUS
 CN Benzamide, 2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-
 N-[1-(2-propynyl)-1H-indazol-5-yl]]- (9CI) (CA INDEX NAME)




RN 657400-32-3 CAPLUS
 CN Benzamide, 2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-
 N-(2-methyl-2H-indazol-5-yl)]- (9CI) (CA INDEX NAME)




RN 657400-33-4 CAPLUS

CN Benzamide, 2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(1-methyl-1H-indazol-5-yl)]- (9CI) (CA INDEX NAME)




RN 657400-34-5 CAPLUS

CN Benzamide, 2-[[[2-[[[(cyclopropylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(1-methyl-1H-indazol-6-yl)]- (9CI) (CA INDEX NAME)




RN 657400-35-6 CAPLUS

CN Benzamide, 2-[[[2-[[[(cyclopropylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(2-methyl-2H-indazol-5-yl)]- (9CI) (CA INDEX NAME)




RN 657400-36-7 CAPLUS

CN Benzamide, N-[1-(2-methoxyethyl)-1H-indazol-6-yl]-2-[[[2-[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-37-8 CAPLUS

CN Benzamide, 2-[[[2-[(methylsulfonyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 657400-38-9 CAPLUS


CN Benzamide, 2-[[[2-[(phenylsulfonyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-39-0 CAPLUS
 CN Benzamide, 2-[[[2-[[[5-methyl-2-pyridinyl]sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657400-40-3 CAPLUS
 CN Benzamide, 2-[[[2-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-41-4 CAPLUS
 CN Benzamide, N-[3-(trifluoromethyl)phenyl]-2-[[[2-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-42-5 CAPLUS

CN Benzamide, N-3-isoquinoliny-2-[[[2-[(methylsulfonyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-43-6 CAPLUS

CN Benzamide, 2-[[[2-[[[3,4-difluorophenyl]sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-44-7 CAPLUS

CN Benzamide, 2-[[[2-[[[4-(phenylmethoxy)phenyl]sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-45-8 CAPLUS

CN Benzamide, 2-[[[2-[[[(5-chloro-2-thienyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-46-9 CAPLUS

CN Benzamide, 2-[[[2-[[[(5-chloro-2-thienyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



RN 657400-47-0 CAPLUS


CN Benzamide, 2-[[[2-[[[(4-methylphenyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657400-48-1 CAPLUS


CN Benzamide, 2-[[[2-[[[(phenylmethyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

NAME)




RN 657400-49-2 CAPLUS

CN Benzamide, N-1H-indazol-5-yl-2-[[[2-[(phenylsulfonyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-50-5 CAPLUS

CN Benzamide, N-1H-indazol-5-yl-2-[[[2-[[[4-methylphenyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-51-6 CAPLUS

CN Benzamide, 2-[[[2-[bis(methylsulfonyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-52-7 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[(1-oxobutyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-53-8 CAPLUS

CN Benzamide, 2-[[[2-[(1-oxobutyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-54-9 CAPLUS

CN Benzamide, 2-[[[2-(acetamido)-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-55-0 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[(1-oxopropyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-56-1 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[(1-oxopentyl)amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-57-2 CAPLUS

CN Benzamide, 2-[[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-58-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 657400-59-4 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-[[4-(2-methylpropyl)benzoyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-60-7 CAPLUS

CN Benzamide, 2-[[[2-[[4-(1,1-dimethylethyl)benzoyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-61-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 657400-62-9 CAPLUS

CN Benzamide, 2-[[[2-[(2,2-dimethyl-1-oxopropyl)amino]-4-pyridinyl]methyl]amino]-N-3-isoquinoliny- (9CI) (CA INDEX NAME)




RN 657400-63-0 CAPLUS

CN Benzamide, 2-[[[2-[[4-(1,1-dimethylethyl)benzoyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-64-1 CAPLUS

CN Benzamide, 2-[[[2-(acetylamino)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-65-2 CAPLUS

CN Benzamide, 2-[[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]methyl]amino]-N-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 657400-66-3 CAPLUS

CN Benzamide, 2-[[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]methyl]amino]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




RN 657400-67-4 CAPLUS

CN Benzamide, 2-[[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]methyl]amino]-N-(2-methyl-2H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 657400-68-5 CAPLUS

CN Benzamide, 2-[[[2-[(5-hydroxy-1-oxopentyl)amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-69-6 CAPLUS

CN Carbamic acid, [4-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 657400-70-9 CAPLUS

CN Carbamic acid, [4-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 657400-71-0 CAPLUS

CN Carbamic acid, [4-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 657400-72-1 CAPLUS

CN Carbamic acid, [4-[[[2-[(1H-indazol-5-ylamino)carbonyl]phenyl]amino]methyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 657400-73-2 CAPLUS

CN Carbamic acid, [4-[[[2-[[[2-methyl-2H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 657400-74-3 CAPLUS

CN Benzamide, 2-[[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-75-4 CAPLUS

CN Benzamide, 2-[[[2-[(2,2-dimethyl-1-oxopropyl)amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-76-5 CAPLUS

CN Benzamide, 2-[[[2-[(2-hydroxyethoxy)acetyl]amino]-4-pyridinyl]methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-77-6 CAPLUS

CN Benzamide, 2-[[[2-(acetylmethylamino)-4-pyridinyl]methyl]amino]-N-3-isoquinoliny]- (9CI) (CA INDEX NAME)




RN 657400-78-7 CAPLUS

CN Benzamide, 2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-79-8 CAPLUS

CN Benzamide, N-3-isoquinoliny]-2-[[[2-(2-oxo-3-oxazolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-80-1 CAPLUS

CN Benzamide, 2-[[[2-(2-oxo-1-imidazolidinyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-81-2 CAPLUS

CN Benzamide, 2-[[[2-(3-methyl-2-oxo-1-imidazolidinyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-82-3 CAPLUS


CN Benzamide, N-3-isoquinolinyl-2-[[[2-(2-oxo-1-imidazolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-83-4 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 657400-84-5 CAPLUS
 CN Benzamide, N-1H-indazol-5-yl-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-85-6 CAPLUS
 CN Benzamide, N-1H-indazol-6-yl-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 657400-86-7 CAPLUS


CN Benzamide, 2-[[[2-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 657400-87-8 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-(tetrahydro-5-oxo-1,4-oxazepin-4(5H)-yl)-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-88-9 CAPLUS

CN Benzamide, 2-[[[2-(5-hydroxy-2-oxo-1-piperidinyl)-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 657400-89-0 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[2-oxo[1(2H),2'-bipyridin]-4'-yl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-90-3 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-oxo[1(2H),2'-bipyridin]-4'-yl)methyl]amino]-N-3-isoquinoliny]- (9CI) (CA INDEX NAME)




RN 657400-91-4 CAPLUS

CN Benzamide, N-(1-methyl-1H-indazol-6-yl)-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-92-5 CAPLUS

CN Benzamide, N-(2-methyl-2H-indazol-6-yl)-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-93-6 CAPLUS

CN Benzamide, N-(2-methyl-2H-indazol-5-yl)-2-[[[2-(2-oxo-1-pyrrolidinyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-94-7 CAPLUS

CN Benzamide, 2-[[[2-(3,5-dioxo-4-morpholinyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-95-8 CAPLUS


CN Benzamide, 2-[[[2-[[[(3-chloropropyl)sulfonyl]amino]-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 657400-96-9 CAPLUS
 CN Benzamide, 2-[[[2-(1,1-dioxido-2-isothiazolidinyl)-4-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657400-97-0 CAPLUS
 CN Benzamide, N-[2-(2-hydroxyethyl)-2H-indazol-5-yl]-2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 657400-98-1 CAPLUS
 CN Benzamide, 2-[[[2-[[[(2-hydroxyethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(2-methyl-2H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 657400-99-2 CAPLUS

CN Benzamide, N-[1-(2-hydroxyethyl)-1H-indazol-6-yl]-2-[[[2-[[[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 657401-00-8 CAPLUS

CN Benzamide, 2-[[[2-[[[(2-hydroxyethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]amino]-N-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




IT 657401-05-3 657401-06-4 657401-07-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of anthranilamidopyridines as inhibitors of vascular endothelial growth factor receptor)


RN 657401-05-3 CAPLUS

CN Benzamide, 2-[[[2-bromo-4-pyridinyl]methyl]amino]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




RN 657401-06-4 CAPLUS

CN Benzamide, 2-[[[(2-bromo-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 657401-07-5 CAPLUS

CN Benzamide, N-[2-(2-methoxyethyl)-2H-indazol-5-yl]-2-[[[2-[(methylamino)carbonyl]amino]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




IT 474799-36-5P 657401-01-9P 657401-04-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anthranilamidopyridines as inhibitors of vascular endothelial growth factor receptor)


RN 474799-36-5 CAPLUS

CN Benzamide, 2-[[[(6-bromo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 657401-01-9 CAPLUS

CN Benzamide, 2-[[[(2-bromo-4-pyridinyl)methyl]amino]-N-(2-methyl-2H-indazol-5-yl)]- (9CI) (CA INDEX NAME)



RN 657401-04-2 CAPLUS

CN Benzamide, 2-[[[(2-bromo-4-pyridinyl)methyl]amino]-N-(1-methyl-1H-indazol-5-yl)]- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:41461 CAPLUS

DOCUMENT NUMBER: 140:93789

TITLE: Preparation of substituted anthranilic amide derivatives as VEGF modulators and methods of use against cancer and other disorders

INVENTOR(S): Huang, Qi; Chen, Guoqing; Li, Aiwen; Riahi, Babak; Tasker, Andrew; Yang, Kevin; Yuan, Chester Chenguang

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 204 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005279	A2	20040115	WO 2003-US21601	20030709
WO 2004005279	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004087568	A1	20040506	US 2003-615809	20030708
CA 2489166	AA	20040115	CA 2003-2489166	20030709
AU 2003256481	A1	20040123	AU 2003-256481	20030709
EP 1519921	A2	20050406	EP 2003-763451	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006502112	T2	20060119	JP 2004-520114	20030709
PRIORITY APPLN. INFO.:			US 2002-395144P	P 20020709
			US 2003-615809	A 20030708
			WO 2003-US21601	W 20030709
OTHER SOURCE(S):			MARPAT 140:93789	
GI				



AB Selected substituted anthranilic amide derivs. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not claimed, .apprx.139 example preps. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates 2-nitro-N-[4-[1-methyl-1-

(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and 2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μ M. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation <1 μ M. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH₂)₁₋₂-R₃; R₁ = (un)substituted 5-6 membered saturated or partially saturated heterocyclyl, 9-10 membered bicyclic

and


13-14 membered tricyclic saturated or partially saturated heterocyclyl, and phenyl; R₂ is ≥ 1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl-C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; R_a = H, C1-2-alkyl; addnl. details are given in the claims.

IT **645418-47-9P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[[pyridin-4-yl)methyl]amino]benzamide **645418-59-3P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[[quinolin-4-yl)methyl]amino]benzamide **645418-61-7P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[[1-oxopyridin-4-yl)methyl]amino]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of substituted anthranilic amide derivs. as VEGF modulators and methods of use against cancer and other disorders)


RN 645418-47-9 CAPLUS

CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 645418-59-3 CAPLUS

CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 645418-61-7 CAPLUS

CN Benzamide, N- (1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl) -2- [[(1-oxido-4-pyridinyl)methyl]amino] - (9CI) (CA INDEX NAME)




IT 453564-10-8P, N- (2-Acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl) -2- [[(quinolin-4-yl)methyl]amino]benzamide
 645418-43-5P, N- [4- [1-Methyl-1- (1-methylpiperidin-4-yl)ethyl]phenyl] -2- [[(pyridin-4-yl)methyl]amino]benzamide
 645418-48-0P, N- (1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl) -2- (4-fluorobenzylamino)benzamide 645418-49-1P,
 N- [4- [1-Methyl-1- (1-methylpiperidin-4-yl)ethyl]phenyl] -2- [[(quinolin-4-yl)methyl]amino]benzamide 645418-50-4P, 2- (4-Fluorobenzylamino) -
 N- [4- [1-methyl-1- (1-methylpiperidin-4-yl)ethyl]phenyl]benzamide
 645418-51-5P, N- (3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl) -2- [[(pyridin-4-yl)methyl]amino]benzamide 645418-52-6P,
 N- (1-Ethyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl) -2- [[(pyridin-4-yl)methyl]amino]benzamide 645418-56-0P, N- [3,3-Dimethyl-1- [(4-methylpiperazin-1-yl)carbonyl] -2,3-dihydro-1H-indol-6-yl] -2- (4-fluorobenzylamino)benzamide 645418-62-8P, N- (3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl) -2- [[(quinolin-4-yl)methyl]amino]benzamide
 645418-63-9P, N- (3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl) -2- [[(1-oxopyridin-4-yl)methyl]amino]benzamide 645418-64-0P,
 N- (4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl) -2- (4-fluorobenzylamino)benzamide 645418-67-3P, N- (4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl) -2-fluoro-6- (4-fluorobenzylamino)benzamide 645418-68-4P, N- (4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl) -3-fluoro-6- (4-fluorobenzylamino)benzamide 645418-69-5P, N- (4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl) -4-fluoro-6- (4-

fluorobenzylamino)benzamide **645418-70-8P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-difluoro-6-(4-fluorobenzylamino)benzamide **645418-71-9P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[2-methoxypyridin-4-yl)methyl]amino]benzamide **645418-74-2P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-fluoro-6-[[2-methoxypyridin-4-yl)methyl]amino]benzamide **645418-75-3P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-6-[[2-methoxypyridin-4-yl)methyl]amino]benzamide **645418-76-4P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-6-[[2-methoxypyridin-4-yl)methyl]amino]benzamide **645418-97-9P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[pyridazin-4-yl)methyl]amino]benzamide **645418-98-0P**, 4,4-Dimethyl-7-[[2-[[2-[(quinoxalin-5-yl)methyl]amino]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester **645418-99-1P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[2-[(quinoxalin-5-yl)methyl]amino]benzamide **645419-00-7P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[2-methylaminopyrimidin-4-yl)methyl]amino]benzamide **645419-14-3P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-2-(4-fluorobenzylamino)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted anthranilic amide derivs. as VEGF modulators and methods of use against cancer and other disorders)


RN 453564-10-8 CAPLUS

CN Benzamide, N-(2-acetyl-1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 645418-43-5 CAPLUS

CN Benzamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 645418-48-0 CAPLUS

CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 645418-49-1 CAPLUS

CN Benzamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 645418-50-4 CAPLUS

CN Benzamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 645418-51-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 645418-52-6 CAPLUS

CN Benzamide, N-(1-ethyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 645418-56-0 CAPLUS

CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino] - (9CI) (CA INDEX NAME)




RN 645418-62-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 645418-63-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 645418-64-0 CAPLUS

CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 645418-67-3 CAPLUS

CN Benzamide, 2-fluoro-6-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-68-4 CAPLUS

CN Benzamide, 5-fluoro-2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-69-5 CAPLUS

CN Benzamide, 4-fluoro-2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-70-8 CAPLUS

CN Benzamide, 4,5-difluoro-2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-71-9 CAPLUS

CN Benzamide, 2-[[[(2-methoxy-4-pyridinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-74-2 CAPLUS

CN Benzamide, 2-fluoro-6-[[[(2-methoxy-4-pyridinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-75-3 CAPLUS

CN Benzamide, 5-fluoro-2-[[[(2-methoxy-4-pyridinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-76-4 CAPLUS

CN Benzamide, 4-fluoro-2-[[[(2-methoxy-4-pyridinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-97-9 CAPLUS

CN Benzamide, 2-[[[(4-pyridazinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)




RN 645418-98-0 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[(5-quinoxalinylmethyl)amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 645418-99-1 CAPLUS


CN Benzamide, 2-[[2-[(5-quinoxalinylmethyl)amino]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinoliny)]- (9CI) (CA INDEX NAME)



RN 645419-00-7 CAPLUS


CN Benzamide, 2-[[[2-(methylamino)-4-pyrimidinyl]methyl]amino]-N-(1,2,3,4-

tetrahydro-4,4-dimethyl-7-isoquinoliny)- (9CI) (CA INDEX NAME)



RN 645419-14-3 CAPLUS

CN Benzamide, 3-fluoro-2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinoliny)]- (9CI) (CA INDEX NAME)



IT 645418-65-1P, 7-[[2-(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester


645418-73-1P, 7-[[2-[[2-Methoxypyridin-4-yl)methyl]amino]benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 645419-02-9P, 4,4-Dimethyl-7-[[2-[[2-methylaminopyrimidin-4-yl)methyl]amino]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted anthranilic amide derivs. as VEGF modulators and methods of use against cancer and other disorders)


RN 645418-65-1 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[2-[(4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 645418-73-1 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-7-[[2-[[[(2-methoxy-4-pyridinyl)methyl]amino]benzoyl]amino]-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 645419-02-9 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[[[(2-methylamino)-4-pyrimidinyl)methyl]amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:36626 CAPLUS

DOCUMENT NUMBER: 140:93929

TITLE: Preparation of N-(pyridinylmethyl)anthranilamides as VEGFR-2 and VEGFR-3 inhibitors for treating diseases caused by persistent angiogenesis

INVENTOR(S): Huth, Andreas; Krueger, Martin; Zorn, Ludwig; Ince, Stuart; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin; Hess-Stumpp, Holger



PATENT ASSIGNEE(S): Schering AG, Germany

10615809.trn

SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10228090	A1	20040115	DE 2002-10228090	20020619
US 2004039019	A1	20040226	US 2003-464853	20030619
PRIORITY APPLN. INFO.:			DE 2002-10228090	A 20020619
			US 2002-404773P	P 20020821

OTHER SOURCE(S): MARPAT 140:93929
 GI



AB Title compds. [I; R1 = (substituted) indazolyl, indolinyl, quinolinyl, Q1; R2 = H, C1-3 alkyl], were prepared Thus, 2-amino-N-(2-oxo-2,3-dihydro-1H-indol-6-yl)benzamide and pyridin-2-one-5-carboxaldehyde in MeOH was treated with ice AcOH followed by stirring over night at room temperature to give 82% N-(2-oxo-2,3-dihydro-1H-indol-6-yl)-2-[(6-oxo-1,6-dihydropyridin-3-yl)methylamino]benzamide. The latter inhibited VEGFR-2 (KDR) with IC50 = 0,05 µM.


IT 643081-97-4P 643081-98-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(pyridinylmethyl)anthranilamides as VEGFR-2 and VEGFR-3 inhibitors for treating diseases caused by persistent angiogenesis)


RN 643081-97-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-1H-indol-6-yl)-2-[[1,6-dihydro-6-oxo-3-pyridinyl)methylamino]- (9CI) (CA INDEX NAME)



RN 643081-98-5 CAPLUS

CN Benzamide, N-[1-(cyanomethyl)-1H-indazol-6-yl]-2-[[1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:950836 CAPLUS

DOCUMENT NUMBER: 140:16722

TITLE: Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

INVENTOR(S): Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 686 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099276	A1	20031204	WO 2003-US13893	20030505
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003273179	A1	20031212	AU 2003-273179	20030505
US 2004254158	A1	20041216	US 2003-430024	20030505
EP 1505966	A1	20050216	EP 2003-755341	20030505
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002
			WO 2003-US13893	W 20030505

OTHER SOURCE(S): MARPAT 140:16722

GI



AB The present application describes 1,1-disubstituted cycloalkyl compds. and derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example preps. are included. A number of I exhibit K_i 's of $<10 \mu\text{M}$ towards factor Xa; also some I are direct acting inhibitors ($K_i < 10 \mu\text{M}$) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is -Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G is consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10 carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.

IT 630385-55-6P 630385-58-9P 630385-59-0P
 630388-70-4P 630388-71-5P 630388-72-6P
 630388-73-7P 630388-74-8P 630388-75-9P
 630388-76-0P 630388-77-1P 630388-84-0P
 630388-85-1P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs. as factor Xa inhibitors for treating thromboembolic disorder)



RN 630385-55-6 CAPLUS

CN Benzeneacetic acid, 4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]- α,α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)





RN 630385-58-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630385-59-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[2-(dimethylamino)-1,1-dimethylethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-70-4 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-oxo-1-pyrrolidinyl)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-71-5 CAPLUS


CN Benzamide, 2-[[[4-[1-[(acetylmethylamino)methyl]cyclopropyl]phenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 630388-72-6 CAPLUS


CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl[(methylamino)carbonyl]amino]methyl]cyclopropyl]phenyl)methyl]amin

o] - (9CI) (CA INDEX NAME)




RN 630388-73-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl(methylsulfonyl)amino]methyl]cyclopropyl]phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 630388-74-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methylsulfonyl)amino]cyclopropyl]phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 630388-75-9 CAPLUS

CN Benzamide, 2-[[[4-[1-(acetaminocyclopropyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)]- (9CI) (CA INDEX NAME)




RN 630388-76-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[[2-hydroxyethyl]amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-77-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[[2-hydroxyethyl]methylamino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-84-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[2-(dimethylamino)-2-oxoethyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-85-1 CAPLUS

CN Benzamide, 2-[[[4-[1-(2-amino-2-oxoethyl)cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

10615809.trn

ACCESSION NUMBER: 2003:950057 CAPLUS
 DOCUMENT NUMBER: 140:16647
 TITLE: Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases
 INVENTOR(S): Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225106	A1	20031204	US 2002-197974	20020717
US 6878714	B2	20050412		
US 2003125339	A1	20030703	US 2002-46681	20020110
US 6995162	B2	20060207		
ZA 2003005197	A	20040319	ZA 2003-5197	20030704
CA 2492100	AA	20040122	CA 2003-2492100	20030715
WO 2004007458	A1	20040122	WO 2003-US22417	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003252011	A1	20040202	AU 2003-252011	20030715
EP 1537084	A1	20050608	EP 2003-764794	20030715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501195	T2	20060112	JP 2004-521959	20030715
BG 108012	A	20041130	BG 2003-108012	20030721
US 2005261313	A1	20051124	US 2004-14184	20041215
US 2006040956	A1	20060223	US 2005-234713	20050923
PRIORITY APPLN. INFO.:				
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A2 20020110
			US 2002-197974	A 20020717
			WO 2003-US22417	W 20030715
OTHER SOURCE(S):	MARPAT 140:16647			
GI				



AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared. Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μ M. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.


IT 453564-10-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)

RN 453564-10-8 CAPLUS

CN Benzamide, N-(2-acetyl-1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinoliny)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:665525 CAPLUS

DOCUMENT NUMBER: 139:345320

TITLE: Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching

AUTHOR(S): Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz

CORPORATE SOURCE: Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:345320

AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research. PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.


IT 269390-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)

RN 269390-69-4 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 618359-41-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)

RN 618359-41-4 CAPLUS

CN Benzamide, N-(2-fluorophenyl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:551370 CAPLUS

DOCUMENT NUMBER: 139:111679

TITLE: Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs

INVENTOR(S): Thomas, Leo; Mark, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 220 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10200633	A1	20030724	DE 2002-10200633	20020110
DE 10256184	A1	20040609	DE 2002-10256184	20021202
CA 2471566	AA	20030717	CA 2003-2471566	20030107
AU 2003205570	A1	20030724	AU 2003-205570	20030107
EP 1465613	A2	20041013	EP 2003-702391	20030107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005525309	T2	20050825	JP 2003-557563	20030107
US 2003162788	A1	20030828	US 2003-339088	20030109
PRIORITY APPLN. INFO.:				
			DE 2002-10200633	A 20020110
			DE 2002-10256184	A 20021202
			US 2002-353397P	P 20020201
			US 2002-435386P	P 20021220
			WO 2003-EP57	W 20030107

OTHER SOURCE(S): MARPAT 139:111679

AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain

an MTP inhibitor and a fibrate. Compound preparation is included.


IT 486436-62-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

RN 486436-62-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino] - (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:454323 CAPLUS

DOCUMENT NUMBER: 139:22501

TITLE: Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors

INVENTOR(S): Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003232804	A1	20031218	US 2002-304070	20021125
AU 2002351179	A1	20030617	AU 2002-351179	20021127




I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 536759-10-1 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-
 [[(dimethylamino) acetyl] methylamino] phenyl] methyl] amino] - (9CI) (CA INDEX
 NAME)





RN 536759-11-2 CAPLUS

CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 536759-12-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 536759-13-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 536759-14-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methy-
mino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:454257 CAPLUS

DOCUMENT NUMBER: 139:7167

TITLE: Preparation of glycinamide heterocyclic derivatives as
factor Xa inhibitors

INVENTOR(S): Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SOURCE: PCT Int. Appl., 448 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2002-304070	20021125
PRIORITY APPLN. INFO.:			US 2001-336994P	P 20011204
OTHER SOURCE(S):			MARPAT 139:7167	
GI				



AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

IT 536759-09-8P 536759-10-1P 536759-11-2P
536759-12-3P 536759-13-4P 536759-14-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)


RN 536759-09-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 536759-10-1 CAPLUS

CN Benzamide, 5-chloro-N- (5-chloro-2-pyridinyl) -2-[[[4-
[[(dimethylamino) acetyl] methylamino] phenyl] methyl] amino] - (9CI) (CA INDEX
NAME)





RN 536759-11-2 CAPLUS

CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 536759-12-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 536759-13-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 536759-14-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:376825 CAPLUS

DOCUMENT NUMBER: 138:385308

TITLE: Preparation of anthranilic acid amides and their use as vascular endothelial growth factor receptor tyrosine kinase inhibitors

INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William

PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040102	A1	20030515	WO 2002-EP12444	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2463968	AA	20030515	CA 2002-2463968	20021107
EP 1446382	A1	20040818	EP 2002-787595	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013970	A	20040831	BR 2002-13970	20021107
JP 2005511602	T2	20050428	JP 2003-542148	20021107
US 2005096356	A1	20050505	US 2003-494591	20021107
ZA 2004002940	A	20050210	ZA 2004-2940	20040419
NO 2004002187	A	20040526	NO 2004-2187	20040526
PRIORITY APPLN. INFO.:			GB 2001-26902	A 20011108
			WO 2002-EP12444	W 20021107

OTHER SOURCE(S): MARPAT 138:385308

GI




AB Anthranilic acid amide derivs. [I; R1, R2 = H, lower alkyl; R3 = lower perfluoroalkyl; X = O, S; e.g., 2-[(6-Methoxy-3-pyridinyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride, m.p. 133-135°], which are vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of neoplastic disease, of retinopathy or age-related macular degeneration, are prepared and a I-containing formulation presented (e.g., a soft capsule).

IT 524941-34-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of anthranilic acid amides)

RN 524941-34-2 CAPLUS

CN Benzamide, 2-[[[6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(2-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 524941-29-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(in the preparation of anthranilic acid amides for use as vascular endothelial growth factor receptor tyrosine kinase inhibitors)

RN 524941-29-5 CAPLUS

CN Benzamide, 2-[[[6-methoxy-3-pyridinyl)methyl]amino]-N-[2-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 524728-97-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of)

RN 524728-97-0 CAPLUS

CN Benzamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 524941-33-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 524941-33-1 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(2-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 524941-28-4P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of anthranilic acid amides and their use as vascular endothelial growth factor receptor tyrosine kinase inhibitors)

RN 524941-28-4 CAPLUS

CN Benzamide, 2-[[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[3-

(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 524941-35-3P 524941-36-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anthranilic acid amides and their use as vascular endothelial growth factor receptor tyrosine kinase inhibitors)


RN 524941-35-3 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 524941-36-4 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[2-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN



ACCESSION NUMBER: 2003:376824 CAPLUS

DOCUMENT NUMBER: 138:368777

TITLE: Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease

INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William
 PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2462390	AA	20030515	CA 2002-2462390	20021107
EP 1446381	A1	20040818	EP 2002-779536	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013939	A	20040831	BR 2002-13939	20021107
JP 2005508382	T2	20050331	JP 2003-542147	20021107
US 2004248947	A1	20041209	US 2004-494222	20040503
NO 2004002137	A	20040525	NO 2004-2137	20040525
PRIORITY APPLN. INFO.:			GB 2001-26901	A 20011108
			GB 2002-12917	A 20020605
			WO 2002-EP12445	W 20021107
OTHER SOURCE(S):			MARPAT 138:368777	
GI				



AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl] and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH₃CN afforded I [Ar = 4-pyridyl; R1 = CF₃; R2 = Br]. The IC₅₀-values that can be found for the compds. I are in range of 0.001 to 1 μM in test for

activity against VEGF-receptor tyrosine kinase.

IT 524728-98-1P 524728-99-2P 524729-02-0P


524729-04-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)


RN 524728-98-1 CAPLUS

CN Benzamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 524728-99-2 CAPLUS

CN Benzamide, N-(4-bromophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 524729-02-0 CAPLUS


CN Benzamide, N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 524729-04-2 CAPLUS

CN Benzamide, N-[4-(1Z)-1-propenyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl


IT 524729-00-8P 524729-03-1P 524729-05-3P
524729-06-4P 524729-07-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyridyl-substituted anthranilic acid amides for treating
neoplastic disease)


RN 524729-00-8 CAPLUS

CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 524729-03-1 CAPLUS

CN Benzamide, N-[4-(1-propynyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 524729-05-3 CAPLUS

CN Benzamide, N-[4-propyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 524729-06-4 CAPLUS

CN Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[1-(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 524729-07-5 CAPLUS

CN Benzamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[[1-(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 524728-97-0P 524729-01-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)


RN 524728-97-0 CAPLUS

CN Benzamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 524729-01-9 CAPLUS

CN Benzamide, 2-[[[6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:42101 CAPLUS

DOCUMENT NUMBER: 138:106502

TITLE: Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)

INVENTOR(S): Priepke, Henning; Huel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

DE 10132686	A1	20030116	DE 2001-10132686	20010705
US 2003073836	A1	20030417	US 2002-187860	20020702
PRIORITY APPLN. INFO.:			DE 2001-10132686	A 20010705
			US 2001-304584P	P 20010711
OTHER SOURCE(S):		MARPAT 138:106502		
GI				



AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared. For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC₅₀ values ≤ 100 μM. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.


IT 486436-62-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)

RN 486436-62-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:882097 CAPLUS

DOCUMENT NUMBER: 137:384763

TITLE: Preparation of cyanoanthranilamides as vascular endothelial growth factor (VEGF) receptor inhibitors

INVENTOR(S): Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz; Ernst, Alexander; Menrad, Andreas; Haberey, Martin

PATENT ASSIGNEE(S): Schering Ag, Germany

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10125295	A1	20021121	DE 2001-10125295	20010515
WO 2003000678	A1	20030103	WO 2002-EP4921	20020503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1387838	A1	20040211	EP 2002-748691	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532281	T2	20041021	JP 2003-507082	20020503
US 2004266770	A1	20041230	US 2004-476761	20040825
PRIORITY APPLN. INFO.:			DE 2001-10123587	A 20010508
			DE 2001-10125295	A 20010515
			WO 2002-EP4921	W 20020503

OTHER SOURCE(S): MARPAT 137:384763

GI



AB Title compds. [I; A = NR7; W = O, S, 2H, NR8; Z = bond, NR10, :N, (branched) (substituted) alkyl; X = alkyl; R1 = (substituted) (branched) alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; Y1-Y5 = N, CY6; Y6 = cyano, halo, alkyl, alkoxy, amino, OH (with the proviso that the ring contains at least one of N and is substituted with at least one of cyano group); D = N, CR3; E = N, CR4; F = N, CR5; G = N, CR6; R3-R6 = H,

halo, (substituted) alkoxy, alkyl, carboxyalkyl; R7 = H, alkyl, etc.; R8-R10 = H, alkyl], were prepared Thus, N-(isoquinolin-3-yl)-2-(4-pyridylmethyl)aminobenzoic acid amide N-oxide was treated one after another with DMF, Et3N, and Me3SiCN followed by heating the bath temperature at 110° to give 14% N-(isoquinolin-3-yl)-2-[4-(2-cyanopyridyl)methyl]aminobenzoic acid amide. The latter inhibited the tyrosine kinase receptor VEGFR II (KDR) with IC50 = 1+10-8 mM.


IT 474799-52-5P 475646-45-8P 475646-46-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyanoanthranilylamides as vascular endothelial growth factor (VEGF) receptor inhibitors)


RN 474799-52-5 CAPLUS

CN Benzamide, 2-[[2-cyano-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)




RN 475646-45-8 CAPLUS

CN Benzamide, 2-[[6-cyano-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)



RN 475646-46-9 CAPLUS

CN Benzamide, 2-[[2-cyano-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)




IT 267891-90-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyanoanthranilylamides as vascular endothelial growth factor (VEGF) receptor inhibitors)

RN 267891-90-7 CAPLUS

CN Benzamide, 2-[[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:882056 CAPLUS

DOCUMENT NUMBER: 137:384762

TITLE: Preparation of cyanoanthranilylamides as vascular endothelial growth factor (VEGF) receptor inhibitors

INVENTOR(S): Huth, Andreas; Krueger, Martin; Ernst, Alexander; Thierauch, Karl-Heinz; Haberey, Martin; Menrad, Andreas

PATENT ASSIGNEE(S): Schering Ag, Germany

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10123587	A1	20021121	DE 2001-10123587	20010508
DE 10123587	B4	20050407		
WO 2003000678	A1	20030103	WO 2002-EP4921	20020503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1387838	A1	20040211	EP 2002-748691	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532281	T2	20041021	JP 2003-507082	20020503
US 2004266770	A1	20041230	US 2004-476761	20040825
PRIORITY APPLN. INFO.:			DE 2001-10123587	A 20010508
			DE 2001-10125295	A 20010515
			WO 2002-EP4921	W 20020503

OTHER SOURCE(S) :
GI

MARPAT 137:384762



AB Title compds. [I; A = NR7; W = O, S, 2H, NR8; Z = bond, NR10, :N, (branched) (substituted) alkyl; X = alkyl; R1 = (substituted) (branched) alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; Y1-Y5 = N, CY6; Y6 = cyano, halo, alkyl, alkoxy, amino, OH (with the proviso that the ring contains at least one of N and is substituted with at least one of cyano group); D = N, CR3; E = N, CR4; F = N, CR5; G = N, CR6; R3-R6 = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R7 = H, alkyl, etc.; R8-R10 = H, alkyl], were prepared Thus, N-(isoquinolin-3-yl)-2-(4-pyridylmethyl)aminobenzoic acid amide N-oxide was treated one after another with DMF, Et3N, and Me3SiCN followed by heating the bath temperature at 110° to give 14% N-(isoquinolin-3-yl)-2-[4-(2-cyanopyridyl)methyl]aminobenzoic acid amide. The latter inhibited the tyrosine kinase receptor VEGFR II (KDR) with IC50 = 1+10-8 mM.


IT 474799-52-5P 475646-45-8P 475646-46-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyanoanthranilylamides as vascular endothelial growth factor (VEGF) receptor inhibitors)


RN 474799-52-5 CAPLUS

CN Benzamide, 2-[[2-cyano-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)




RN 475646-45-8 CAPLUS


CN Benzamide, 2-[[6-cyano-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)



RN 475646-46-9 CAPLUS
 CN Benzamide, 2-[[[(2-cyano-3-pyridinyl)methyl]amino]-N-3-isoquinoliny]- (9CI)
 (CA INDEX NAME)




IT 267891-90-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of cyanoanthranilamides as vascular endothelial growth factor
 (VEGF) receptor inhibitors)
 RN 267891-90-7 CAPLUS
 CN Benzamide, 2-[[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-
 isoquinoliny]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:880425 CAPLUS
 DOCUMENT NUMBER: 138:106488
 TITLE: Anthranilic Acid Amides: A Novel Class of
 Antiangiogenic VEGF Receptor Kinase Inhibitors
 AUTHOR(S): Manley, Paul W.; Furet, Pascal; Bold, Guido; Brueggen,
 Josef; Mestan, Juergen; Meyer, Thomas; Schnell,
 Christian R.; Wood, Jeanette; Haberey, Martin; Huth,
 Andreas; Krueger, Martin; Menrad, Andreas; Ottow,

Eckhard; Seidelmann, Dieter; Siemeister, Gerhard;
Thierauch, Karl-Heinz
CORPORATE SOURCE: Oncology Research, Novartis Pharma AG, Basel, CH-4057,
Switz.
SOURCE: Journal of Medicinal Chemistry (2002), 45(26),
5687-5693
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:106488
GI



AB Two readily synthesized anthranilamide, VEGF receptor tyrosine kinase inhibitors have been prepared and evaluated as angiogenesis inhibitors. 2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide [I; R = 3-CF₃C₆H₄ (II)] and N-3-isoquinoliny-2-[(4-pyridinylmethyl)amino]benzamide [I; R = 3-isoquinoliny (III)] potently and selectively inhibit recombinant VEGFR-2 and VEGFR-3 kinases. As a consequence of their physicochem. properties, these anthranilamides readily penetrate cells and are absorbed following once daily oral administration to mice. Both II and III potently inhibit VEGF-induced angiogenesis in an implant model, with ED₅₀ values of 7 mg/kg. In a mouse orthotopic model of melanoma, II and III potently inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases. The anthranilamides II and III represent a new structural class of VEGFR kinase inhibitors, which possess potent antiangiogenic and antitumor properties.


IT 267891-44-1P 269390-77-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation and antiangiogenic and antitumor activity of VEGF receptor kinase inhibitor anthranilic acid amides)

RN 267891-44-1 CAPLUS

CN Benzamide, N-3-isoquinoliny-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269390-77-4 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:868928 CAPLUS

DOCUMENT NUMBER: 137:352900

TITLE: Selective anthranilamide pyridine amides as inhibitors
of VEGFR-2 and VEGFR-3INVENTOR(S): Ernst, Alexander; Huth, Andreas; Krueger, Martin;
Thierauch, Karl-Heinz; Menrad, Andreas; Haberey,
Martin

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090352	A2	20021114	WO 2002-EP4924	20020503
WO 2002090352	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10123574	A1	20021128	DE 2001-10123574	20010508
DE 10125294	A1	20021121	DE 2001-10125294	20010515
DE 10164590	A1	20030710	DE 2001-10164590	20011221

CA 2453223	AA	20021114	CA 2002-2453223	20020503
EP 1392680	A2	20040303	EP 2002-735333	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009485	A	20040706	BR 2002-9485	20020503
CN 1518546	A	20040804	CN 2002-809580	20020503
JP 2004528379	T2	20040916	JP 2002-587431	20020503
US 2004254185	A1	20041216	US 2004-477119	20040623
PRIORITY APPLN. INFO.:			DE 2001-10123574	A 20010508
			DE 2001-10125294	A 20010515
			DE 2001-10164590	A 20011221
			WO 2002-EP4924	W 20020503
OTHER SOURCE(S):		MARPAT 137:352900		
GI				



AB Title compds. I [G, L, M, Q = N, (un)substituted CH, ≤1 of them being N; R = (un)substituted N heterocycle; R¹ = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl] were prepared. I are inhibitors of VEGFR-2 and VEGFR-3 and are used as medicaments for treating diseases that are caused by persistent angiogenesis, such as psoriasis, Kaposi's sarcoma, restenosis, such as e.g. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibromatosis, in eye diseases such as diabetic retinopathy, neovascular glaucoma, in kidney diseases such as glomerulonephritis, diabetic nephropathy, malign nephrosclerosis, thrombic micro-angiopathic syndrome, transplant rejection and glomerulopathy, in fibrotic diseases such as hepatic cirrhosis, mesangial-cell proliferative diseases, arteriosclerosis, damage to the nerve tissue and inhibition of the re-occlusion of vessels after balloon catheter treatment, in vessel prosthetics or after the use of mech. devices for keeping vessels open, e.g. stents, as immunosuppressants, to support wound healing without scars and in cases of age spots and contact dermatitis. I can also be used as inhibitors of VEGFR-3 in lymphangiogenesis for hyperplastic and dysplastic changes in the lymphatic system. Thus, 2-amino-N-isoquinolin-3-ylbenzamide was treated with 2-bromo-5-pyridinecarboxaldehyde, followed by carboxylation and amidation to give the amide II. II had IC₅₀ for inhibition of VEGFR-2 of 40 nM and for inhibition of cytochrome 450 isoenzyme 2C9 of 2.9 μM.

IT 474798-25-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)

RN 474798-25-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-4-[[[2-[(3-

isoquinolinylamino)carbonyl]phenyl]amino)methyl]- (9CI) (CA INDEX NAME)




IT 474760-08-2P 474799-36-5P 474799-37-6P
474799-38-7P 474799-39-8P 474799-40-1P
474799-46-7P 474799-47-8P 474799-52-5P
474799-55-8P 474799-57-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)


RN 474760-08-2 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[(1-oxido-4-pyridinyl)methyl]amino]- (9CI)
(CA INDEX NAME)




RN 474799-36-5 CAPLUS

CN Benzamide, 2-[[[(6-bromo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)




RN 474799-37-6 CAPLUS

CN Benzamide, 2-[[[(3-bromo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI)
(CA INDEX NAME)




RN 474799-38-7 CAPLUS

CN Benzamide, 2-[[[(2-bromo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI)
(CA INDEX NAME)




RN 474799-39-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474799-40-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474799-46-7 CAPLUS

CN Benzamide, 2-[[[(6-bromo-3-pyridinyl)methyl]amino]-N-(2,3-dihydro-2-oxo-1H-indol-5-yl)- (9CI) (CA INDEX NAME)




RN 474799-47-8 CAPLUS

CN Benzamide, 2-[[[(6-cyano-3-pyridinyl)methyl]amino]-N-(2,3-dihydro-2-oxo-1H-indol-5-yl)- (9CI) (CA INDEX NAME)




RN 474799-52-5 CAPLUS

CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI) (CA INDEX NAME)



RN 474799-55-8 CAPLUS


CN Benzamide, 2-[[[(2-cyano-4-pyridinyl)methyl]amino]-N-(7-methoxy-3-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 474799-57-0 CAPLUS

CN Benzamide, 2-[[[(2-bromo-4-pyridinyl)methyl]amino]-N-(2-methyl-2H-indazol-6-

yl) - (9CI) (CA INDEX NAME)




IT 474797-95-0P 474797-96-1P 474797-97-2P
 474797-98-3P 474797-99-4P 474798-00-0P
 474798-01-1P 474798-02-2P 474798-03-3P
 474798-04-4P 474798-05-5P 474798-06-6P
 474798-07-7P 474798-08-8P 474798-09-9P
 474798-10-2P 474798-11-3P 474798-12-4P
 474798-13-5P 474798-14-6P 474798-15-7P
 474798-16-8P 474798-17-9P 474798-18-0P
 474798-19-1P 474798-20-4P 474798-21-5P
 474798-22-6P 474798-23-7P 474798-24-8P
 474798-26-0P 474798-27-1P 474798-28-2P
 474798-29-3P 474798-30-6P 474798-31-7P
 474798-32-8P 474798-33-9P 474798-34-0P
 474798-35-1P 474798-36-2P 474798-37-3P
 474798-38-4P 474798-39-5P 474798-40-8P
 474798-41-9P 474798-42-0P 474798-43-1P
 474798-44-2P 474798-45-3P 474798-46-4P
 474798-47-5P 474798-48-6P 474798-49-7P
 474798-50-0P 474798-51-1P 474798-52-2P
 474798-53-3P 474798-54-4P 474798-55-5P
 474798-56-6P 474798-57-7P 474798-58-8P
 474798-59-9P 474798-60-2P 474798-61-3P
 474798-62-4P 474798-63-5P 474798-64-6P
 474798-65-7P 474798-66-8P 474798-67-9P
 474798-68-0P 474798-69-1P 474798-70-4P
 474798-71-5P 474798-72-6P 474798-73-7P
 474798-74-8P 474798-75-9P 474798-76-0P
 474798-77-1P 474798-78-2P 474798-79-3P
 474798-80-6P 474798-81-7P 474798-82-8P
 474798-83-9P 474798-84-0P 474798-85-1P
 474798-86-2P 474798-87-3P 474798-88-4P
 474798-89-5P 474798-90-8P 474798-91-9P
 474798-92-0P 474798-93-1P 474798-94-2P
 474798-96-4P 474798-97-5P 474798-98-6P
 474798-99-7P 474799-00-3P 474799-01-4P
 474799-02-5P 474799-03-6P 474799-04-7P
 474799-05-8P 474799-06-9P 474799-07-0P
 474799-08-1P 474799-09-2P 474799-10-5P
 474799-11-6P 474799-12-7P 474799-13-8P
 474799-14-9P 474799-15-0P 474799-16-1P
 474799-17-2P 474799-18-3P 474799-19-4P
 474799-20-7P 474799-21-8P 474799-22-9P
 474799-23-0P 474799-24-1P 474799-27-4P
 474799-28-5P 474799-29-6P 474799-30-9P
 474799-31-0P 474799-32-1P 474799-33-2P
 474799-34-3P 474799-35-4P 474808-03-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinolinylcarbamoylethylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)


RN 474797-95-0 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474797-96-1 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474797-97-2 CAPLUS

CN 2-Pyridinecarboxamide, N-cyclopropyl-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474797-98-3 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 474797-99-4 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-00-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-01-1 CAPLUS


CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-02-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-03-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-04-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-05-5 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-06-6 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-07-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-08-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-09-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474798-10-2 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 474798-11-3 CAPLUS
 CN 2-Pyridinecarboxamide, N-ethyl-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-12-4 CAPLUS
 CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-13-5 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 474798-14-6 CAPLUS

CN 2-Pyridinecarboxamide, N-cyclopentyl-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-15-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 474798-16-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 474798-17-9 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474798-18-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474798-19-1 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-20-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-21-5 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-22-6 CAPLUS

CN 2-Pyridinecarboxamide, N-cyclohexyl-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-23-7 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-fluorophenyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-24-8 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474798-26-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-(5-hydroxypentyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-27-1 CAPLUS
 CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-28-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-29-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-30-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474798-31-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 474798-32-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 474798-33-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-34-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxy-2-methylpropyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-35-1 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxy-1,1-dimethylethyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-36-2 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 474798-37-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-38-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-39-5 CAPLUS


CN 2-Pyridinecarboxamide, N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474798-40-8 CAPLUS


CN 2-Pyridinecarboxamide, N-[1-(hydroxymethyl)cyclopentyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-41-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-42-0 CAPLUS


CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474798-43-1 CAPLUS


CN 2-Pyridinecarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-44-2 CAPLUS


CN 2-Pyridinecarboxamide, N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474798-45-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 474798-46-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S,2S)-2-hydroxycyclohexyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-47-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-48-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(1R)-2-methoxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 474798-49-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(1S)-2-methoxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 474798-50-0 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 474798-51-1 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 474798-52-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-(2-hydroxybutyl)-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-53-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-54-4 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-55-5 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-56-6 CAPLUS

CN 2-Pyridinecarboxamide, N-(5-hydroxypentyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-57-7 CAPLUS


CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-58-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-59-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-60-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-61-3 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-62-4 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxy-2-methylpropyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-63-5 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-64-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-65-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-66-8 CAPLUS


CN 2-Pyridinecarboxamide, N-4-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-67-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-3-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-68-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-2-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-69-1 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[[[2-[(4-methyl-1-piperazinyl)carbonyl]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 474798-70-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[3-fluoro-2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-71-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[3-fluoro-2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-72-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[3-fluoro-2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(2S)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-73-7 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[[3-fluoro-2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-74-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[[3-fluoro-2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-75-9 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-76-0 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-77-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl] - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 474798-78-2 CAPLUS



CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl] - (9CI) (CA
INDEX NAME)

Absolute stereochemistry.





RN 474798-79-3 CAPLUS

CN 2-Pyridinecarboxamide, N-4-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl] - (9CI) (CA
INDEX NAME)




RN 474798-80-6 CAPLUS

CN 2-Pyridinecarboxamide, N-3-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-81-7 CAPLUS

CN 2-Pyridinecarboxamide, N-(5-hydroxypentyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-82-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-83-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 474798-84-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-85-1 CAPLUS

CN 2-Pyridinecarboxamide, N-2-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-86-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-87-3 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-88-4 CAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxy-2-methylpropyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474798-89-5 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474798-90-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474798-91-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(2R)-2-hydroxypropyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 474798-92-0 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-93-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-94-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-96-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-97-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[[[2-methyl-2H-indazol-6-yl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-98-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[[[2-methyl-2H-indazol-6-yl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474798-99-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[(1H-indazol-5-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-00-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[(1H-indazol-5-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-01-4 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(2S)-2-hydroxypropyl]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 474799-02-5 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(1S)-2-hydroxy-1-methylethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-03-6 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-04-7 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]-N-[(2R)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-05-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[[[7-methoxy-2-oxo-2H-1-benzopyran-3-yl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-06-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[[[7-methoxy-2-oxo-2H-1-benzopyran-3-yl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-07-0 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[[[(7-methoxy-2-oxo-2H-1-benzopyran-3-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-08-1 CAPLUS


CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[[[(7-methoxy-3-methyl-2-quinolinyl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474799-09-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[[[7-methoxy-3-methyl-2-quinolinyl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474799-10-5 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[[[7-methoxy-3-methyl-2-quinolinyl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-11-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-12-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-13-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-14-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[(1-methyl-1H-indazol-6-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-15-0 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-16-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-17-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-18-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-[(1H-indazol-6-ylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474799-19-4 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[[[7-methoxy-2-oxo-2H-1-benzopyran-3-yl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474799-20-7 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[[[3-isoquinolinylamino]carbonyl]phenyl]amino]methyl]-N-propyl]- (9CI) (CA INDEX NAME)




RN 474799-21-8 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 474799-22-9 CAPLUS

CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 474799-23-0 CAPLUS


CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 474799-24-1 CAPLUS
 CN 2-Pyridinecarboxamide, 5-[[[2-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474799-27-4 CAPLUS
 CN Benzamide, 2-[[[3,3'-bipyridin]-4-ylmethyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)




RN 474799-28-5 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[[[3-(3-thienyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 474799-29-6 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474799-30-9 CAPLUS
 CN 2-Pyridinecarboxamide, 5-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 474799-31-0 CAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 474799-32-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 474799-33-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474799-34-3 CAPLUS


CN Benzamide, N-3-isoquinolinyl-2-[[[2-(4-morpholinylcarbonyl)-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 474799-35-4 CAPLUS


CN Benzamide, N-3-isoquinolinyl-2-[[[3-[(trimethylsilyl)ethynyl]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 474808-03-2 CAPLUS

CN 2-Pyridinecarboxamide, N-cyclopropyl-4-[[[2-[(3-isoquinolinylamino)carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:868925 CAPLUS

DOCUMENT NUMBER: 137:352899

TITLE: Pyridylmethylantranilamide N-oxides as inhibitors of VEGFR II kinase

INVENTOR(S): Ernst, Alexander; Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090349	A1	20021114	WO 2002-EP4923	20020503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10123573	A1	20021128	DE 2001-10123573	20010508

DE 10123573 B4 20050602
 DE 10125293 A1 20021121 DE 2001-10125293 20010515
 EP 1389201 A1 20040218 EP 2002-740563 20020503
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004528378 T2 20040916 JP 2002-587429 20020503
 US 2005032816 A1 20050210 US 2004-476755 20040624
 PRIORITY APPLN. INFO.: DE 2001-10123573 A 20010508
 DE 2001-10125293 A 20010515
 WO 2002-EP4923 W 20020503
 OTHER SOURCE(S): MARPAT 137:352899
 GI



AB Title compds. I [D, E, F, G = N, (un)substituted CH; A = (un)substituted NH; W = O, S, H₂, (un)substituted NH; X, Z = (un)substituted alkylene; R₁ = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; R₂ = (un)substituted hetaryl N-oxide; R₃ = H, alkyl] were prepared. These compds. can be used in the treatment of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndromes, transplant rejections and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell-proliferative diseases, arteriosclerosis, injuries of the nerve tissue, and for inhibiting the reocclusion of vessels after balloon catheter treatment, for use in vascular prosthetics or after inserting mech. devices for holding vessels open such as, e.g. stents, as immunosuppressants, as an aid in scar-free wound healing, and for treating age spots and contact dermatitis. They can also be used as VEGFR-3 inhibitors in lymphangiogenesis. Thus, the N-oxide II was obtained by reductive alkylation of 2-amino-N-isoquinolin-3-ylbenzamide with isonicotinaldehyde N-oxide and had IC₅₀ for inhibition of VEGFR II of 0.03 μM.


IT 269391-06-2P 474760-08-2P 474760-09-3P
 474760-10-6P 474760-11-7P 474760-12-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyridylmethylantranilamide N-oxides as inhibitors of VEGFR II kinase)

RN 269391-06-2 CAPLUS


CN Benzamide, 2-[[[(1-oxido-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 474760-08-2 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[[[(1-oxido-4-pyridinyl)methyl]amino]- (9CI)
 (CA INDEX NAME)




RN 474760-09-3 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[[[(1-oxido-3-pyridinyl)methyl]amino]- (9CI)
 (CA INDEX NAME)




RN 474760-10-6 CAPLUS
 CN Benzamide, N-(7-methoxy-2-oxo-2H-1-benzopyran-3-yl)-2-[[[(1-oxido-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 474760-11-7 CAPLUS
 CN Benzamide, N-[1-(cyanomethyl)-1H-indazol-6-yl]-2-[[[(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 474760-12-8 CAPLUS
 CN Benzamide, 2-[[[2-bromo-1-oxido-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



IT 267891-44-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyridylmethylantranilamide N-oxides as inhibitors of VEGFR II kinase)
 RN 267891-44-1 CAPLUS
 CN Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:658116 CAPLUS
 DOCUMENT NUMBER: 137:201332
 TITLE: Preparation of heterocyclalkylamine derivatives as remedies for angiogenesis mediated diseases
 INVENTOR(S): Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander;

Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 502 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066470	A1	20020829	WO 2002-US743	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125339	A1	20030703	US 2002-46681	20020110
US 6995162	B2	20060207		
CA 2434277	AA	20020829	CA 2002-2434277	20020111
BR 2002006435	A	20030923	BR 2002-6435	20020111
EP 1358184	A1	20031105	EP 2002-717325	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300324	A	20031215	EE 2003-324	20020111
JP 2004531484	T2	20041014	JP 2002-565984	20020111
NZ 526868	A	20050429	NZ 2002-526868	20020111
CN 1671700	A	20050921	CN 2002-806202	20020111
ZA 2003005197	A	20040319	ZA 2003-5197	20030704
NO 2003003181	A	20030911	NO 2003-3181	20030711
BG 108012	A	20041130	BG 2003-108012	20030721
US 2006040956	A1	20060223	US 2005-234713	20050923
PRIORITY APPLN. INFO.:			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
			WO 2002-US743	W 20020111
OTHER SOURCE(S):	MARPAT 137:201332			
GI				



AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.


IT 453564-10-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453564-10-8 CAPLUS

CN Benzamide, N-(2-acetyl-1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinoliny)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:603273 CAPLUS

DOCUMENT NUMBER: 138:122629

TITLE: Synthesis of 1,4-benzodiazepine-2,5-dione derivatives

AUTHOR(S): Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min

CORPORATE SOURCE: Dep. of Chem., National Taiwan Univ., Taipei, Taiwan

SOURCE: Heterocycles (2002), 57(8), 1501-1506

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:122629

AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-Methoxyphenyl)-1-[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid Me ester was described.


IT 489446-50-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate derivs.)

RN 489446-50-6 CAPLUS



CN Benzamide, N-(4-methoxyphenyl)-2-[[[(3-methoxyphenyl)methyl]amino]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:555472 CAPLUS
 DOCUMENT NUMBER: 137:125085
 TITLE: Preparation of urea derivatives as integrin alpha 4 antagonists
 INVENTOR(S): Jimenez Mayorga, Juan Miguel; Bach Tana, Jordi; Ontoria Ontoria, Jesus Maria; Navarro Romero, Eloisa
 PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057242	A2	20020725	WO 2002-EP331	20020115
WO 2002057242	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2200617	A1	20040301	ES 2001-126	20010119
ES 2200617	B1	20050501		
CA 2434939	AA	20020725	CA 2002-2434939	20020115
EE 200300327	A	20031015	EE 2003-327	20020115
EP 1383750	A2	20040128	EP 2002-710010	20020115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517143	T2	20040610	JP 2002-557923	20020115
BR 2002006588	A	20040622	BR 2002-6588	20020115
CN 1531425	A	20040922	CN 2002-806525	20020115
NZ 527031	A	20050930	NZ 2002-527031	20020115
ZA 2003005535	A	20041018	ZA 2003-5535	20030717
NO 2003003269	A	20030919	NO 2003-3269	20030718
BG 108004	A	20040930	BG 2003-108004	20030718
US 2004142982	A1	20040722	US 2004-466665	20040223
PRIORITY APPLN. INFO.:			ES 2001-126	A 20010119
			WO 2002-EP331	W 20020115
OTHER SOURCE(S):			MARPAT 137:125085	
GI				




AB The title compds. [I; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl, alkylaryl, etc.; R3, R4 = H, alkyl; R2 and R3, together with the atoms to which they are attached, may form a 4-8 membered ring; R5 = alkyl, cycloalkyl, aryl, etc.; L1 = S, SO, SO2, CO, etc.; L2 = a bond, O, S, SO, etc.; W = O, S, (un)substituted NH, N(CN); X = (CH2)naryl, (CH2)nheteroaryl; Y = monocyclic (hetero)aryl; Z = CONH2, CO2R, PO3R, SO3R, etc.; R = H, alkyl, cycloalkyl, etc.; n = 0-2], novel antagonists of $\alpha 4\beta 1$ integrin and/or $\alpha 4\beta 7$ integrin useful in preventing or treating an immune or inflammatory diseases or disorders, were prepared and formulated. Thus, reacting 2-amino-N-cyclohexyl-N-methylbenzamide with (S)-3-[4-(2,6-dichlorobenzoylamino)phenyl]-2-isocyanatopropionic acid Me ester (preparation given) in CH2Cl2 (yield 50%) followed by hydrolysis of the intermediate ester (77%) afforded (S)-II which showed IC50 of < 100 nM in the $\alpha 4\beta 1$ assay.

IT 444087-28-9P 444087-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ureas as integrin alpha 4 antagonists)


RN 444087-28-9 CAPLUS

CN Benzamide, N-cyclohexyl-2-[(cyclohexylmethyl)amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 444087-29-0 CAPLUS

CN Benzamide, N-cyclohexyl-N-methyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:408645 CAPLUS

DOCUMENT NUMBER: 137:6352

TITLE: Preparation of benzanilide derivatives as inhibitors of activated blood coagulation factor X

INVENTOR(S): Ishihara, Tsukasa; Hirayama, Fukushi; Sugasawa, Keizo; Koga, Yuji; Kadokura, Takeshi; Shigenaga, Takeshi

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042270	A1	20020530	WO 2001-JP10176	20011121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2002024064	A5	20020603	AU 2002-24064	20011121
CA 2424522	AA	20030331	CA 2001-2424522	20011121
EP 1336605	A1	20030820	EP 2001-997188	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004077555	A1	20040422	US 2003-399625	20030910
PRIORITY APPLN. INFO.:			JP 2000-356146	A 20001122
			JP 2000-390321	A 20001222
			WO 2001-JP10176	W 20011121
OTHER SOURCE(S):			MARPAT 137:6352	
GI				



AB The title compds. I [X1 = CONR5, etc.; X2 = CONR6, etc.; R1 = halo, etc.; R2, R3 = H, halo, CN, etc.; R4 = H, SO3H, etc.; ring A = benzene ring, etc.; ring B = piperidine ring (with substituent on N), etc.; further details on ring B are given; R5, R6 = H, alkyl] are prepared For example, 2'-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4'-bromo-6'-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide was prepared and its activity against the activated blood coagulation factor X was demonstrated.



IT 432029-20-4P 432029-21-5P 432029-22-6P
432029-23-7P 432029-24-8P 432029-25-9P
432029-26-0P 432029-27-1P 432029-29-3P
432029-42-0P 432029-43-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzanilide derivs. as inhibitors of activated blood coagulation factor X)

RN 432029-20-4 CAPLUS



CN Benzamide, N-(5-chloro-2-pyridinyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 432029-21-5 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 432029-22-6 CAPLUS
 CN Benzamide, N-(5-bromo-2-pyridinyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 432029-23-7 CAPLUS
 CN Benzamide, N-(5-bromo-2-pyridinyl)-5-chloro-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 432029-24-8 CAPLUS


CN Benzamide, 3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 432029-25-9 CAPLUS


CN Benzamide, N-(4-chlorophenyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 432029-26-0 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 432029-27-1 CAPLUS


CN Benzamide, 3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-(3-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 432029-29-3 CAPLUS



CN Benzamide, 3-hydroxy-N-(4-methoxyphenyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 432029-42-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 432029-43-1 CAPLUS

CN Benzamide, N-(5-bromo-2-pyridinyl)-5-chloro-3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:171866 CAPLUS


10615809.trn

DOCUMENT NUMBER: 136:232313
 TITLE: Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors
 INVENTOR(S): Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 322 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018350	A1	20020307	WO 2001-JP7397	20010829
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001082520	A5	20020313	AU 2001-82520	20010829
JP 2002145778	A2	20020522	JP 2001-259683	20010829
PRIORITY APPLN. INFO.:			JP 2000-264499	A 20000829
			WO 2001-JP7397	W 20010829

OTHER SOURCE(S): MARPAT 136:232313

GI



AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-containing heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K2CO3 and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temperature and stirred at 65° for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 μM inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation containing II were also prepared


IT 403515-72-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)

RN 403515-72-0 CAPLUS

CN Benzamide, 2-[[[4-amino-2-methyl-5-pyrimidinyl)methyl]amino]-N-[1,1'-biphenyl]-3-yl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:171853 CAPLUS

DOCUMENT NUMBER: 136:232201

TITLE: Preparation of cyclic amine derivatives as CCR3 antagonists

INVENTOR(S): Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuaki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Iura, Yosuke

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080187	A5	20020313	AU 2001-80187	20010827
PRIORITY APPLN. INFO.:			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OTHER SOURCE(S): MARPAT 136:232201

GI



AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)*n*; *n* = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared In an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μ M to 0.45 μ M.


IT 403477-79-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amine derivs. as CCR3 antagonists)

RN 403477-79-2 CAPLUS

CN Benzamide, 2-[[[(2-chlorophenyl)methyl]amino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:11104 CAPLUS

DOCUMENT NUMBER: 136:69743

TITLE: Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.

INVENTOR(S): Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert

PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
US 6844367	B1	20050118	US 2000-663420	20000915
US 2003162690	A1	20030828	US 2002-126976	20020422
US 2004097561	A1	20040520	US 2003-687334	20031015
US 6835739	B2	20041228		
US 2005261346	A1	20051124	US 2004-942733	20040915
US 2006020039	A1	20060126	US 2005-35767	20050114
PRIORITY APPLN. INFO.:			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 1999-154332P	P 19990917
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422
			US 2003-687334	A1 20031015

OTHER SOURCE(S): MARPAT 136:69743

AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkyl naphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkyl naphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.


IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-70-8P 358659-71-9P 358659-72-0P
 358659-73-1P 358659-74-2P 358659-75-3P
 358659-76-4P 358659-77-5P 358659-78-6P
 358659-79-7P 358659-80-0P 358659-81-1P
 358659-82-2P 358659-83-3P 358659-84-4P
 358659-85-5P 358659-86-6P 358659-87-7P
 358659-88-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl benzamides and related compds. as Factor Xa inhibitors)



RN 358659-61-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-62-8 CAPLUS

CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 358659-63-9 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 358659-69-5 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-70-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-
[(dimethylamino)iminomethyl]phenyl]methyl]amino]-3-methoxy- (9CI) (CA
INDEX NAME)




RN 358659-71-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-
1H-imidazol-2-yl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-72-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-
(5-chloro-2-pyridinyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-73-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-77-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-80-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)





RN 358659-81-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-83-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-85-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-86-6 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-87-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:833307 CAPLUS

DOCUMENT NUMBER: 136:53680


TITLE: Preparation of anthranilic acid arylamides as inhibitors of tyrosine kinase KDR and FLT.

INVENTOR(S): Krueger, Martin; Huth, Andreas; Petrov, Orlin; Seidelmann, Dieter; Thierauch, Karl-Heinz; Haberey,

PATENT ASSIGNEE(S) : Martin; Menrad, Andreas; Ernst, Alexander
 SOURCE: Schering Aktiengesellschaft, Germany
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085719	A1	20011115	WO 2001-EP5214	20010508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10023486	C1	20020314	DE 2000-10023486	20000509
CA 2407852	AA	20011115	CA 2001-2407852	20010508
EP 1280799	A1	20030205	EP 2001-940416	20010508
EP 1280799	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010621	A	20030325	BR 2001-10621	20010508
JP 2003532725	T2	20031105	JP 2001-582320	20010508
AT 258174	E	20040215	AT 2001-940416	20010508
EE 200200625	A	20040415	EE 2002-625	20010508
PT 1280799	T	20040630	PT 2001-940416	20010508
ES 2214424	T3	20040916	ES 2001-1940416	20010508
NZ 521700	A	20050930	NZ 2001-521700	20010508
RU 2264399	C2	20051120	RU 2002-131887	20010508
NO 2002005358	A	20021108	NO 2002-5358	20021108
BG 107261	A	20030630	BG 2002-107261	20021108
ZA 2002009896	A	20040305	ZA 2002-9896	20021205
US 2004102441	A1	20040527	US 2003-275480	20030624
US 2006014747	A1	20060119	US 2005-218423	20050906
PRIORITY APPLN. INFO.:			DE 2000-10023486	A 20000509
			WO 2001-EP5214	W 20010508
			US 2003-275480	A3 20030624

OTHER SOURCE(S) : MARPAT 136:53680
 GI



AB Title compds. [I; R1 = (substituted) oxobenzopyran-3-yl, quinolinyl, Ph, isoquinolinyl, benzimidazolyl, etc.; R2 = pyridyl, 2-oxopyridyl, 2-hydroxypyridyl; R3 = H, F], were prepared Thus, N-(2-oxo-2H-1-benzopyran-3-yl)-2-aminobenzamide (preparation given) was stirred with 4-pyridinecarboxaldehyde in AcOH/MeOH; NaBH₃CN was added to give N-(2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridyl)methyl]aminobenzamide. The latter inhibited KDR with IC₅₀ = 0.003 μM.


IT 381694-53-7P 381694-55-9P 381694-58-2P
381694-61-7P 381694-64-0P 381694-67-3P
381694-70-8P 381694-73-1P 381694-76-4P
381694-79-7P 381694-82-2P 381694-85-5P
381694-88-8P 381694-91-3P 381694-94-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anthranilic acid arylamides as inhibitors of tyrosine kinase KDR and FLT)


RN 381694-53-7 CAPLUS

CN Benzamide, N-(2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 381694-55-9 CAPLUS

CN Benzamide, N-(6-chloro-1H-indazol-5-yl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 381694-58-2 CAPLUS

CN Benzamide, N-(7-methyl-2-oxo-2H-1-benzopyran-6-yl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 381694-61-7 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-(2-oxo-2H-1-benzopyran-3-yl)]- (9CI) (CA INDEX NAME)




RN 381694-64-0 CAPLUS

CN Benzamide, N-(7-methoxy-2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-67-3 CAPLUS

CN Benzamide, N-(6-chloro-2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-70-8 CAPLUS

CN Benzamide, N-(6-bromo-2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-73-1 CAPLUS

CN Benzamide, N-(6-methoxy-2-oxo-2H-1-benzopyran-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-76-4 CAPLUS

CN Benzamide, N-(5-chloro-1H-indazol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-79-7 CAPLUS

CN Benzamide, N-(6-methyl-1H-indazol-5-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-82-2 CAPLUS

CN Benzamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-85-5 CAPLUS

CN Benzamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-88-8 CAPLUS

CN Benzamide, N-[2,5-bis(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 381694-91-3 CAPLUS

CN Benzamide, N-(4-bromo-3-isoquinoliny)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 381694-94-6 CAPLUS

CN Benzamide, N-(6-chloro-3-quinolinyl)-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:833281 CAPLUS

DOCUMENT NUMBER: 135:357850

TITLE: Preparation of 2-(4-pyridylmethylamino)benzamides as vascular endothelial growth factor receptor inhibitors.

INVENTOR(S): Seidelmann, Dieter; Krueger, Martin; Ottow, Eckhard; Huth, Andreas; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085691	A1	20011115	WO 2001-EP5267	20010509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

DE 10023485	A1	20011122	DE 2000-10023485	20000509
US 2003176469	A1	20030918	US 2003-275585	20030509
US 6818661	B2	20041116		
US 2005054692	A1	20050310	US 2004-945690	20040921

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 135:357850
 GI



AB Title compds. [I; A = NR7; W = O, S, H2, NR8; Z = bond, NR10, N; R1 = (substituted) alkyl, alkenyl, cycloalkyl, cycloalkenyl; X = alkyl; R2 = (substituted) mono- or bicyclic heteroaryl; R3-R6 = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R7 = H, alkyl, cycloalkyl; R8, R9, R10 = H, alkyl], were prepared Thus, 4-methylcyclohexylamine in PhMe was treated with Me3Al in PhMe under ice cooling; Me N-(4-pyridylmethyl)anthranilate (preparation given) in PhMe was then added followed by warming to room temperature


and then reflux for 1 h to give 90% N-(4-methylcyclohexyl)-2-(4-pyridylmethylamino)benzamide. Tested I inhibited VEGFR I (FLT) with IC50 = 100-2000 μ M.

IT 373362-95-9P 373362-96-0P 373362-97-1P
 373362-99-3P 373363-00-9P 373363-01-0P
 373363-03-2P 373363-12-3P 373363-14-5P
 373363-16-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-(4-pyridylmethylamino)benzamides as vascular endothelial growth factor receptor inhibitors)

RN 373362-95-9 CAPLUS


CN Benzamide, N-(4-methylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 373362-96-0 CAPLUS


CN Benzamide, N-cyclopropyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX

NAME)




RN 373362-97-1 CAPLUS

CN Benzamide, N-cyclohexyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 373362-99-3 CAPLUS

CN Benzamide, N-cyclooctyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 373363-00-9 CAPLUS

CN Benzamide, N-(2-methylcyclohexyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 373363-01-0 CAPLUS

CN Benzamide, N-(2,3-dimethylcyclohexyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 373363-03-2 CAPLUS


CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-tricyclo[3.3.1.1.3,7]dec-1-yl-
(9CI) (CA INDEX NAME)



RN 373363-12-3 CAPLUS

CN Benzamide, N-[(1S,2S)-2-(phenylmethoxy)cyclohexyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 373363-14-5 CAPLUS


CN Benzamide, N-[(1S,2S)-2-(benzyloxy)cyclohexyl]-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 373363-16-7 CAPLUS
 CN Benzamide, N-(trans-4-methylcyclohexyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:833262 CAPLUS

DOCUMENT NUMBER: 135:357772

TITLE: Preparation of (heterocyclyl)anthranilamides as inhibitors of vascular endothelial growth factor receptors.

INVENTOR(S): Krueger, Martin; Huth, Andreas; Petrov, Orlin; Seidelmann, Dieter; Thierauch, Karl-Heinz; Haberey, Martin; Menrad, Andreas; Ernst, Alexander

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001085671	A2	20011115	WO 2001-EP5168	20010507
WO 2001085671	A3	20020411		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10023484	A1	20011122	DE 2000-10023484	20000509
CA 2407817	AA	20021030	CA 2001-2407817	20010507
EP 1280762	A2	20030205	EP 2001-938194	20010507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010486	A	20030401	BR 2001-10486	20010507
JP 2003533450	T2	20031111	JP 2001-582272	20010507
EE 200200626	A	20040415	EE 2002-626	20010507
NZ 521701	A	20051028	NZ 2001-521701	20010507
RU 2263664	C2	20051110	RU 2002-131885	20010507
NO 2002005357	A	20021108	NO 2002-5357	20021108
BG 107260	A	20030630	BG 2002-107260	20021108
ZA 2002009905	A	20040305	ZA 2002-9905	20021205
US 2004029880	A1	20040212	US 2003-275479	20030623
US 7012081	B2	20060314		
US 2005261343	A1	20051124	US 2005-193421	20050801
PRIORITY APPLN. INFO.:			DE 2000-10023484	A 20000509
			WO 2001-EP5168	W 20010507
			US 2003-275479	A3 20030623
OTHER SOURCE(S):			MARPAT 135:357772	
GI				



AB Title compds. [I; A = NR7; D = N, CR3; E = N, CR4; F = N, CR5; G = N, CR6; W = O, S, H2, NR8; Z = bond, NR10, N, alkyl, etc.; R1 = (substituted) alkyl, alkenylcycloalkyl, cycloalkenyl, aryl, heteroaryl; R2 = alicyclyl, ketoalicyclyl, heterocyclyl; R3-R6 = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R7 = H, alkyl; R8, R9, R10 = H, alkyl], were prepared Thus, 3-aminoisoquinoline in PhMe at 4° was treated with Me3Al in PhMe; Me 2-(4,4-ethylenedioxcyclohexylmethyl)aminobenzoate (preparation given) was added followed by heating at 120° for 2 h to give 39.3% 2-[4,4-N-(isoquinolinolin-3-yl)-2-(4,4-ethylenedioxy)cyclohexylmethyl]aminobenzamide. This was stirred 3 h with HCl in acetone/H2O to give 2-[4,4-N-(isoquinolin-3-yl)-2-(4-oxocyclohexylmethyl)]aminobenzamide. The latter inhibited VEGFR1I (KDR) with IC50 = 0.02 μM.


IT 372143-15-2P 372143-21-0P 372143-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heterocyclyl)anthranilamides as inhibitors of vascular endothelial growth factor receptors)


RN 372143-15-2 CAPLUS

CN Benzamide, 2-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-3-isoquinolinyl-
(9CI) (CA INDEX NAME)




RN 372143-21-0 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 372143-23-2 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[[[4-oxocyclohexyl)methyl]amino]- (9CI)
(CA INDEX NAME)



L4 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:661392 CAPLUS

DOCUMENT NUMBER: 135:226888

TITLE: Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.

INVENTOR(S): Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert

PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 322 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6844367	B1	20050118	US 2000-663420	20000915
CA 2401778	AA	20010907	CA 2001-2401778	20010228
EP 1259485	A2	20021127	EP 2001-918257	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 311366	E	20051215	AT 2001-918257	20010228
US 2006020039	A1	20060126	US 2005-35767	20050114
PRIORITY APPLN. INFO.:				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			US 1999-154332P	P 19990917
			WO 2001-US6255	W 20010228

OTHER SOURCE(S): MARPAT 135:226888

AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-70-8P 358659-71-9P 358659-72-0P
 358659-73-1P 358659-74-2P 358659-75-3P
 358659-76-4P 358659-77-5P 358659-78-6P
 358659-79-7P 358659-80-0P 358659-81-1P
 358659-82-2P 358659-83-3P 358659-84-4P
 358659-85-5P 358659-86-6P 358659-87-7P


358659-88-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl benzamides and related compds. as Factor Xa inhibitors)



RN 358659-61-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-62-8 CAPLUS

CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 358659-63-9 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 358659-69-5 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-70-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-
[(dimethylamino)iminomethyl]phenyl]methyl]amino]-3-methoxy- (9CI) (CA
INDEX NAME)




RN 358659-71-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-
1H-imidazol-2-yl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-72-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidyliminomethyl)phenyl]methyl]amino]-5-chloro-N-
(5-chloro-2-pyridinyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-73-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl)methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-77-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-80-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)





RN 358659-81-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-83-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-85-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-86-6 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-87-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:661391 CAPLUS

DOCUMENT NUMBER: 135:210946

TITLE: Preparation of pyridylamides as Factor Xa inhibitors.

INVENTOR(S): Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert

PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6844367	B1	20050118	US 2000-663420	20000915
US 2006020039	A1	20060126	US 2005-35767	20050114
PRIORITY APPLN. INFO.:			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			US 1999-154332P	P 19990917

OTHER SOURCE(S): MARPAT 135:210946


AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclyl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (preparation given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino]phenylcarboxamide.

IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-70-8P 358659-71-9P 358659-72-0P
 358659-73-1P 358659-74-2P 358659-75-3P
 358659-76-4P 358659-77-5P 358659-78-6P
 358659-79-7P 358659-80-0P 358659-81-1P
 358659-82-2P 358659-83-3P 358659-84-4P
 358659-85-5P 358659-86-6P 358659-87-7P
 358659-88-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridylamides as Factor Xa inhibitors)



RN 358659-61-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-62-8 CAPLUS

CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 358659-63-9 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 358659-69-5 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-70-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-
[(dimethylamino)iminomethyl]phenyl]methyl]amino]-3-methoxy- (9CI) (CA
INDEX NAME)




RN 358659-71-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-
1H-imidazol-2-yl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-72-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-5-chloro-N-
(5-chloro-2-pyridinyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-73-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-77-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-80-0 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)





RN 358659-81-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-83-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS

CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-85-5 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-86-6 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:167959 CAPLUS

DOCUMENT NUMBER: 134:222527


TITLE: Preparation of (ar)alkylsulfonylbenzamides as hypolipemic agents

INVENTOR(S): Kirsch, Reinhard; Schaefer, Hans-Ludwig; Falk, Eugen; Hemmerle, Horst

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016094	A1	20010308	WO 2000-EP8027	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19941540	A1	20010308	DE 1999-19941540	19990901
DE 19941540	C2	20020829		
DE 10027611	A1	20011213	DE 2000-10027611	20000606
CA 2383781	AA	20010308	CA 2000-2383781	20000817
BR 2000013727	A	20020507	BR 2000-13727	20000817
EP 1218341	A1	20020703	EP 2000-953172	20000817
EP 1218341	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508380	T2	20030304	JP 2001-519664	20000817
EE 200200095	A	20030415	EE 2002-95	20000817
AU 774071	B2	20040617	AU 2000-65712	20000817
AT 302754	E	20050915	AT 2000-953172	20000817
NO 2002000811	A	20020430	NO 2002-811	20020219
PRIORITY APPLN. INFO.:			DE 1999-19941540	A 19990901
			DE 2000-10027611	A 20000606
			WO 2000-EP8027	W 20000817

OTHER SOURCE(S): MARPAT 134:222527
 GI




AB Title compds. [I; R, R1-R3 = alkyl, NR6R7, pyridylmethyl, phenyl(alkyl), etc.; R6,R7 = H, alkyl, alkoxy(alkyl), aryl(alkyl), etc.] were prepared Thus, 4-chloro-2-fluorobenzoic acid was converted in 7 steps to I (R = CH2Ph, R1 = 4-phenyl-1-piperidinyl, R2 = NHCH2CH2NMe2, R3 = NEt2). Data for biol. activity of I were given.

IT 328392-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (ar)alkylsulfonylbenzamides as hypolipemic agents)

RN 328392-15-0 CAPLUS
 CN Benzamide, N-methyl-5-[(methylphenylamino)sulfonyl]-N-phenyl-2-[(2-pyridinylmethyl)amino]-4-[[2-(1-pyrrolidiny)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:165753 CAPLUS

DOCUMENT NUMBER: 134:207721

TITLE: Preparation of sulfonylcarboxamides and their use in treatment or prophylaxis of hyperlipidemia

INVENTOR(S): Kirsch, Reinhard; Schaefer, Hans-Ludwig; Falk, Eugen; Hemmerle, Horst

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 18 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19941540	A1	20010308	DE 1999-19941540	19990901
DE 19941540	C2	20020829		
CA 2383781	AA	20010308	CA 2000-2383781	20000817
WO 2001016094	A1	20010308	WO 2000-EP8027	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013727	A	20020507	BR 2000-13727	20000817

EP 1218341	A1	20020703	EP 2000-953172	20000817
EP 1218341	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508380	T2	20030304	JP 2001-519664	20000817
EE 200200095	A	20030415	EE 2002-95	20000817
AU 774071	B2	20040617	AU 2000-65712	20000817
AT 302754	E	20050915	AT 2000-953172	20000817
US 6342512	B1	20020129	US 2000-654841	20000901
US 2002072520	A1	20020613	US 2001-963380	20010927
US 6552048	B2	20030422		
NO 2002000811	A	20020430	NO 2002-811	20020219
ZA 2002001593	A	20030929	ZA 2002-1593	20020226
PRIORITY APPLN. INFO.:				
			DE 1999-19941540	A 19990901
			DE 2000-10027611	A 20000606
			WO 2000-EP8027	W 20000817
			US 2000-654841	A3 20000901

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Sulfonylcarboxamides such as I, II, and III were prepared Thus, I was prepared in 7 steps starting with chlorosulfonylation of 4-chloro-2-fluorobenzoic acid and proceeding via 5-(benzylsulfonyl)-4-chloro-N,N-diethyl-2-fluorobenzamide. At 20 mg/kg p.o. III lowered total cholesterol, LDL cholesterol, and triglycerides in hyperlipidemic hamsters by 16, 57, and 11%, resp.

IT 328392-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonylcarboxamides for treatment or prophylaxis of hyperlipidemia)

RN 328392-15-0 CAPLUS

CN Benzamide, N-methyl-5-[(methylphenylamino)sulfonyl]-N-phenyl-2-[(2-pyridinylmethyl)amino]-4-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:457059 CAPLUS

DOCUMENT NUMBER: 133:89437

TITLE: Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors

INVENTOR(S): Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajjan Pariyadan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong

PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.

SOURCE: PCT Int. Appl., 403 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039118	A1	20000706	WO 1999-US29946	19991215
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2361149	AA	20000706	CA 1999-2361149	19991215
EP 1140903	A1	20011010	EP 1999-964279	19991215
EP 1140903	B1	20040804		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002533454	T2	20021008	JP 2000-591029	19991215
AT 272633	E	20040815	AT 1999-964279	19991215
ES 2226485	T3	20050316	ES 1999-964279	19991215
US 6635657	B1	20031021	US 2001-857751	20010608
US 2004029874	A1	20040212	US 2003-629760	20030729
US 6759414	B2	20040706		
US 2005282862	A1	20051222	US 2003-629817	20030729
PRIORITY APPLN. INFO.:			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
			US 2001-857751	A3 20010608

OTHER SOURCE(S): MARPAT 133:89437

GI



AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.



IT 280769-11-1P 280769-16-6P 280769-22-4P
 280769-23-5P 280769-24-6P 280769-46-2P
 280769-68-8P 280769-83-7P 280770-51-6P
 280770-52-7P 280770-59-4P 280770-66-3P
 280770-79-8P 280770-91-4P 280770-93-6P
 280770-95-8P 280771-47-3P 280771-49-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors)


RN 280769-11-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI)
 (CA INDEX NAME)




RN 280769-16-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-22-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-cyano-4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-23-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 280769-24-6 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 280769-46-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[2-[[[5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 280769-68-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[2-[[[5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-1-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 280769-83-7 CAPLUS


CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-51-6 CAPLUS
 CN Benzoic acid, 4-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 280770-52-7 CAPLUS
 CN Benzoic acid, 4-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-3-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 280770-59-4 CAPLUS
 CN Benzamide, 5-chloro-N-(5-methyl-2-pyridinyl)-2-[[[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-66-3 CAPLUS

CN Benzamide, 5-chloro-N-(5-methyl-2-pyridinyl)-2-[[[1-(tetrahydro-3-thienyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-79-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-methyl-2-[[4-(piperidin-1-yl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-91-4 CAPLUS



CN 1-Piperidineacetic acid, 4-[[[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 280770-93-6 CAPLUS
 CN Benzamide, 5-chloro-N-(5-fluoro-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 280770-95-8 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 280771-47-3 CAPLUS
 CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 280771-49-5 CAPLUS
 CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 280769-12-2P 280769-26-8P 280769-27-9P
 280769-33-7P 280769-48-4P 280769-49-5P
 280769-50-8P 280769-51-9P 280769-52-0P
 280769-53-1P 280769-54-2P 280769-56-4P
 280769-57-5P 280769-64-4P 280769-65-5P
 280769-70-2P 280769-74-6P 280769-76-8P
 280769-84-8P 280769-85-9P 280769-86-0P
 280769-89-3P 280769-91-7P 280769-92-8P
 280769-93-9P 280769-94-0P 280769-95-1P
 280769-96-2P 280769-97-3P 280769-98-4P
 280769-99-5P 280770-00-5P 280770-01-6P
 280770-02-7P 280770-03-8P 280770-04-9P
 280770-05-0P 280770-06-1P 280770-07-2P
 280770-08-3P 280770-09-4P 280770-10-7P
 280770-11-8P 280770-12-9P 280770-13-0P
 280770-14-1P 280770-15-2P 280770-16-3P
 280770-17-4P 280770-18-5P 280770-19-6P
 280770-20-9P 280770-21-0P 280770-22-1P
 280770-23-2P 280770-24-3P 280770-25-4P
 280770-26-5P 280770-27-6P 280770-28-7P
 280770-29-8P 280770-30-1P 280770-31-2P
 280770-32-3P 280770-33-4P 280770-34-5P
 280770-35-6P 280770-36-7P 280770-37-8P
 280770-38-9P 280770-39-0P 280770-40-3P

280770-41-4P 280770-42-5P 280770-43-6P
 280770-44-7P 280770-45-8P 280770-46-9P
 280770-53-8P 280770-54-9P 280770-55-0P
 280770-56-1P 280770-58-3P 280770-60-7P
 280770-61-8P 280770-62-9P 280770-63-0P
 280770-64-1P 280770-65-2P 280770-67-4P
 280770-68-5P 280770-69-6P 280770-70-9P
 280770-71-0P 280770-72-1P 280770-73-2P
 280770-74-3P 280770-75-4P 280770-76-5P
 280770-77-6P 280770-78-7P 280770-80-1P
 280770-81-2P 280770-82-3P 280770-83-4P
 280770-84-5P 280770-85-6P 280770-86-7P
 280770-87-8P 280770-88-9P 280770-89-0P
 280770-90-3P 280770-92-5P 280770-94-7P
 280770-96-9P 280770-97-0P 280770-98-1P
 280770-99-2P 280771-00-8P 280771-01-9P
 280771-02-0P 280771-03-1P 280771-04-2P
 280771-44-0P 280771-48-4P 280771-50-8P
 280771-51-9P 280771-52-0P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl-substituted aromatic amides as factor Xa

inhibitors)



RN 280769-12-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-26-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280769-27-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-33-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-[4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-1-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 280769-32-6

CMF C24 H24 Cl N5 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 280769-48-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-[(methylsulfonyl)amino]-2-[[[1-(4-pyridinyl)-4-piperidinyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 280769-49-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(cyclopropylmethyl)-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-50-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(4-pyridinylmethyl)-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-51-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-52-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-53-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2,2-dimethylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-54-2 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280769-56-4 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-methyl-4-pyridinyl)-4-piperidinyl]methyl]amino]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 280769-57-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)





RN 280769-64-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]-4-fluorophenyl]amino]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)





RN 280769-65-5 CAPLUS

CN Benzamide, 2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280769-70-2 CAPLUS

CN Benzamide, 5-chloro-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280769-74-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-76-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[2-[(hydroxyamino)iminomethyl]-4-pyridinyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-84-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-ethylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-85-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-86-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-89-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(3-thienylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-91-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-pyridinylmethyl)-4-piperidyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-92-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(2-methylphenyl)methyl]-4-piperidyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-93-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(2-methoxyphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-94-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280769-95-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(3-hydroxyphenyl)methyl]-4-piperidinyl]methyl]amino]-(9CI) (CA INDEX NAME)





RN 280769-96-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-thienylmethyl)-4-piperidinyl]methyl]amino]-(9CI) (CA INDEX NAME)





RN 280769-97-3 CAPLUS

CN Benzamide, 2-[[[1-[(2-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-(9CI) (CA INDEX NAME)




RN 280769-98-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(2-fluorophenyl)methyl]-4-piperidinyl]methyl]amino]-(9CI) (CA INDEX NAME)





RN 280769-99-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(3-fluorophenyl)methyl]-4-piperidinyl]methyl]amino]-(9CI) (CA INDEX NAME)





RN 280770-00-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]-(9CI) (CA INDEX NAME)





RN 280770-01-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(4-methylphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-02-7 CAPLUS

CN Benzamide, 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 280770-03-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(3-methoxyphenyl)methyl]-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-04-9 CAPLUS

CN Benzamide, 2-[[[1-[(4-bromophenyl)methyl]-4-piperidinyl)methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-05-0 CAPLUS


CN Benzamide, 2-[[[1-[(2-bromophenyl)methyl]-4-piperidinyl)methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-06-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(3-methylphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-07-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(cyclohexylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-08-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(3-furanylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-09-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-10-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-furanylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-11-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(3-pyridinylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-12-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1H-imidazol-2-ylmethyl)-4-piperidiny]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-13-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(4-methoxyphenyl)ethyl]-4-piperidiny]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-14-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-thienyl)ethyl]-4-piperidiny]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-15-2 CAPLUS

CN Benzamide, 2-[[[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-16-3 CAPLUS

CN Benzamide, 2-[[[1-[1-(4-chlorophenyl)ethyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-17-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2,5-dimethyl-3-furanyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-18-5 CAPLUS

CN Benzamide, 2-[[[1-[1-(3-chlorophenyl)ethyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 280770-19-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-20-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-ethylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-21-0 CAPLUS

CN Benzamide, N- (5-chloro-2-pyridinyl) -2- [[[1- (tetrahydro-2H-thiopyran-4-yl) -4-piperidinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 280770-22-1 CAPLUS

CN Benzamide, N- (5-chloro-2-pyridinyl) -2- [[[1- (1-cyclopropylethyl) -4-piperidinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 280770-23-2 CAPLUS

CN Benzamide, N- (5-chloro-2-pyridinyl) -2- [[[1- (1-cyclohexyl-4-piperidinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 280770-24-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-25-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-3-thienyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-26-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(cyclopentyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-27-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2-pyridinyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-28-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(cyclobutyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-29-8 CAPLUS


CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-propylbutyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-30-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(2,3-dihydro-1H-inden-2-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-31-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-thiazolyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-32-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-pyridinyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-33-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-furanyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-34-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-fluorophenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-35-6 CAPLUS



CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-36-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-methoxyphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-37-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(4-methylphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-38-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-methoxyphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-39-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-hydroxyphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-40-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-hydroxyphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-41-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-methylphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-42-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-phenylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-43-6 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(2-fluorophenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-44-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-methylphenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-45-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1'-methyl[1,4'-bipiperidin]-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-46-9 CAPLUS



CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[(1-methyl-4-piperidinyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 280770-53-8 CAPLUS


CN Benzoic acid, 4-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-3-[[[1-(1-methylethyl)-4-piperidinyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 280770-54-9 CAPLUS


CN Benzoic acid, 4-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-3-[[[1-(4-pyridinyl)-4-piperidinyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 280770-55-0 CAPLUS

CN Benzamide, 2-[[[1-[2-(aminothioxomethyl)-4-pyridinyl]-4-piperidinyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 280770-56-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 280770-58-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[2-(hydroxymethyl)-4-pyridinyl]-4-piperidinyl]methyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 280770-57-2


CMF C24 H26 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 280770-60-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-methyl-2-pyridinyl)-2-[[[1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-61-8 CAPLUS

CN Benzamide, 5-chloro-2-[[[1-(cycloheptyl-4-piperidinyl)methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 280770-62-9 CAPLUS


CN Benzamide, 5-chloro-2-[[[1-(1-methylpropyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-63-0 CAPLUS
 CN Benzamide, 5-chloro-2-[[[1-(1-ethylpropyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 280770-64-1 CAPLUS
 CN Benzamide, 5-chloro-2-[[[1-(1-cyclohexyl-4-piperidinyl)methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280770-65-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-methyl-2-pyridinyl)-2-[[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-67-4 CAPLUS

CN Benzamide, 5-chloro-N- (5-methyl-2-pyridinyl) -2- [[1- (tetrahydro-1,1-dioxido-3-thienyl) -4-piperidinyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 280770-68-5 CAPLUS

CN Benzamide, 5-chloro-2- [[1- (1-cyclopentyl-4-piperidinyl) methyl] amino] -N- (5-methyl-2-pyridinyl) - (9CI) (CA INDEX NAME)



RN 280770-69-6 CAPLUS


CN Benzamide, 5-chloro-2- [[1- (1-cyclopropylethyl) -4-piperidinyl]methyl]amino] -N- (5-methyl-2-pyridinyl) -, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 280770-70-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-cyclopropylethyl)-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-71-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-cyclopentyl-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-72-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-cyclohexyl-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-73-2 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-74-3 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(cycloheptyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-75-4 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(3,3,3-trifluoro-1-methylpropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-76-5 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-3-thienyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-77-6 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-78-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(tetrahydro-1-oxido-2H-thiopyran-4-yl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-80-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-methyl-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-81-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-cyclopropylethyl)-4-piperidinyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)





RN 280770-82-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-cyclohexyl)-4-piperidinyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)





RN 280770-86-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(1-oxobutyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-87-8 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(2-methyl-1-oxopropyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-88-9 CAPLUS


CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(2-thienylcarbonyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-89-0 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(4-morpholinylcarbonyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-90-3 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-γ-oxo-, methyl ester (9CI) (CA INDEX NAME)





RN 280770-92-5 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 280770-94-7 CAPLUS

CN Benzamide, 5-chloro-N-(5-fluoro-2-pyridinyl)-2-[[[1-(1-methylethyl)-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-96-9 CAPLUS

CN Benzamide, 2-[[[1-(1-acetyl-4-piperidinyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 280770-97-0 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 280770-98-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(2-cyano-1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280770-99-2 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-β-methyl-, methyl ester (9CI) (CA INDEX NAME)





RN 280771-00-8 CAPLUS

CN 1-Piperidinepropanamide, 4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 280771-01-9 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 280771-02-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)





RN 280771-03-1 CAPLUS



CN 1-Piperidinepropanoic acid, 4-[[[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 280771-04-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[1-(2-cyanoethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280771-44-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-4-(hydroxymethyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 280771-48-4 CAPLUS


CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[[1-(1-methylethyl)-4-piperidinyl)methyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 280771-50-8 CAPLUS

CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[[1-(4-pyridinyl)-4-piperidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 280771-51-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[2-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-(methoxycarbonyl)phenyl]amino]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)





RN 280771-52-0 CAPLUS

CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[[1-(2-cyano-4-





(preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors)

1-Piperidinecarboxylic acid, 4-[[[4-amino-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



CN 1-Piperidinecarboxylic acid, 4-[[[5-carboxy-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)





IT 280772-19-2P 280772-20-5P 280772-28-3P
 280772-41-0P 280772-98-7P 280772-99-8P
 280773-00-4P 280773-99-1P 280774-00-7P
 280774-05-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of heteroaryl-substituted aromatic amides as factor Xa
 inhibitors)



RN 280772-19-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[[[5-chloro-2-
 pyridinyl]amino]carbonyl]-4-fluorophenyl]amino]methyl]-, 1,1-dimethylethyl
 ester (9CI) (CA INDEX NAME)




RN 280772-20-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-chloro-2-[[[5-chloro-2-
 pyridinyl]amino]carbonyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)





RN 280772-28-3 CAPLUS

CN Benzamide, 5-amino-N-(5-chloro-2-pyridinyl)-2-[[[1-(4-pyridinyl)-4-
 piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280772-41-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-methyl-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 280772-98-7 CAPLUS

CN Benzoic acid, 4-[[5-chloro-2-pyridinyl)amino]carbonyl]-3-[(4-piperidinylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)





RN 280772-99-8 CAPLUS

CN Benzamide, N-(5-fluoro-2-pyridinyl)-5-methyl-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 280773-00-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-5-[(methylsulfonyl)amino]-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 280773-99-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-5-(hydroxymethyl)phenyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 280774-00-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-4-(hydroxymethyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 280774-05-2 CAPLUS

CN Benzoic acid, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[(4-piperidinylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:457052 CAPLUS

DOCUMENT NUMBER: 133:89436

TITLE: Antithrombotic aryl amides and their preparation

INVENTOR(S): Beight, Douglas Wade; Craft, Trelia Joyce; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajjan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Kyle, Jeffrey Alan

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2000039111 A1 20000706 WO 1999-US29832 19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2358091 AA 20000706 CA 1999-2358091 19991215
EP 1140881 A1 20011010 EP 1999-964269 19991215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2004522689 T2 20040729 JP 2000-591022 19991215
US 6610704 B1 20030826 US 2001-857747 20010608
US 2003191153 A1 20031009 US 2003-374124 20030225
US 6716855 B2 20040406
US 2003199505 A1 20031023 US 2003-378108 20030226
US 6716839 B2 20040406
US 2003199504 A1 20031023 US 2003-377906 20030228
US 6710057 B2 20040323
US 2003212069 A1 20031113 US 2003-382614 20030305
US 6780878 B2 20040824
PRIORITY APPLN. INFO.: US 1998-113778P P 19981223
WO 1999-US29832 W 19991215
US 2001-857747 A3 20010608
OTHER SOURCE(S): CASREACT 133:89436; MARPAT 133:89436
GI



AB Title compds. I [A3-A6, together with the 2 C atoms to which they are attached, form a substituted benzene, A3 = CR3, A4 = CR4, A5 = CR5, A6 = CR6, R3 = H, R4 or R5 = H, Me, F, Cl, carboxy, alkoxycarbonyl, amino, sulfonylamido, and the other of R4 or R5 = H, R6 = H; A3-A6, together with the 2 C atoms to which they are attached, form a substituted heteroarom. ring in which either one of A3-A6 = N and the others = CR3-CR6, or 2 non-adjacent A3-A6 are each N, and each of the others is CR3-CR6, resp., where R3-R6 = H, Me, or 1 of R3-R6 attached to a C not bonded to an N is Cl and the others are H, preferably, none of A3-A6 = N and each of R3-R6 = H, or each of R3, R4 and R6 = H and R5 = Cl, or A3 = N and each of A4-A6 = CH; L1 = NHCO, CONH, CH2NH; Q1 = (un)substituted Ph, 2-furanyl, 2-thienyl, 4-thiazolyl, 2-pyridyl, 2-naphthyl, 1,2-dihydrobenzofuran-5-yl or -6-yl, 1,2-benzisoxazol-6-yl, 6-indolyl, 6-indolinyl, 6-indazolyl, 5-benzimidazolyl, 5-benzotriazolyl; R2 = NHCH2Q2, Q2 = substituted Ph or (un)substituted 4-piperidinyl, preferably, R2 = 4-(4-morpholinyl)benzylamino, [1-(4-pyridinyl)piperidin-4-ylmethyl]amino, (1-isopropylpiperidin-4-ylmethyl)amino] or their pharmaceutically acceptable salts and pharmaceutical compns., useful as inhibitors of blood-coagulation factor Xa (no data), are claimed, along with a process for their preparation and synthetic intermediates. In an example, I [A3 = N,



A4-A6 = CH; L1 = NHCO; Q1 = 4-MeOC6H4; R2 = [1-(4-pyridinyl)piperidin-4-ylmethyl]amino] is prepared in 3 steps starting from 2-chloro-3-nitropyridine and 1-(4-pyridyl)piperidine-4-methylamine (preparation given).

IT 280556-80-1P 280556-81-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation as intermediate in synthesis of antithrombotic aryl or heteroaryl amides)



RN 280556-80-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-chloro-2-[(2-pyridinylamino)carbonyl]phenyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 280556-81-2 CAPLUS

CN Benzamide, 5-chloro-2-[(4-piperidinylmethyl)amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)





IT 280556-69-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl amides as antithrombotics)

RN 280556-69-6 CAPLUS

CN Benzamide, 5-chloro-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:335388 CAPLUS

DOCUMENT NUMBER: 132:347491

TITLE: Preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors

INVENTOR(S): Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestan, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346898	AA	20000518	CA 1999-2346898	19991108
BR 9915210	A	20010724	BR 1999-15210	19991108
TR 200101237	T2	20010821	TR 2001-200101237	19991108
EP 1129075	A1	20010905	EP 1999-971802	19991108
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529453	T2	20020910	JP 2000-581000	19991108
AU 758230	B2	20030320	AU 2000-13811	19991108
NZ 511339	A	20030725	NZ 1999-511339	19991108
NO 2001001894	A	20010704	NO 2001-1894	20010417
ZA 2001003290	A	20030123	ZA 2001-3290	20010423


US 2002019414	A1	20020214	US 2001-850434	20010507
US 6448277	B2	20020910		
ZA 2001004673	A	20020909	ZA 2001-4673	20010607
US 2003064992	A1	20030403	US 2002-180289	20020626
US 6878720	B2	20050412		
US 2004198782	A1	20041007	US 2004-828951	20040421
US 7002022	B2	20060221		

PRIORITY APPLN. INFO.:

		GB 1998-24579	A	19981110
		WO 1999-EP8545	W	19991108
		US 2001-850434	A3	20010507
		US 2002-180289	A3	20020626

OTHER SOURCE(S): MARPAT 132:347491

GI



AB Use of title compds. I; W = O, S; X = NR₈; Y = CR₉R₁₀(CH₂)_n, SO₂; R₉, R₁₀ = H, alkyl; n = 0-3; R₁ = aryl; R₂ = mono- or bicyclic heteroaryl with the exception that R₂ cannot = 2-phthalimidyl, and when Y = SO₂ cannot represent 2,1,3-benzothiadiazol-4-yl; R₃-R₆ = H, substituent; R₇, R₈ = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixture of 4-pyridinecarboxaldehyde and 2-amino-N-(4-trifluoromethylphenyl)benzamide (preparation given) in MeOH containing

HOAc was treated with NaBH₃CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethyl)phenyl]benzamide. Tested I inhibited Flt-1 VEGF receptor tyrosine kinase with IC₅₀ = 0.18-0.56 μM.

IT 269390-66-1P 269390-67-2P 269390-68-3P
 269390-69-4P 269390-70-7P 269390-71-8P
 269390-72-9P 269390-73-0P 269390-74-1P
 269390-75-2P 269390-76-3P 269390-77-4P
 269390-78-5P 269390-79-6P 269390-80-9P
 269390-81-0P 269390-82-1P 269390-83-2P
 269390-84-3P 269390-85-4P 269390-86-5P
 269390-87-6P 269390-88-7P 269390-89-8P
 269390-90-1P 269390-91-2P 269390-92-3P
 269390-93-4P 269390-94-5P 269390-95-6P
 269390-96-7P 269390-97-8P 269390-98-9P
 269390-99-0P 269391-00-6P 269391-01-7P
 269391-02-8P 269391-06-2P 269391-08-4P
 269391-09-5P 269391-10-8P 269391-11-9P
 269391-12-0P 269391-13-1P 269391-14-2P
 269391-15-3P 269391-16-4P 269391-17-5P
 269391-18-6P 269391-19-7P 269391-20-0P
 269391-21-1P 269391-22-2P 269391-49-3P
 269391-50-6P 269391-53-9P 269391-54-0P
 269391-55-1P 269391-56-2P 269391-57-3P

269391-58-4P 269391-59-5P 269391-60-8P


269391-61-9P 269391-62-0P 269391-63-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)


RN 269390-66-1 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269390-67-2 CAPLUS

CN Benzamide, N-[3-fluoro-4-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-68-3 CAPLUS

CN Benzamide, N-phenyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-69-4 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269390-70-7 CAPLUS


CN Benzamide, N-(3-fluoro-4-methylphenyl)-2-[(4-pyridinylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 269390-71-8 CAPLUS

CN Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-72-9 CAPLUS

CN Benzamide, N-[3-chloro-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-73-0 CAPLUS

CN Benzamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-74-1 CAPLUS

CN Benzamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-75-2 CAPLUS

CN Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-76-3 CAPLUS

CN Benzamide, N-[3-methoxy-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-77-4 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269390-78-5 CAPLUS

CN Benzamide, N-[3-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269390-79-6 CAPLUS


CN Benzamide, N-(3-cyanophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269390-80-9 CAPLUS


CN Benzamide, N-[3-(methylthio)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI)

(CA INDEX NAME)




RN 269390-81-0 CAPLUS

CN Benzamide, N-[3-(acetylamino)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 269390-82-1 CAPLUS

CN Benzamide, N-[3-[(aminocarbonyl)amino]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-83-2 CAPLUS

CN Benzamide, N-[3-(dimethylamino)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 269390-84-3 CAPLUS

CN Benzamide, 5-methoxy-2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269390-85-4 CAPLUS
 CN Benzamide, 3-methyl-2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 269390-86-5 CAPLUS
 CN Benzamide, 4,5-difluoro-2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269390-87-6 CAPLUS
 CN Benzamide, N-methyl-2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269390-88-7 CAPLUS
 CN Benzamide, N-[3-(methylsulfonyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269390-89-8 CAPLUS
 CN Benzamide, N-[3-(methylsulfinyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 269390-90-1 CAPLUS
 CN Benzamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 269390-91-2 CAPLUS
 CN Benzamide, N-(3-chlorophenyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 269390-92-3 CAPLUS
 CN Benzamide, N-(3-bromophenyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 269390-93-4 CAPLUS
 CN Benzamide, N-(3-methylphenyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269390-94-5 CAPLUS
 CN Benzamide, N-(3-benzoylphenyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 269390-95-6 CAPLUS
 CN Benzamide, N-[3-(aminocarbonyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269390-96-7 CAPLUS
 CN Benzamide, 2-methyl-N-(4-methylphenyl)-6-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269390-97-8 CAPLUS

CN Benzamide, 2-[(3-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 269390-98-9 CAPLUS

CN Benzamide, 2-[(4-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 269390-99-0 CAPLUS

CN Benzamide, 2-[(5-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 269391-00-6 CAPLUS

CN Benzamide, 2-[[[(2-methyl-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269391-01-7 CAPLUS

CN Benzamide, 2-[[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269391-02-8 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[[(4-quinolinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 269391-06-2 CAPLUS

CN Benzamide, 2-[[[(1-oxido-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269391-08-4 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-methyl-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269391-09-5 CAPLUS


CN Benzamide, 2-chloro-N-(4-chlorophenyl)-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 269391-10-8 CAPLUS


CN Benzamide, N-(8-hydroxy-2-naphthalenyl)-2-[(4-pyridinylmethyl)amino]-

(9CI) (CA INDEX NAME)




RN 269391-11-9 CAPLUS

CN Benzamide, 4-chloro-N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino] - (9CI)
(CA INDEX NAME)




RN 269391-12-0 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-5-methyl-2-[(4-pyridinylmethyl)amino] - (9CI)
(CA INDEX NAME)




RN 269391-13-1 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl) - (9CI) (CA INDEX NAME)




RN 269391-14-2 CAPLUS

CN Benzamide, N-[1,1'-biphenyl]-4-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-15-3 CAPLUS

CN Benzamide, 5-chloro-N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-16-4 CAPLUS

CN Benzamide, N-2-naphthalenyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-17-5 CAPLUS

CN Benzamide, N-(4-methoxy-2-naphthalenyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-18-6 CAPLUS

CN Benzamide, N-(3-bromo-2-naphthalenyl)-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 269391-19-7 CAPLUS

CN Benzoic acid, 4-[[2-[(4-pyridinylmethyl)amino]benzoyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 269391-20-0 CAPLUS

CN Benzamide, N-[4-[[[(1-methylethyl)amino]carbonyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269391-21-1 CAPLUS

CN Benzamide, N-(3-chloro-4-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 269391-22-2 CAPLUS

CN Benzamide, N-(2-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269391-49-3 CAPLUS

CN Benzamide, N-(3-fluoro-4-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269391-50-6 CAPLUS

CN Benzamide, 3-methyl-2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 269391-53-9 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-(4-chlorophenyl)-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 269391-54-0 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-4,5-dimethyl-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 269391-55-1 CAPLUS

CN Benzamide, 5-chloro-N-(4-propylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 269391-56-2 CAPLUS

CN Benzamide, N-(4-propylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA
INDEX NAME)




RN 269391-57-3 CAPLUS

CN Benzamide, N-(7-hydroxy-1-naphthalenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 269391-58-4 CAPLUS

CN Benzamide, N-1-naphthalenyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-59-5 CAPLUS

CN Benzamide, N-(4-methoxyphenyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 269391-60-8 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethoxy)phenyl] - (9CI) (CA INDEX NAME)




RN 269391-61-9 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[4-(trifluoromethoxy)phenyl] - (9CI) (CA INDEX NAME)




RN 269391-62-0 CAPLUS

CN Benzeneacetic acid, 3-[[2-[(4-pyridinylmethyl)amino]benzoyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 269391-63-1 CAPLUS

CN Benzamide, N-(4-phenoxyphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:335387 CAPLUS

DOCUMENT NUMBER: 132:334364

TITLE: Preparation of anthranilic acid amides as vascular endothelial growth factor receptor inhibitors.

INVENTOR(S): Huth, Andreas; Seidelmann, Dieter; Thierauch, Karl-Heinz; Bold, Guido; Manley, Paul William; Furet, Pascal; Wood, Jeanette Marjorie; Mestan, Jurgen; Bruggen, Jose; Ferrari, Stefano; Kruger, Martin; Ottow, Eckhard; Menrad, Andreas; Schirner, Michael

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany; Novartis Aktiengesellschaft

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
WO 2000027819	A3	20000817		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19910396	A1	20000907	DE 1999-19910396	19990303
DE 19910396	C2	20011213		
CA 2350208	AA	20000518	CA 1999-2350208	19991109
BR 9915553	A	20010814	BR 1999-15553	19991109
EP 1129074	A2	20010905	EP 1999-953967	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101307	T2	20020521	TR 2001-200101307	19991109
JP 2002529452	T2	20020910	JP 2000-580999	19991109
EE 200100258	A	20021216	EE 2001-258	19991109
NZ 511413	A	20040130	NZ 1999-511413	19991109
AU 771180	B2	20040318	AU 2000-10454	19991109
NO 2001002245	A	20010710	NO 2001-2245	20010507
BG 105588	A	20020430	BG 2001-105588	20010611
HK 1041882	A1	20050318	HK 2002-103628	20020514
PRIORITY APPLN. INFO.:			GB 1998-24579	A 19981110
			DE 1999-19910396	A 19990303
			WO 1999-EP8478	W 19991109
OTHER SOURCE(S): MARPAT 132:334364				
GI				



AB Title compds. [I; A = NR₂; W = O, S, H₂, NR₈; Z = NR₁₀, N, NR₁₀(CH₂)_q, alkyl, etc.; q = 1-6; AZR₁ = tetrahydroisoquinolinyl, indazolyl, 5-chloroindolyl, etc.; R₁ = (substituted) aryl, heteroaryl; R₂ = H, alkyl; R₃ = (substituted) mono- or bicyclic aryl, heteroaryl; R₄-R₇ = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R₅R₆ = dioxetanyl; R₈, R₁₀ = H, alkyl]. Thus, Me N-(4-pyridylmethyl)anthranilate (preparation given) was stirred with Ph(CH₂)₃NH₂ and Me₃Al were stirred in PhMe to give N-(3-phenylprop-1-yl)-N₂-(4-pyridylmethyl)anthranilamide. The latter inhibited VEGFR I with IC₅₀ = 0.05 μM.


IT 267891-06-5P 267891-12-3P 267891-15-6P
 267891-19-0P 267891-20-3P 267891-23-6P
 267891-24-7P 267891-25-8P 267891-26-9P
 267891-29-2P 267891-31-6P 267891-32-7P
 267891-33-8P 267891-35-0P 267891-36-1P
 267891-39-4P 267891-40-7P 267891-41-8P
 267891-42-9P 267891-43-0P 267891-44-1P
 267891-45-2P 267891-46-3P 267891-47-4P
 267891-48-5P 267891-49-6P 267891-50-9P
 267891-51-0P 267891-52-1P 267891-53-2P
 267891-55-4P 267891-56-5P 267891-57-6P
 267891-58-7P 267891-59-8P 267891-64-5P
 267891-65-6P 267891-66-7P 267891-67-8P
 267891-68-9P 267891-69-0P 267891-70-3P
 267891-72-5P 267891-73-6P 267891-74-7P

267891-75-8P 267891-76-9P 267891-77-0P
 267891-78-1P 267891-79-2P 267891-80-5P
 267891-81-6P 267891-82-7P 267891-83-8P
 267891-84-9P 267891-85-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anthranilic acid amides as VEGF receptor inhibitors)


RN 267891-06-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-12-3 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 267891-15-6 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 267891-19-0 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)




RN 267891-20-3 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 267891-23-6 CAPLUS

CN Benzamide, N-1-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-24-7 CAPLUS

CN Benzamide, N-(5-chloro-2-pyrimidinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-25-8 CAPLUS


CN Benzamide, N-[1-[(1-bromo-3-isoquinolinyl)amino]-3-isoquinolinyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



RN 267891-26-9 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)





RN 267891-29-2 CAPLUS



CN Benzamide, N-2-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-31-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI)
 (CA INDEX NAME)




RN 267891-32-7 CAPLUS
 CN Benzamide, N-3-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-33-8 CAPLUS
 CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 267891-35-0 CAPLUS
 CN Benzamide, N-(5-phenyl-1H-pyrazol-3-yl)-2-[(4-pyridinylmethyl)amino]-
 (9CI) (CA INDEX NAME)




RN 267891-36-1 CAPLUS
 CN Benzamide, N-(trans-4-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 267891-39-4 CAPLUS
 CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-7-
 quinolinyl)- (9CI) (CA INDEX NAME)




RN 267891-40-7 CAPLUS

CN Benzamide, N-(2-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-41-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-42-9 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 267891-43-0 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)




RN 267891-44-1 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-45-2 CAPLUS

CN Benzamide, N-1H-indol-5-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-46-3 CAPLUS

CN Benzamide, N-(3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-47-4 CAPLUS

CN Benzamide, N-(6-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-48-5 CAPLUS

CN Benzamide, N-(7-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 267891-49-6 CAPLUS

CN Benzamide, N-(6-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 267891-50-9 CAPLUS

CN Benzamide, N-(7-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 267891-51-0 CAPLUS

CN Benzamide, N-(6-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-52-1 CAPLUS

CN Benzamide, N-(7-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-53-2 CAPLUS

CN Benzamide, N-(5-chloro-2-quinazolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-55-4 CAPLUS


CN Benzamide, 2-chloro-6-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)




RN 267891-56-5 CAPLUS
 CN Benzamide, 5-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI)
 (CA INDEX NAME)




RN 267891-57-6 CAPLUS
 CN Benzamide, 4-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI)
 (CA INDEX NAME)



RN 267891-58-7 CAPLUS
 CN Benzamide, 4-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI)
 (CA INDEX NAME)




RN 267891-59-8 CAPLUS
 CN Benzamide, 4,5-difluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-64-5 CAPLUS

CN Benzamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 267891-65-6 CAPLUS

CN Benzamide, N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-66-7 CAPLUS

CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-67-8 CAPLUS

CN Benzamide, 4-fluoro-N-1H-indazol-5-yl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-68-9 CAPLUS

CN Benzamide, N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-69-0 CAPLUS

CN Benzamide, N-1H-benzimidazol-2-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-70-3 CAPLUS

CN Benzamide, N-6-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-72-5 CAPLUS

CN Benzamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-73-6 CAPLUS

CN Benzamide, N-6-benzothiazolyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-74-7 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)




RN 267891-75-8 CAPLUS

CN Benzamide, N-1H-indazol-6-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 267891-76-9 CAPLUS

CN Benzamide, N-4-pyridinyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-77-0 CAPLUS

CN Benzamide, N-(1-methyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-78-1 CAPLUS

CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-79-2 CAPLUS

CN Benzamide, N-1H-benzimidazol-5-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267891-80-5 CAPLUS

CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 267891-81-6 CAPLUS

CN Benzamide, N-2-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 267891-82-7 CAPLUS

CN Benzamide, 5-fluoro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 267891-83-8 CAPLUS


CN Benzamide, 5-chloro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 267891-84-9 CAPLUS
 CN Benzamide, N-2-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino] - (9CI)
 (CA INDEX NAME)



RN 267891-85-0 CAPLUS
 CN Benzamide, N-6-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino] - (9CI)
 (CA INDEX NAME)




IT 267891-96-3 267891-98-5 267891-99-6
 267892-02-4 267892-04-6 267892-09-1
 267892-11-5 267892-14-8 267892-15-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of anthranilic acid amides as VEGF receptor inhibitors)
 RN 267891-96-3 CAPLUS
 CN Benzamide, N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 267891-98-5 CAPLUS


CN Benzamide, N-2,1,3-benzothiadiazol-5-yl-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)



RN 267891-99-6 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267892-02-4 CAPLUS


CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267892-04-6 CAPLUS

CN Benzamide, N-5-isoquinolinyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267892-09-1 CAPLUS

CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267892-11-5 CAPLUS

CN Benzamide, 5-chloro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 267892-14-8 CAPLUS

CN Benzamide, N-2-benzothiazolyl-4-fluoro-2-[(4-pyridinylmethyl)amino] - (9CI)
(CA INDEX NAME)



RN 267892-15-9 CAPLUS

CN Benzamide, N-(4-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




IT 267891-90-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-90-7 CAPLUS

CN Benzamide, 2-[[[1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 49 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:409260 CAPLUS

DOCUMENT NUMBER: 131:73440

TITLE: Preparation of aromatic amide derivatives as ACC inhibitor

INVENTOR(S): Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi

PATENT ASSIGNEE(S): Fujirebio, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11171848	A2	19990629	JP 1998-270721	19980925
PRIORITY APPLN. INFO.:			JP 1997-277942	A 19970926
OTHER SOURCE(S):	MARPAT	131:73440		

GI




AB Title compds. [I; R = 3-CF₃C₆H₄, C₆H₅(CH₂)₂, C₆H₅, CH₃(CH₂)₅, CH₃(CH₂)₃, CH₃(CH₂)₂, CH₃CH₂, CH₃, C₆H₅(CH₂)₃, etc.; R₁ = H, CH₃(CH₂)₄, 5-CH₃(CH₂)₅CC, 5-CH₃CH₂CC, 5-(CH₃)₃CCC, 4-C₆H₅CH₂O, 4-C₆H₅CC, 3-C₆H₅CC, 3-C₆H₅CC, 3-(4-NO₂C₆H₄)CC, 3-(4-NCC₆H₄)CC, 3-(4-HOC₆H₄)CC, etc.; R₂ = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R₃ = H, CH₃, etc.; R₄ = CO₂H, AcNHSO₂, CH₃(CH₂)₄CONHSO₂, 4-CF₃C₆H₄CONHSO₂, PhCONHSO₂, (CH₃)₃CONHSO₂, CH₃(CH₂)₂NHCONHSO₂, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF₃C₆H₄; R₁ = H; R₂ = H; R₃ = H; X = CH; dotted bonds were double bonds) was prepared with 72% yield from 3-EtO₂CC₆H₄NH₂ and 3-(2-HO₂CC₆H₄NH)C₆H₄CF₃.

IT 228580-72-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-72-1 CAPLUS

CN Benzoic acid, 2-[[4-(phenylethynyl)-2-[(phenylmethyl)amino]benzoyl]amino]-(9CI) (CA INDEX NAME)




IT 228580-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-60-7 CAPLUS

CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 228580-61-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-61-8 CAPLUS

CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:236274 CAPLUS

DOCUMENT NUMBER: 128:282780

TITLE: Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein

INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5739135	A	19980414	US 1995-472067	19950606
CA 2091102	AA	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5595872	A	19970121	US 1993-117362	19930903
US 5789197	A	19980804	US 1995-486924	19950607
US 6492365	B1	20021210	US 1995-486929	19950607
US 5712279	A	19980127	US 1996-548811	19960111
IL 116917	A1	20000831	IL 1996-116917	19960126
TW 486469	B	20020511	TW 1996-85100978	19960126
CA 2213466	AA	19960829	CA 1996-2213466	19960201
WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9647631	A1	19960911	AU 1996-47631	19960201
AU 699865	B2	19981217		
CN 1176640	A	19980318	CN 1996-192015	19960201
CN 1108301	B	20030514		
EP 886637	A1	19981230	EP 1996-903604	19960201
EP 886637	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11500442	T2	19990112	JP 1996-525679	19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
AT 283851	E	20041215	AT 1996-903604	19960201
ES 2233961	T3	20050616	ES 1996-903604	19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220
US 5883099	A	19990316	US 1997-896872	19970721
US 6034098	A	20000307	US 1997-898304	19970721
US 6066650	A	20000523	US 1997-898303	19970721
FI 9703416	A	19970820	FI 1997-3416	19970820
NO 9703821	A	19970820	NO 1997-3821	19970820
LT 4367	B	19980825	LT 1997-152	19970919
LV 11951	B	19981120	LV 1997-171	19970919
US 2003166590	A1	20030904	US 2001-933593	20010821
PRIORITY APPLN. INFO.:				
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1992-847503	A 19920306
			US 1993-15449	B2 19930222
			US 1995-472067	A2 19950606
			US 1995-486929	A3 19950607

OTHER SOURCE(S) : MARPAT 128:282780
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)₂; X = CHR₈, C(O), CHR₉CHR₁₀, CR₉:CR₁₀ (wherein R₈-R₁₀ = H, alkyl, alkenyl, etc.); Y = (CH₂)_m, C(O) (m = 2-3); R₁ = alkyl, alkenyl, alkynyl, etc.; R₂-R₄ = H, halo, alkyl, etc.; R₅ = alkyl, alkenyl, alkynyl, etc.; R₆ = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared. Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et₃N in CH₂Cl₂ afforded 84% the title compound III.HCl [Q = C(O); R₁ = 3,3-diphenylpropyl; R₅ = Ph; R₆ = H]. Compds. I-V are effective at 5-500 mg/day.


IT 182429-79-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)


RN 182429-79-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:265454 CAPLUS

DOCUMENT NUMBER: 126:277494

TITLE: Preparation of piperazinybenzamides, piperidylbenzamides, and analogs thereof as inflammation and allergy inhibitors

INVENTOR(S): Kawagoe, Keiichi; Shidonii, Kurifuoodo Baafuoodo; Yokohama, Shuichi; Miwa, Tamotsu; Nakajima, Hiroto; Tsukada, Wataru

PATENT ASSIGNEE(S): Daiichi Seiyaku Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 67 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09059236	A2	19970304	JP 1995-214431	19950823
PRIORITY APPLN. INFO.:			JP 1995-214431	19950823
OTHER SOURCE(S):	MARPAT	126:277494		

GI




AB The title compds. I [R1 = halo, etc.; R2 = halo, nitro, etc.; A = C(:Z)NR3R4, etc.; Z = O, etc.; R3 = (un)substituted aromatic hydrocarbon, etc.; R4 = H, etc.] are prepared N-(4-Chlorophenyl)-3-(4-methyl-1-piperaziny)-2-nitrobenzamide at 50 mg/kg orally gave 79% inhibition of adjuvant arthritis in rats.

IT 188602-70-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinybenzamides, piperidylbenzamides, and analogs thereof as inflammation and allergy inhibitors)

RN 188602-70-2 CAPLUS

CN Benzamide, 3-chloro-N-(4-chlorophenyl)-2-[(2-pyridinylmethyl)amino] - (9CI)
(CA INDEX NAME)



L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:641305 CAPLUS

DOCUMENT NUMBER: 125:275663

TITLE: Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors

INVENTOR(S): Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5739135	A	19980414	US 1995-472067	19950606
AU 9647631	A1	19960911	AU 1996-47631	19960201
AU 699865	B2	19981217		
EP 886637	A1	19981230	EP 1996-903604	19960201
EP 886637	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11500442	T2	19990112	JP 1996-525679	19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
AT 283851	E	20041215	AT 1996-903604	19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220

FI 9703416	A	19970820	FI 1997-3416	19970820
NO 9703821	A	19970820	NO 1997-3821	19970820
LT 4367	B	19980825	LT 1997-152	19970919
PRIORITY APPLN. INFO.:			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			US 1992-847503	A 19920306
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			WO 1996-US824	W 19960201

OTHER SOURCE(S): MARPAT 125:275663
GI




AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO₂; 1 of Z4,Z5 = NR1 and the other = CH₂; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SOO-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorenecarboxamide (preparation given) was alkylated by I(CH₂)₄OSiMe₂CMe₃ (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

IT 182429-79-4P 182433-96-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)


RN 182429-79-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 182433-96-1 CAPLUS
 CN 9H-Fluorene-9-carboxamide, 9-[4-[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L4 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:571361 CAPLUS
 DOCUMENT NUMBER: 117:171361
 TITLE: Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
 AUTHOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
 CORPORATE SOURCE: Perm. Farm. Inst., Perm, Russia
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI



AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranilanilides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

IT 139602-64-5P 139602-66-7P 139602-67-8P


139602-68-9P 139602-69-0P 139602-71-4P

139602-72-5P 139602-73-6P 143424-22-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)



RN 139602-64-5 CAPLUS

CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS

CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-67-8 CAPLUS

CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 139602-68-9 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)




RN 139602-69-0 CAPLUS

CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA
INDEX NAME)




RN 139602-71-4 CAPLUS

CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 139602-72-5 CAPLUS

CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 139602-73-6 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)




RN 143424-22-0 CAPLUS

CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:128388 CAPLUS
 DOCUMENT NUMBER: 116:128388
 TITLE: Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
 INVENTOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
 PATENT ASSIGNEE(S): Perm Pharmaceutical Institute, USSR
 SOURCE: U.S.S.R. From: Otkrytiya, Izobret. 1991, (28), 258. CODEN: URXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1156362	A1	19910730	SU 1983-3573020	19830217
PRIORITY APPLN. INFO.: GI			SU 1983-3573020	19830217





AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4-(3H)-quinazolinon-1-yl perchlorates.
 IT 139602-64-5 139602-65-6 139602-66-7
 139602-67-8 139602-68-9 139602-69-0
 139602-70-3 139602-71-4 139602-72-5
 139602-73-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate for quinazolinon-1-yl perchlorate derivs.)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 139602-65-6 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)-
 (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 139602-68-9 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[2,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)





RN 139602-69-0 CAPLUS

CN Benzamide, 2-[[3,4-dimethoxyphenyl)methyl]amino]-N-phenyl-(9CI) (CA INDEX NAME)




RN 139602-70-3 CAPLUS


CN Benzamide, 2-[[3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)-(9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 139602-73-6 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]-
 (9CI) (CA INDEX NAME)



L4 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1984:611088 CAPLUS
 DOCUMENT NUMBER: 101:211088
 TITLE: Studies of 4[3H]-quinazolinone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2-methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
 AUTHOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
 CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI




AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-EtOC6H4, R1 = NO2) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1-p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH containing 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.
 IT 92944-76-8P 92944-77-9P 92944-78-0P
 92944-79-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)
 RN 92944-76-8 CAPLUS
 CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 92944-77-9 CAPLUS

CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 92944-78-0 CAPLUS

CN Benzamide, N-(4-methoxyphenyl)-2-[[[(4-nitrophenyl)methyl]amino]benzamide]- (9CI) (CA INDEX NAME)




RN 92944-79-1 CAPLUS


CN Benzamide, N-(4-ethoxyphenyl)-2-[[[(4-nitrophenyl)methyl]amino]benzamide]- (9CI) (CA INDEX NAME)



L4 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1984:34516 CAPLUS
 DOCUMENT NUMBER: 100:34516
 TITLE: New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
 AUTHOR(S): Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
 CORPORATE SOURCE: Chem. Res. Co., San Giovanni, Italy
 SOURCE: Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:34516
 GI




AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N- α -chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.
 IT 88369-73-7P 88369-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 88369-73-7 CAPLUS
 CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 88369-74-8 CAPLUS

CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



L4 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1983:558250 CAPLUS

DOCUMENT NUMBER: 99:158250

TITLE: Antihypertensive sulfamoylbenzamides

PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58124766	A2	19830725	JP 1982-4979	19820118
JP 02033030	B4	19900725		
PRIORITY APPLN. INFO.:			JP 1982-4979	19820118
OTHER SOURCE(S):		CASREACT 99:158250		

GI



AB I [R₁ = H, (substituted) alkyl; R₂ = substituted Ph, (substituted) benzyl] were prepared via condensation of II with HNR₁CH₂R₂. Thus, heating a mixture of 6 g II (R = Cl) with 25 mL H₂NCH₂Ph at 90° for 45 h gave 5 g I


(R1 = H, R2 = Ph). At 30 mg/kg/day p.o. I decreased deoxycorticosterone acetate/saline-induced hypertension (182-195 mmHg) in rats by 9-24% in 5 days.

IT 87445-66-7P 87445-71-4P 87445-72-5P
87445-73-6P 87445-74-7P 87445-75-8P
87445-76-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihypertensive activity of)


RN 87445-66-7 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 87445-71-4 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(4-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)




RN 87445-72-5 CAPLUS


CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(2-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)




RN 87445-73-6 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(2,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI)
 (CA INDEX NAME)




RN 87445-74-7 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(3,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI)
 (CA INDEX NAME)




RN 87445-75-8 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[3-methylphenyl)methyl]amino] - (9CI) (CA INDEX NAME)



RN 87445-76-9 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[2-methylphenyl)methyl]amino] - (9CI) (CA INDEX NAME)



L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1980:41519 CAPLUS
 DOCUMENT NUMBER: 92:41519
 TITLE: Chemistry of salicylic acid and anthranilic acid. IV. Synthesis of 6-chloro-5-sulfamoyl- and 6-chloro-3-sulfamoylanthranilic acid derivatives
 AUTHOR(S): Asakawa, Hiroyuki; Matano, Mitsuo
 CORPORATE SOURCE: Chem. Res. Lab., Takeda Chem. Ind., Osaka, 532, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1979), 27(6), 1287-98
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 92:41519
 GI




AB Title chlorosulfamoylanthranilic acids I (R = PhCH₂, Bu, EtOCH₂CH₂, EtSCH₂CH₂, HOCH₂CH₂; R₁ = e.g. H, o-tolyl, tetrahydrofuryl, Et₂NCH₂CH₂) and II (R₂ = PhCH₂, H) were prepared to compare the diuretic activities of the two positional isomers. An o-Cl group to the CO₂H enhanced the hypoglycemic activity of anthranilic acids but had no effect on the diuretic activity of sulfamoylanthranilic acids. I had greater diuretic activity than II.

IT 72290-01-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and diuretic activity of)

RN 72290-01-8 CAPLUS

CN Benzamide, 3-(aminosulfonyl)-6-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1977:534708 CAPLUS

DOCUMENT NUMBER: 87:134708

TITLE: Substituted anthranilamides and preparation thereof

INVENTOR(S): Shetty, Bolva V.

PATENT ASSIGNEE(S): Pennwalt Corp., USA

SOURCE: Can., 26 pp.

CODEN: CAXXA4

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1000736	A1	19761130	CA 1971-103215	19710120
PRIORITY APPLN. INFO.:			CA 1971-103215	A 19710120


AB Substituted anthranilamides 5,2,4-(RR1NO2S) (R2HN)ClC6H2CONHC6H2R3R4R5 (I: R, R1 = H, alkyl, Ph, PhCH2; R2 = H, alkyl, PhCH2, Ac; R3, R4, R5 = H, alkyl, alkoxy, NH2, etc.), useful in the synthesis of diuretic 1,2,3,4-tetrahydro-7-chloro-3-phenyl-6-sulfamoyl-4-quinazolinone derivs., were prepared by one of several routes. Thus, 2,5-MeClC6H3NH2 was converted by sequential acetylation, sulfamoylation, oxidation, and hydrolysis, then treatment with COCl2-AcOH, followed by 2-MeC6H4NH2, into I (R = R1 = R2 = R3 = R4 = H, R5 = 2-Me).

IT 23375-97-5P 28524-75-6P 28524-80-3P
31933-24-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23375-97-5 CAPLUS


CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-75-6 CAPLUS


CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-

[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS

CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)



L4 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1977:467996 CAPLUS

DOCUMENT NUMBER: 87:67996

TITLE: Substituted anthranilamides

INVENTOR(S): Shetty, Bolva V.

PATENT ASSIGNEE(S): Pennwalt Corp., USA

SOURCE: Can., 26 pp.

CODEN: CAXXA4

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE


CA 1000736

19761130

CA 1971-103215

19710120

GI




AB Sixteen anthranilamides I ($R = H, PhCH_2, CH_2CH_2NEt, CH_2CH_2OH$; $R_1 = R_2 = H, Me, PhCH_2$, or $R_1 = H, R_2 = Me$; R_3, R_4, R_5 independently = $H, Me, Cl, MeO, SO_2NH_2, Et, OH$), which are useful in the preparation of quinazolinone derivs., were prepared by different routes. Thus, sequential treatment of 5,2,4-(ClO₂S)Cl₂C₆H₂CO₂H with (PhCH₂)₂NH, SOCl₂, 2-MeC₆H₄NH₂, and PhCH₂NH₂ gave I ($R = R_1 = R_2 = PhCH_2, R_3 = 2-Me, R_4 = R_5 = H$).

IT 23375-97-5P 28524-75-6P 28524-80-3P
31933-24-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1973:537186 CAPLUS
 DOCUMENT NUMBER: 79:137186
 TITLE: 3-Aryl-6-sulfamoyl-7-halo-1,2,3,4-tetrahydro-4-quinazolinones
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp.
 SOURCE: U.S., 15 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3761480	A	19730925	US 1972-235087	19720315
US 3567746	A	19710302	US 1968-743615	19680710
PRIORITY APPLN. INFO.:			US 1968-743615	A2 19680710
			US 1970-874960	A1 19701107

GI For diagram(s), see printed CA Issue.

AB Cyclization of I by condensation with R1CHO or the acetal gave II with diuretic activity. Thus, PhCH2CH(OMe)2 was reacted with I (R = 2-Me) in HOAc containing H2SO4 and stirred overnight to give II (R = 2-Me, R1 = PhCH2). An addnl. 53 examples are given.


IT 23375-97-5 28524-80-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with aldehydes)

RN 23375-97-5 CAPLUS


CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 28524-75-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation with aldehydes)

RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1971:405517 CAPLUS

DOCUMENT NUMBER: 75:5517

TITLE: Diuretic sulfamoyl o-benzotoluidides

INVENTOR(S): Shetty, Bola V.

PATENT ASSIGNEE(S): Pennwalt Corp.

SOURCE: U.S., 7 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 3567746	A	19710302	US 1968-743615	19680710

US 3761480	A	19730925	US 1972-235087	19720315
US 3862949	A	19750128	US 1972-315702	19721215
PRIORITY APPLN. INFO.:			US 1968-743615	A2 19680710
			US 1969-874960	A2 19691107
			US 1970-50895	A1 19700629
			US 1970-874960	A1 19701107


AB 5-Chloro-o-toluidine with Ac₂O gave 5'-chloro-2'-methylacetanilide, which was heated with ClSO₃H and NH₄OH to give 5'-chloro-2'-methyl-4'-sulfamoylacetanilide (I). I was oxidized with KMnO₄ to give N-acetyl-4-chloro-5-sulfamoylanthranilic acid, which was refluxed in aqueous NaOH to give 4-chloro-5-sulfamoylanthranilic acid (II). II in Ac₂O was treated with COCl₂ to give 7-chloro-6-sulfamoylisatoic anhydride, which was heated with o-toluidine to give 2-amino-4-chloro-5-sulfamoyl-N-o-tolylbenzamide (III). Nine other benzamides were similarly prepared. III heated with MeCHO and MeO(CH₂)₂OMe in DMF gave 2-methyl-3-o-tolyl-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone (IV). The 2-Ph, 2-Me, and 2-(CH₂Cl) analogs of IV were similarly prepared.

IT 23375-97-5P 28524-75-6P 28524-80-3P
31933-24-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:141846 CAPLUS
 DOCUMENT NUMBER: 74:141846
 TITLE: N- and N,N-Alkyl, -acyl, and -arylsulfamyltetrahydroquinazolinones as diuretics
 INVENTOR(S): Shetty, Bola V.
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3557111	A	19710119	US 1968-717437	19680329
GB 1256969	A	19711215	GB 1969-1256969	19690320
PRIORITY APPLN. INFO.:			US 1968-717437	A 19680329

AB The title tetrahydroquinazolinones which have diuretic and saluretic properties, are prepared 5-Chloro-o-toluidine in H2O was stirred 4 hr with Ac2O to give 5-chloro-2-methylacetanilide (I), m. 138-9°. I was cautiously added to ClSO3H under N, then NaCl added, the mixture heated 3 hr, and treated with NH4OH to give 5-chloro-2-methyl-4-sulfamoylacetamide (II) m. 248-50°. II was oxidized with KMnO4 to N-acetyl-4-chloro-5-sulfamoylanthranilic acid (III), m. 264-66°. III refluxed 3 hr with 3N NaOH, then brought to pH 4 with HCl gave 4-chloro-5-sulfamoylanthranilic acid (IV) m. 275-6°. IV in HOAc with COCl2 gave 7-chloro-6-sulfamoylisatoic acid (V), m. 290-2°. V, under N, heated with 1,2-MeC6H4NH2 gave 2-amino-4-chloro-5-sulfamoyl-N-(o-tolyl)benzamide (VI) m. 289-92°. To VI in HOAc was added


MeCH(OMe)₂ in H₂SO₄ and the mixture stirred 3.5 hr to give 2-methyl-3-(o-tolyl)-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone (VII) m. 246-50°. VII in C₅H₅N, stirred 6 hr with Ac₂O gave 7-chloro-6-acetylsulfamoyl-2-methyl-3-(o-tolyl)-1,2,3,4-quinazolinone m. 243-6°. An addnl. 3 examples are described.

IT 28524-75-6P 28524-80-3P 31933-24-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS

CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1970:477191 CAPLUS

DOCUMENT NUMBER: 73:77191

TITLE: Synthesis and activity of some 3-aryl- and

3-aralkyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamides

AUTHOR(S): Shetty, Bola V.; Campanella, Liborio A.; Thomas, Telfer L.; Fedorchuk, M.; Davidson, T. A.; Michelson, L.; Volz, H.; Zimmerman, S. E.; Belair, E. J.; Truant, A. P.

CORPORATE SOURCE: Dep. Chem., Pennwalt Corp., Rochester, NY, USA

SOURCE: Journal of Medicinal Chemistry (1970), 13(5), 886-95
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 73:77191


GI For diagram(s), see printed CA Issue.

AB A series of 3-aryl- and 3-aralkyl di- and -tetrahydro-4-oxo-6-quinazolinesulfonamides were synthesized and tested for pharmacol. activity. Several of the compds. were potent diuretics, especially I (metolazone), a potent, virtually nontoxic diuretic and natriuretic.

IT 23375-97-5P 28524-75-6P 28524-80-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1969:470632 CAPLUS
 DOCUMENT NUMBER: 71:70632
 TITLE: 1-Benzyl-2-methyl-3-(o-tolyl)-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Wallace and Tiernan Inc.
 SOURCE: U.S., 5 pp. Continuation-in-part of U.S. 3360518
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3452019	A	19690624	US 1967-683450	19671116


PRIORITY APPLN. INFO.: US 1967-683450 A 19671116

AB The title compound I, useful as a diuretic, saluretic, and antihypertensive, was prepared Thus, 800 g. of 2,4-dichlorobenzoic acid was added to 4 kg. of ClSO₃H at room temperature, the mixture refluxed 90 min., left to cool to 30°, 8 kg. of ice and 5 l. of H₂O added slowly, the mixture cooled to 0°, 8 l. of 28% NH₄OH added, acidified with HCl after 2 hrs., and the precipitate filtered, washed, dried, and clarified with C to give 790 g. 2,4-dichloro-5-sulfamylbenzoic acid, m. 225-8° (H₂O). This compound (270 g.) was added to 500 cc. of PhCH₂NH₂, the temperature quickly raised to 130°, kept 1 hr., cooled to 100°, the mixture poured into 5 l. of ice water, acidified with 400 cc. of HCl, and stirred 4 hrs. and the precipitate filtered to give 192 g. of 4-chloro-5-sulfamyl-N-benzylanthranilic acid, m. 242-6° (decomposition) (95% EtOH). This compound (35.0 g.) and 15 cc. of liquid COCl₂ was added to 400 cc. glacial AcOH, the mixture stirred 24 hrs., and the precipitate filtered, washed with Et₂O and air dried to give 25.2 g. 4-benzyl-6-chloro-7-sulfamylisatoic anhydride. This compound (25 g.) was added to 300 cc. of o-toluidine at room temperature, the mixture quickly warmed to 190°, kept 5 min., left to cool (50°), poured into 3 l. of Et₂O, and the precipitate washed and dried to give 2-benzylamino-4-chloro-5-sulfamyl-N-(O-tolyl)benzamide (II). Acetal (3.0 g.) was added to a suspension of 5.3 g. II in AcOH followed by 4 drops of H₂SO₄ dropwise during 5 min., the solution stirred overnight, the precipitate filtered, washed with Et₂O and dried to give 3.2 g. of I, m. 193-5° (AcOH). Some pharmacol. data are given.

IT 23375-97-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 23375-97-5 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)



L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1949:6357 CAPLUS

DOCUMENT NUMBER: 43:6357

ORIGINAL REFERENCE NO.: 43:1344h-i,1345a-i,1346a

TITLE: Nitrobenzoyl compounds and processes in their reduction. IV. Reduction processes in the nitrobenzoyl compounds of benzylidenephénylhydrazines

AUTHOR(S): Lockemann, Georg; Rein, Herbert

CORPORATE SOURCE: Robert-Koch-Inst., Berlin

SOURCE: Chemische Berichte (1947), 80, 485-93

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


OTHER SOURCE(S): CASREACT 43:6357

AB Expts. analogous to those described in parts I-III have been carried out with derivs. of BzH instead of AcH. Since phenylhydrazones of aromatic aldehydes are much more stable than those of aliphatic aldehydes, it was to be expected that they would behave differently on reduction. The Schlosser and Skraup [Monatsh. 2, 519(1881)] method of preparing the O₂NC₆H₄CO₂H was shortened from 18 to about 1 hr. The p-acid was obtained in 90% yield by treating 50 g. p-O₂NC₆H₄Me and 375 g. Na₂Cr₂O₇ in 400 cc. water dropwise, with vigorous stirring, under a reflux condenser, with 250 cc. concentrated H₂SO₄, kept boiling (about 1 hr.) until drops of the nitrotoluene no longer appeared in the condenser, pouring upon ice, washing the precipitate with dilute HCl, and purifying it by reprecipitation from NaOH. m-O₂NC₆H₄Me gave 85% of the acid with 300 g. Na₂Cr₂O₇ and 200 cc. H₂SO₄. o-O₂NC₆H₄CO₂H cannot be prepared in this way and a com. product was used. After numerous trials it was found o-O₂NC₆H₄COCl can be purified by vacuum distillation entirely without danger in the presence of excess PCl₅; the carefully dried o-O₂NC₆H₄CO₂H, m. 147°, (37.5 g.) is intimately mixed, by shaking in a flask under an upright condenser, with about 10% excess PCl₅ (50 g.), gently warmed on a water bath until solution is complete (1-1.5 hrs.), and the POCl₃ distilled off in vacuo from a retort; the o-O₂NC₆H₄COCl distills over under 11 mm. at 160-75° (oil-bath temperature) as a light yellow refractive oil solidifying in the cold to snow-white crystals, m. 24-5°; yield, about 85%. The three 2-benzylidene-1-nitrobenzoyl-1-phenylhydrazines (I) were prepared as described in part I [Ann. 342, 39(1905)] from PhCH:NNHPh and the O₂NC₆H₄COCl in dry ether: p- (75% yield), needles from benzene-petr. ether, m. 191°, gradually turns yellow: m- (60%), m. 128° (from alc.); o- (35%), m. 137° (from alc.), requires a higher temperature for its preparation (PhCH:NNHPh in boiling pyridine

treated in the course of 15 min. with o-O₂NC₆H₄COCl in xylene at 80°, heated another 15 min. on the water bath, and the product saturated in cold alc. with HCl gas gave the HCl salt, needles, sinters 190°, m. 208-9° (decomposition), of 1-o-nitrobenzoyl-1-

phenylhydrazine, yellow needles from alc., m. 101-2°). The course of the reduction of the I depends on the strength of the acid used for the generation of the H. The (benzylideneamino)benzanilides, PhCH:NC₆H₄CONHPh (II) (p-, needles weathering in the air; m-, needles from absolute alc., m. 166°; o-, yellowish needles from absolute alc., m. 218°, shows blue fluorescence in absolute alc.), which were readily obtained from the H₂NC₆H₄CONHPh (III) warmed a short time with BzH in alc., are almost completely hydrolyzed when reduced in dilute H₂SO₄; only the p-compound gave a little (about 5%) PhCH₂NHC₆H₄CONHPh. On the other hand, in EtOH-glacial AcOH, the benzylaminobenzanilides (IV) were obtained in considerable yields: p-, platelets from dilute MeOH, m. 177-8° (60%); m-, needles from absolute alc., m. 121° (35%); o-, needles from absolute alc., m. 134°, shows blue fluorescence in solution (42% yield). The I behave similarly; in AcOH all gave II, III, PhCH₂NH₂, and NH₃, whereas in dilute H₂SO₄ III could be detected with certainty only in the case of the p-isomer. In AcOH the reaction proceeds according to the scheme PhCH:NN(COC₆H₄NO₂)Ph (I) + H₂O → BzH + H₂NN(COC₆H₄NO₂)Ph (V) (1); V + 8H → NH₃ + PhNHCOC₆H₄NH₂ (III) + 2H₂O (2); III + BzH → PhNHCOC₆H₄N:CHPh (II) + H₂O (3); II + 2H → PhNHCOC₆H₄NHCH₂Ph (IV). BzH is first split off hydrolytically (1); the nascent H reduces the NO₂ group to NH₂ and the N-N bond of the hydrazine group is ruptured with formation of NH₃ (2); the liberated BzH condenses with the newly formed NH₂ group (3); and the resulting II takes up H to form IV. In dilute H₂SO₄ the relatively firmly attached PhCH: remains on the N while the bond between the two N atoms is ruptured, with addition of H: I + 8H → PhCH₂NH₂ + III. As was to be expected, the p-, m-, and o-IV were obtained directly (in 90, 60, and 70% yields) from the nitrobenzanilides in alc., AcOH, CuSO₄ solution, and Zn dust slowly treated with BzH in alc., whereas the usual procedure (action of PhCH₂Cl on the III) gave, with much smaller yields, very difficultly separable mixts. of primary, secondary, and tertiary amines. The structure of the IV was established by hydrolysis with fuming HCl in sealed tubes at 130-40° to the benzylaminobenzoic acids [p-, m. 164° (from benzene-petr. ether); m-, brownish crystals from water, m. 115° (uncor.); o-, needles from CHCl₃, m. 175°], identical with the products synthesized from H₃NC₆H₄CO₂H and PhCH₂Cl.

IT 855245-86-2, Benzanilide, 2-benzylamino-
(preparation of)
RN 855245-86-2 CAPLUS
CN Benzanilide, 2-benzylamino- (5CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

360.61

527.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

Page 471

CA SUBSCRIBER PRICE

-49.50

-49.50

STN INTERNATIONAL LOGOFF AT 08:41:03 ON 16 MAR 2006